Document:

<Page>

                                                                   Exhibit 10.13

                             CONFIDENTIAL TREATMENT

                                    AGREEMENT

This Agreement (the "Agreement") is entered into as of the last date of
signature appearing below (the "EFFECTIVE DATE") between NeoGenesis Drug
Discovery, Inc., a Delaware corporation ("NEOGENESIS") and Schering Corporation,
a New Jersey corporation ("SCHERING"), and sets forth the terms and conditions
that will apply to the provision by NeoGenesis to Schering of certain screening
and analysis services.

                                   BACKGROUND

Schering is interested in identifying potential pharmaceutical products for
treatment of certain human diseases and wishes to identify compounds that
exhibit a high degree of chemical binding and functional activity to specific
protein targets. NeoGenesis has certain technology and know-how, including
screening processes of libraries of mass-encoded small molecule compounds,
relating to the identification, discovery, validation and optimization of novel
compounds which may be useful for development of novel therapeutics employing
targets implicated in a disease process. The parties wish to pursue a
collaborative screening process to identify compounds exhibiting a high degree
of chemical binding activity to targets designated by Schering from among the
NeoGenesis libraries of mass-encoded small molecule compounds and which have
activity in target-specific functional assays. The terms and conditions set
forth below shall govern the performance of such collaborative effort.

1.   DEFINITIONS.

     The following capitalized terms used in this Agreement, whether in the
singular or plural, shall have the meaning set forth below.

     1.1 "ACTIVE COMPOUND" means any Compound identified as having binding
activity when tested against a Target pursuant to the Screening Program and
which (a) has Kd values of [*] and (b) has demonstrated bioactivity in
functional assays against the applicable Target as determined by the Steering
Committee following Schering's performance of the procedure specified in
Paragraph 3 of ATTACHMENT A.

     1.2 "AFFILIATE" means with respect to either party, any Person that,
directly or indirectly, is controlled by, controls or is under common control
with such party. For purposes of this definition, control means, with respect to
any Person, the direct or indirect ownership of fifty percent (50%) or more of
the outstanding voting securities of an entity, or the right to receive fifty
percent (50%) or more of the profits or earnings of an entity, or the possession
otherwise, directly or indirectly, of the power to direct the management,
business and affairs of an entity.

     1.3 "ALIS" means the Automated Ligand Identification System, an automated,
ultra-high throughput ligand selection system proprietary to NeoGenesis that is
used to identify multiple classes of chemical ligands against a target protein.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

     1.4 "CHEMOTYPE" means a family or group of Compounds closely structurally
related to one or more Active Compounds.

     1.5 "CIP" means "Carriage and Insurance Paid", as that expression is
defined in Incoterms 2000, ICC Publishing S.A.

     1.6 "COMMERCIALLY REASONABLE EFFORTS" shall mean, with respect to (a) any
objective by either party, reasonable, diligent, good faith efforts to
accomplish such objective as such Party would normally use to accomplish a
similar objective under similar circumstances; and (b) with respect to any
objective relating to the development or commercialization of any Licensed
Product efforts and resources normally used by such party with respect to a
product owned by such party or to which such party has similar rights which is
of similar market potential at a similar stage in the development or life of
such product, taking into account issues of safety, efficacy, product profile,
the competitiveness of the marketplace, the proprietary position of the product,
the regulatory structure involved, profitability of the product and other
relevant commercial factors.

     1.7 "COMPOUND" shall mean all proprietary compounds contained in the
NeoMorph Screening Library or any NeoMorph Focused Libraries which are screened
by NeoGenesis against one or more Targets in performance of the Screening
Program.

     1.8 "COMPOUND PATENT RIGHTS" shall mean any Schering Patent Rights which
claim Selected Compounds, Derivative Compounds, Designated Compounds or Licensed
Product, or the manufacture or use thereof.

     1.9 "CONFIDENTIAL INFORMATION" means any proprietary or confidential
information of either party (including but not limited to all Schering Know-How
and all NeoGenesis Know-How) disclosed to the other party pursuant to this
Agreement in written or other tangible medium and marked as confidential, or if
disclosed orally or displayed, confirmed in writing within thirty (30) days of
disclosure.

     1.10 "DERIVATIVE COMPOUND" means a compound which is derived from a
Selected Compound or a Lead Compound by or on behalf of Schering, or by
NeoGenesis in performance of medicinal chemistry optimization pursuant to
Section 2.2(b), and having activity against the same Target as such Selected
Compound and/or Lead Compound. A compound will be deemed to have been "derived"
from a Selected Compound or a Lead Compound if it (i) is the result of a
chemical modification made to a Selected Compound or Lead Compound, (ii) is
otherwise derived from a chemical synthesis program based upon a Selected
Compound or Lead Compound, or (iii) is based on proprietary structure-function
data obtained from Selected Compounds or Lead Compounds. Derivative Compounds
will include, without limitation, all Compounds contained in the NeoMorph
Focused Library(ies).

     1.11 "DESIGNATED COMPOUND" means any Selected Compound or Derivative
Compound which becomes the subject of a development program conducted by
Schering or its Affiliates, as further defined in Section 2.8(b) of the
Agreement.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

     1.12 "EMEA" means the European Medicines Evaluation Authority, or any
successor thereto.

     1.13 "FDA" means the United States Food and Drug Administration, or any
successor thereto.

     1.14 "FD&C ACT" means the United States Federal Food, Drug and Cosmetic Act
of 1938, as amended.

     1.15 "FIELD" means the treatment or prevention of any disease or condition
in humans or animals.

     1.16 "FIRST COMMERCIAL SALE" means, with respect to a Licensed Product, the
first sale (or other transfer for value in an arms-length transaction) for end
use of such Licensed Product in a country within the Territory after obtaining
all necessary Regulatory Approvals for the marketing and sale of the Licensed
Product in such country.

     1.17 "FTE" means the equivalent of a full time (12) months (including
normal vacations, sick days and holidays) work of an individual scientist,
carried out by one or more employees or agents of NeoGenesis, who devotes a
portion of his or her time to performing the Screening Program.

     1.18 "GOOD CLINICAL PRACTICE" means the then current standards for clinical
trials for pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good clinical practice as are required by the European Union and
other Regulatory Authorities in countries in which the Product is intended to be
sold, to the extent such standards are not in contravention with United States
Good Clinical Practices.

     1.19 "GOOD LABORATORY PRACTICE" means the then current standards for
laboratory activities for pharmaceuticals, as set forth in the FD&C Act and
applicable regulations promulgated thereunder, as amended from time to time, and
such standards of good laboratory practice as are required by the European Union
and other Regulatory Authorities in countries in which the Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Laboratory Practices.

     1.20 "GOOD MANUFACTURING PRACTICE" means the current standards for the
manufacture of pharmaceuticals, as set forth in the FD&C Act and applicable
regulations promulgated thereunder, as amended from time to time, and such
standards of good manufacturing practice as are required by the European Union
and other Regulatory Authorities in countries in which the Product is intended
to be sold, to the extent such standards are not in contravention with United
States Good Manufacturing Practices.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

     1.21 "IMPROVED ACTIVE COMPOUND" means any Compound identified as a result
of initial optimization of one or more Active Compounds by NeoGenesis (as
described in paragraph 4 of ATTACHMENT A) and having binding activity when
tested against a Target pursuant to the Screening Program with a Kd value of
[*].

     1.22 "IND" means an investigational new drug application, as defined in the
FD&C Act and applicable regulations thereunder, or any equivalent document,
filed with the FDA and necessary for beginning clinical trials of any Licensed
Product in humans or any application or other documentation filed with any
Regulatory Authority of a country other than the United States prior to
beginning clinical trials of any Licensed Product in humans in that country.

     1.23 "INTERNATIONAL AGREEMENT" means the contemporaneous Agreement entered
into by NeoGenesis and Schering's Affiliate, Schering-Plough Ltd. relating to
countries and territories outside of the Territory.

     1.24 "INVENTIONS" means any and all discoveries, developments, inventions
and innovations (whether or not patentable) that are conceived and/or reduced to
practice (i) solely by one or more employees or consultants of NeoGenesis in
connection with the performance of the Screening Program; (ii) solely by one or
more employees or consultants of Schering in connection with the performance of
the Screening Program; or (iii) jointly by one or more employees or consultants
of NeoGenesis and one or more employees or consultants of Schering in connection
with the performance of the Screening Program.

     1.25 "LEAD COMPOUNDS" means those Selected Compounds which are designated
by Schering as Lead Compounds (pursuant to Section 2.2(b) of the Agreement) for
the performance of medicinal chemistry optimization by NeoGenesis.

     1.26 "LICENSED PRODUCT(S)" means any pharmaceutical product which contains
as an active ingredient a Selected Compound or Derivative Compound, and which is
covered by one or more claims of a NeoGenesis Patent Right and/or Compound
Patent Right.

     1.27 "MAJOR MARKET COUNTRY" means the United States, Japan, or any three or
more of the following European countries, the United Kingdom, France, Germany,
Italy or Spain, as the case may be.

     1.28 "NDA" means a new drug application or product license application,
each as defined in the FD&C Act and applicable regulations thereunder, seeking
approval to market and sell a Licensed Product in the United States.

     1.29 "NEOGENESIS KNOW-HOW" means all proprietary information, data and
know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries,
NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, Improved Active
Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Products together with, where applicable, any analogs, derivatives or
fragments thereof, which is (i) owned

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

or controlled by NeoGenesis as of the Effective Date, or (ii) developed by or on
behalf of NeoGenesis during the term of this Agreement.

     1.30 "NEOGENESIS PATENT RIGHTS" means any and all patents and patent
applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned by NeoGenesis
(and/or any of its Affiliates), or to which NeoGenesis (and/or any of its
Affiliates) through license or otherwise acquires rights, and which have claims
covering: (i) the NeoMorph Screening Library, the NeoMorph Focused Libraries,
NeoMorph Chemistry, ALIS or QSCD; or (ii) any Active Compounds, Improved Active
Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or
Licensed Products, or the manufacture or use of any of the foregoing; or (iii)
NeoGenesis Inventions (as defined in Section 3.5(a)); or (iv) NeoGenesis' rights
in Joint Inventions (as defined in Section 3.5(b)), as well as all divisionals,
continuations, continuations-in-part, reissues, re-examinations, extensions,
renewals, registrations, supplementary protection certificates and/or foreign
counterparts of any of the foregoing which are owned or controlled by NeoGenesis
and its Affiliates during the term of this Agreement. The NeoGenesis Patent
Rights shall include those listed in ATTACHMENT B pursuant to Section 3.8.

     1.31 "NEOMORPH CHEMISTRY" means the process, proprietary to NeoGenesis, of
forming libraries and sub-libraries of discrete compounds by coupling a broad
set of diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

     1.32 "NEOMORPH FOCUSED LIBRARIES" means any and all compounds or
collections of compounds synthesized by NeoGenesis which are derived from or
based upon Lead Compounds, and which are designed to optimize the structure of
such Lead Compounds with respect to activity against one or more specific
Targets.

     1.33 "NEOMORPH SCREENING LIBRARY" means the entire collection of libraries
consisting of mass-encoded small molecule organic compounds owned by NeoGenesis
and developed with NeoMorph Chemistry, comprising at least twelve million
(12,000,000) different compounds.

     1.34 "NET SALES" means the proceeds actually received by Schering or any of
its Affiliates or sub-licensees on all sales of a Product in the Territory to an
unaffiliated third party (whether an end-user, a distributor or otherwise), and
exclusive of intercompany transfers or sales, less the reasonable and customary
deductions from such gross amounts including: (i) normal and customary trade,
cash and quantity discounts, allowances and credits; (ii) credits or allowances
actually granted for damaged goods, returns or rejections of a Product and
retroactive price reductions; (iii) sales or similar taxes (including duties,
value added taxes or other governmental charges otherwise measured by the
billing amount, when included in billing); (iv) freight, postage, shipping,
customs duties and insurance charges; (v) charge back payments and rebates
granted to managed health care organizations or to federal, state and local
governments, their agencies, and purchasers and reimbursers or to trade
customers, including but not limited to, wholesalers and chain and pharmacy
buying groups; (vi) commissions paid to third parties other than sales personnel
and sale representatives or sales agents; and (vii) rebates (or equivalents
thereof) granted to or charged by national, state or local governmental
authorities in countries

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

other than the United States. If a Product is sold in the form of a combination
product with one or more other active ingredients, Net Sales for such
combination product with one or more active ingredients will be calculated by
multiplying actual Net Sales of such combination product by the fraction A/(A+B)
where:
     "A" is the invoice price of the Product contained in the combination
     product if sold separately by Schering or any of its Affiliates or
     sub-licensee; and
     "B" is the aggregate invoice price of any other active component(s)
     in the combination product if sold separately by Schering or any of its
     Affiliates or sub-licensee.
If one or more of the other active ingredients in the combination product are
not sold separately, then the above formula shall be modified such that:
     "A" shall be the fully allocated manufacturing cost to Schering or any of
     its Affiliates or sub-licensee of the Product, and
     "B" shall be the fully allocated manufacturing cost to Schering or any of
     its Affiliates or sub-licensee of any other active component(s) in the
     combination,
such fully allocated manufacturing costs being determined in accordance with
generally accepted accounting principles.

     1.35 "PERSON" means any individual, corporation, association, partnership
(general or limited), joint venture, trust, estate, limited liability company,
limited liability partnership, unincorporated organization, government (or any
agency or political subdivision thereof) or other legal entity or organization.

     1.36 "PRELIMINARY COMPOUND" means any Compound identified as having binding
activity when tested against a Target pursuant to the Screening Program and
which has Kd values of [*] or such other binding affinity threshold for a
specific Target as shall be agreed upon by the parties in writing.

     1.37 "QSCD" means Quantisized Surface Complimentary Diversity, a model
proprietary to NeoGenesis, in terms of which discrete chemical compliments to
the surfaces of a Target are defined.

     1.38 "REGULATORY APPROVAL" means, for any country in the Territory, those
authorizations by the appropriate Regulatory Authority(ies) required for the
manufacture, importation, distribution, marketing, promotion, pricing and sale
of the Licensed Product(s) in such country, including, without limitation, any
NDAs, Health Registration Dossiers, supplements, amendments, pre- and
post-approvals, marketing authorizations based upon such approvals (including
any prerequisite manufacturing approvals or authorizations related thereto) and
pricing, third party reimbursement or labeling approval(s), technical, medical
and scientific licenses, registrations or authorizations.

     1.39 "REGULATORY AUTHORITY" means any national, supra-national, regional,
state or local regulatory agency, department, bureau, commission, council or
other governmental entity in the Territory, including, without limitation, the
FDA and the EMEA.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

     1.40 "SCHERING KNOW-HOW" means all information, data and know-how which is
owned or controlled by Schering or its Affiliates as of the Effective Date, or
developed by or on behalf of Schering or its Affiliates during the term of this
Agreement, related to the Screening Program, the Targets, Active Compounds,
Improved Active Compounds, Selected Compounds, Derivative Compounds, Designated
Compounds or Licensed Products. Schering Know-How includes, without limitation,
all processes, formulas, discoveries and inventions whether relating to
biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical safety, quality control and clinical data, including, without
limitation, clinical study data related to Designated Compounds and/or Licensed
Products. Schering Know-How also includes relevant medical information relating
to the Licensed Products (such as Regulatory Authority questions, responses
thereto and adverse drug event history) in the possession of Schering, its
Affiliates or sublicensees.

     1.41 "SCHERING PATENT RIGHTS" means any and all patents and patent
applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned by Schering (and/or
any of its Affiliates), or to which Schering (and/or any of its Affiliates)
through license or otherwise acquires rights, which have claims covering: (i)
Selected Compounds, Derivative Compounds, Designated Compounds or Licensed
Products, or the manufacture or use of any of the foregoing; (ii) the Targets;
or (iii) Schering Inventions (as defined in Section 3.5(a)) or Joint Inventions
(as defined in Section 3.5(b)), as well as all divisionals, continuations,
continuations-in-part, reissues, re-examinations, extensions, renewals,
registrations, supplementary protection certificates and/or foreign counterparts
of any of the foregoing which are owned or controlled by Schering and its
Affiliates during the term of this Agreement.

     1.42 "SELECTED COMPOUND" means any and all Active Compounds and/or Improved
Active Compounds which have demonstrated bioactivity in secondary functional
assays against the applicable Target as determined by Schering in accordance
with Section 2.7, and which are designated by Schering pursuant to Section
2.7(a) of the Agreement.

     1.43 "SCREENING PROGRAM" means the screening program described in
ATTACHMENT A (including as it may be amended by the Steering Committee) to
identify Active Compounds and Improved Active Compounds against one or more
Targets.

     1.44 "STEERING COMMITTEE" means the joint steering committee established by
the parties pursuant to Section 2.6 of the Agreement.

     1.45 "SUCCESS CRITERIA" means the success criteria, to be defined by the
Steering Committee with respect to a given Target, for determining whether or
not Selected Compounds and/or Derivative Compounds have a certain desired degree
of chemical binding activity, activity in Target-based functional assays, and
other chemical, biological, pharmacological and toxicological properties,
suitable for drug development.

     1.46 "TARGET" means a specific biological target (including, without
limitation, nucleic acids and proteins, and/or active fragments thereof) that a
small molecule is screened against in

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

order to determine whether the small molecule demonstrates a specific
biochemical or pharmaceutical effect, selected by Schering and accepted by
NeoGenesis in accordance with Section 2.1(b) for which NeoGenesis will perform
the Screening Program.

     1.47 "TERRITORY" means the United States and all of its territories,
possessions and commonwealths, except for the Commonwealth of Puerto Rico.

     1.48 "VALID CLAIM" means a composition-of-matter or method-of-use claim of
an issued and unexpired patent included within (i) the NeoGenesis Patent Rights
or (ii) Compound Patent Rights, and in each case which has not been revoked or
held unenforceable or invalid by a decision of a court or other governmental
agency of competent jurisdiction, unappealable or unappealed within the time
allowed for appeal, and which has not been disclaimed, denied or admitted to be
invalid or unenforceable through reissue or disclaimer or otherwise.

2.   SCREENING PROGRAM

     2.1  DELIVERY OF TARGETS.

          (a) Schering shall deliver one or more of the Targets listed in
ATTACHMENT A to NeoGenesis for screening within [*] following the Effective
Date. Schering shall provide the Targets in the quantities and formats specified
in ATTACHMENT A, along with a written description of the concentration and
volume of the Target.

          (b) From time to time during the term of this Agreement, Schering may
select additional Targets for screening under the Screening Program. In such
event, Schering shall notify NeoGenesis in writing of the additional Target(s)
to be provided for screening. NeoGenesis shall notify Schering in writing within
[*] of such notice whether the Target is approved for inclusion in the Screening
Program. Subject to the terms of Section 2.1(c), the Target will be accepted for
inclusion in the Screening Program unless the proposed Target: (i) is subject to
an exclusivity period in an existing agreement between NeoGenesis and a third
party; or (ii) is the subject of an existing internal research program at
NeoGenesis. The parties shall promptly amend ATTACHMENT A to include each
additional Target added to the Screening Program pursuant to this Section
2.1(b). Schering shall thereafter provide the Targets to NeoGenesis in
appropriate quantities and formats for screening, along with a written
description of the concentration and volume of the Target. The Steering
Committee shall establish a schedule for delivery of the additional Targets to
NeoGenesis based on the time necessary to prepare and validate the approved
Target; PROVIDED, that such period shall not exceed nine (9) months from
NeoGenesis' notice to Schering that a Target is approved.

          (c) The parties acknowledge and agree that the Screening Program will
be limited to active screening and/or optimization programs at NeoGenesis
directed to [*] distinct Targets, based upon research support for [*] FTEs at
NeoGenesis. In the event that the screening and optimization programs directed
to a specific Target are completed or discontinued, Schering shall have the
right to select an additional Target to replace such discontinued Target.
Further, in

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

the event that the number of FTEs working on the Screening Program is increased,
pursuant to Section 2.2(f), the limit on the number of active Targets shall be
increased proportionately.

          (d) All Targets to be supplied by Schering hereunder shall be
delivered CIP to NeoGenesis' Cambridge facility using a carrier selected by
Schering. The Targets are and shall remain the sole and exclusive property of
Schering. NeoGenesis will only use the Targets for screening in performance of
the Screening Program and will not use the Targets for any other purpose without
Schering's prior written consent.

          (e) Schering will identify to NeoGenesis all Targets provided by
Schering for use in the Screening Program. The identity of the Targets and any
other information related thereto will be considered Schering Confidential
Information. During the applicable Exclusivity Period (as defined below) for a
Target, NeoGenesis shall not screen the NeoMorph Screening Library for itself or
for any third party against the same Target, without Schering's prior written
approval. The "Exclusivity Period" for a given Target shall begin on the date
the Target is accepted for inclusion in the Screening Program pursuant to
Section 2.1(b) and shall expire:

          (i)  if NeoGenesis does not perform any medicinal chemistry
               optimization activities pursuant to Section 2.2(b) to develop
               NeoMorph Focused Libraries with respect to the Target, [*] after
               NeoGenesis delivers to Schering the Final Target Report with
               respect to such Target; or

          (ii) if NeoGenesis does perform medicinal chemistry optimization
               activities pursuant to Section 2.2(b) to develop NeoMorph Focused
               Libraries with respect to such Target, [*] after the later of the
               date upon which Schering files an IND for a Licensed Product
               directed to the Target or discontinues the development of
               Licensed Products against such Target.

Upon the expiration of the Screening Program, and annually thereafter, Schering
shall notify NeoGenesis in writing of the list of Targets with respect to which
Schering has ongoing programs to discover and develop Licensed Products.
Schering shall promptly notify NeoGenesis in writing in the event that it
discontinues the development of Licensed Products against a Target. For purposes
of this Section 2.1(e), Schering shall be deemed to have discontinued
development of Licensed Products against a Target if it ceases to maintain a
minimum of [*] FTEs assigned full time to work on the discovery and pre-clinical
development of Licensed Products against a Target. During the term of the
Screening Program, if NeoGenesis intends to screen the NeoMorph Screening
Libraries (including all newly created Compounds contained therein) for a third
party against a Target with respect to which Schering's Exclusivity Period has
expired pursuant to subsection (i), above, NeoGenesis shall first offer Schering
the opportunity to screen the NeoMorph Screening Libraries against the Target.
Schering shall have [*] in which to accept or reject such offer. If Schering
accepts the offer, such screening shall be conducted under the terms of this
Agreement and Schering shall have a renewed Exclusivity Period with respect to
such Target. If NeoGenesis does perform medicinal chemistry optimization
activities pursuant to Section 2.2(b) to develop NeoMorph Focused Libraries with
respect to a Target, then notwithstanding the expiration of the applicable
Exclusivity Period

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       9

<Page>

pursuant subsection (ii), above, NeoGenesis shall be permanently prohibited
from screening the NeoMorph Screening Libraries against the Target for itself
and in such instance may only perform such screening for third parties. In
the event that NeoGenesis does screen the NeoMorph Screening Libraries
against a Target for itself or a third party as permitted under this Section
2.1(e), NeoGenesis shall not use (i) any Schering Know-How (including without
limitation any of Schering's proprietary information related to the existence
of or uses for the Target), or (ii) any NeoGenesis Know-How related to the
Target and developed in performance of the Screening Program, in connection
with such screening activities.

          (f) For purposes of this Agreement, and in particular with respect to
the provisions of Sections 2.1(b) and 2.1(e), a Target identified by Schering
for screening under this Agreement will encompass the nucleic acid or amino acid
sequence of the actual Target to be provided by Schering, and in the case of a
Target which is a human biological molecule, shall be further defined by the
nucleic acid or protein encoded by the specified genomic location of origin
(which will be identified by Schering in the notification to NeoGenesis of a
proposed Target pursuant to Section 2.1(b)) and natural polymorphic variants
thereof such as SNP, insertion, deletion and splice variants or the synthetic
equivalent thereof. If a Target can not be distinguished from another biological
target based on the above, then the Target shall be considered the same as
another biological target if the other biological target comprises a contiguous
region of [*] residues that is [*] to the Target or is derived from such Target
by modification. If a Target is a biological molecule of non-human origin, then
the Target shall be considered the same as another target if they are both
derived from the comparable chromosomal location of related strains of the
applicable species. For example, a target defined by the [*] shall be considered
the same as a target specified by the [*] gene from any other strain of HCV
including targets derived by modification. Similarly, a target specified by a
chromosomal location in one particular strain of [*] shall be considered
identical to a target specified by the analogous location in a second strain of
bacteria. If the chromosomal locations of two targets can not be defined, then a
target shall be considered the same as a second target if it comprises a
contiguous region of [*] residues that is [*] to said second target or is
derived from such a second Target by modification. It is expressly understood
that a non-human target falling outside the criteria defined above may not be
screened using the NeoMorph Screening Libraries with the intent of developing a
product affecting the activity of a human target that would meet the identity
criteria. For clarity, a primate ortholog of a human gene or protein may not be
screened using the Neomorph Screening Libraries if the intent is to develop a
product for human use against an otherwise excluded target. Nothing in this
paragraph shall limit the screening of non-human targets for non-human usage.

     2.2  SCREENING PROGRAM.

     (a) During the term of the Screening Program, NeoGenesis will utilize its
proprietary technology and methods, including without limitation the ALIS
method, to screen the NeoMorph Screening Library for activity with respect to
each Target for purposes of identifying Active Compounds for further evaluation
and development. Screening will be performed pursuant to the protocol for the
Screening Program, as set forth in paragraphs 1-2 of ATTACHMENT A. With respect
to each accepted Target provided by Schering under Section 2.1, NeoGenesis shall

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

complete the screening of the NeoMorph Screening Library within [*] following
the date that the Target is delivered to NeoGenesis. The results of such
screening shall be provided to Schering through the Steering Committee in the
form of a Preliminary Target Report (as defined in ATTACHMENT A). NeoGenesis
shall provide Schering with samples of all Preliminary Compounds selected by the
Steering Committee for further evaluation by Schering pursuant to paragraph 3 of
ATTACHMENT A. Schering will evaluate such Preliminary Compounds in Target-based
functional assays and/or secondary assays to identify Active Compounds, and will
report the results of such evaluations to the Steering Committee, and NeoGenesis
will promptly thereafter provide Schering with all available structural
information for each Active Compound so identified. NeoGenesis will, at the
direction of the Steering Committee, conduct initial optimization activities, as
described in paragraph 4, of ATTACHMENT A, to identify Improved Active
Compounds. It is acknowledged that all compounds generated from such initial
optimization activities and having activity against the relevant Target shall be
deemed to be Improved Active Compounds; provided that such optimization
activities and all Improved Active Compounds arising therefrom shall not be
deemed to be optimization of Lead Compounds for purposes of Section 2.1(e) or
for determining Schering's financial obligations under Sections 4.3 and 4.4.

     (b) NeoGenesis will, at the direction of the Steering Committee, conduct a
full program of medicinal chemistry optimization activities, based upon those
Selected Compounds identified as Lead Compounds that are suitable for
optimization. Such optimization activities shall include the design and
preparation of NeoMorph Focused Libraries based upon such Lead Compounds, and
the screening of the NeoMorph Focused Libraries against the relevant Target(s).
The parties acknowledge and agree that, subject to the terms of Sections 3.5(a),
and effective on the date that Schering acquires an exclusive license to the
relevant Selected Compound(s) pursuant to Sections 2.7(c), 3.1 and 3.2, any and
all Compounds which are included in NeoMorph Focused Libraries prepared against
the relevant Target shall be the exclusive property of Schering. NeoGenesis
shall not use the NeoMorph Focused Libraries, any Compounds contained therein,
or any structural information or other know-how related thereto, for any purpose
other than the performance of the Screening Program. NeoGenesis shall not
provide any NeoMorph Focused Libraries, any Compounds contained therein, or any
structural information or other NeoGenesis Know-How related thereto, to any
third party without the prior written consent of Schering. Notwithstanding the
foregoing limitations, it is expressly understood and agreed that NeoGenesis
may, through use of the NeoMorph Screening Library on behalf of third parties
independently generate results or data similar to the results or data generated
in the course of the Screening Program and that the use of such independently
generated results or data shall not constitute a breach of NeoGenesis'
obligations under this Section 2.2(b); PROVIDED, that NeoGenesis has complied
with its obligations to mask Compounds in accordance with Section 2.3 of this
Agreement.

     (c) NeoGenesis shall not perform any tests on or using any of the Targets
that are outside the scope of the Screening Program, or attempt to modify the
Targets supplied by Schering, including, without limitation, the making of any
derivatives, analogs or components thereof. In the event that NeoGenesis does
not consume all of the Targets supplied by Schering in performance of the
Screening Program, NeoGenesis will upon completion of the Screening

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

Program promptly, return to Schering any quantities of such Target(s) and any
derivatives, analogs or components thereof.

     (d) The term of the Screening Program shall begin on the Effective Date and
shall continue in effect for a period of two (2) years. Schering shall have the
right to extend the term of the Screening Program for up to three additional one
(1) year terms, by providing NeoGenesis with written notice to that effect at
least sixty (60) days prior to the expiration of the then current term of the
Screening Program and subject to the provisions of Section 4.1 concerning
research funding for such extension term. The Screening Program shall remain in
effect for the period specified in this Section 2.2(d), including as it may be
extended, unless sooner terminated in accordance with Section 8.2 or Section
9.5.

     (e) During the term of the Screening Program, upon request, NeoGenesis
shall provide Schering with samples of Selected Compounds and Derivative
Compounds from NeoMorph Focused Libraries in a form and quantity suitable to
enable Schering to conduct additional testing to confirm the specific binding
activity of such Compounds and to evaluate and determine the functional activity
of the Selected Compounds and/or Derivative Compounds. Schering may also elect
to perform medicinal chemistry research using such Selected Compounds and/or
Derivative Compounds to discover and evaluate additional Derivative Compounds.
Schering shall keep NeoGenesis reasonably informed of the results of such
activities through the Steering Committee.

     (f) During the term of the Screening Program NeoGenesis shall provide
appropriately trained dedicated scientific personnel to perform the Screening
Program in accordance with the terms of this Agreement. During the initial two
(2) year term of the Screening Program, NeoGenesis shall provide such support at
the level of [*] FTEs during each year of the Screening Program, it being
understood that NeoGenesis may allocate such FTE time within any calendar year
in a manner consistent with its obligations under the Screening Program based on
the workload for such Screening Program at any particular time during the
Screening Program. In addition, NeoGenesis will, upon written request by
Schering, provide additional FTE support for the Screening Program of up to an
additional [*] FTEs during the term of the Screening Program. In the event that
the term of the Screening Program is extended pursuant to Section 2.2(d), the
Steering Committee shall establish the number of FTEs to be provided by
NeoGenesis for performance of the Screening Program during the extended term.

     (g) NeoGenesis shall monitor expenditures, in accordance with its corporate
policies, to ensure that the funds provided by Schering are spent in accordance
with this Agreement. NeoGenesis shall keep and maintain adequate books and
records to furnish information to Schering regarding calculation of the amounts
expended by NeoGenesis on the Screening Program according to the provisions of
this Agreement. During the Screening Program and for two (2) years following the
expiration of the Screening Program, NeoGenesis shall permit Schering to examine
such books and records during normal business hours, upon thirty (30) days
notice to NeoGenesis. Upon the expiration of the two (2) year period, the
calculation of the amounts expended on each year of the Screening Program shall
be binding and

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

conclusive upon the parties and NeoGenesis shall be released from any further
accountability with respect to the Screening Program.

     (h) NeoGenesis will perform its screening obligations in accordance with
all applicable laws, rules and regulations.

     2.3  COMPOUND MASKING.

          (a) Upon the identification of Preliminary Compounds and Active
Compounds through screening of the NeoMorph Screening Library against a
particular Target, NeoGenesis shall mask such Preliminary Compounds and Active
Compounds from the NeoMorph Screening Library by removing such Compounds from
the compound resource information associated with the NeoMorph Screening Library
and shall take all other steps reasonably necessary to ensure that information
with regard to such Compounds is not available or accessible to any third party,
including third parties for which NeoGenesis is screening the NeoMorph Screening
Library against other biological targets. NeoGenesis shall similarly mask any
Improved Active Compounds which are discovered pursuant to Section 2.2(a).

          (b) NeoGenesis shall have the right to unmask any Preliminary
Compounds which are not confirmed as Active Compounds and are not in the same
Chemotype as such Active Compounds. In addition, upon expiration of Schering's
right to designate Selected Compounds with regard to a specific Target, pursuant
to Section 2.7(a), NeoGenesis shall have the right to unmask any Active
Compounds and/or Improved Active Compounds identified through screening against
that Target which are not (i) Selected Compounds or (ii) Preliminary Compounds,
Active Compounds and/or Improved Active Compounds of the same Chemotype as such
Selected Compounds.

     2.4  GRANT OF RESEARCH LICENSES.

          (a) Schering hereby grants NeoGenesis a nonexclusive, nontransferable,
royalty-free license under the Schering Patent Rights and to use the Schering
Know-How solely for the purpose of conducting the Screening Program. NeoGenesis
will not use Schering Know-How or Schering Patent Rights for any other purpose,
and shall not offer or grant a sub-license to use Schering Know-How or Schering
Patent Rights to any third party, without the express prior written consent of
Schering.

          (b) NeoGenesis hereby grants Schering a nonexclusive, nontransferable,
royalty-free license under the NeoGenesis Patent Rights and to use the
NeoGenesis Know-How solely for the purpose of conducting Schering's activities
under the Screening Program. Schering will not use NeoGenesis Know-How or
NeoGenesis Patent Rights for any other purpose, and shall not offer or grant a
sub-license to use NeoGenesis Know-How or NeoGenesis Patent Rights to any third
party, without the express prior written consent of NeoGenesis (not to be
unreasonably withheld).

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

          (c) With respect to Selected Compounds identified pursuant to Section
2.7(a), NeoGenesis hereby grants Schering, during the relevant Option Period (as
defined in Section 2.7(b)), an exclusive, nontransferable, royalty-free license
under the NeoGenesis Patent Rights and to use the NeoGenesis Know-How solely for
the purpose of performing research and development work necessary to enable
Schering to determine whether or not to exercise its option to obtain an
exclusive license with respect to such Selected Compounds.

     2.5  RECORD KEEPING AND REPORTS.

          (a) NeoGenesis will keep and maintain complete and accurate records
of all laboratory data and results generated in the course of the Screening
Program, including records of all Preliminary Compounds, Active Compounds, and
Improved Active Compounds identified, and any Inventions discovered and/or
developed by NeoGenesis, during the Screening Program. All such written records
of NeoGenesis shall be open to inspection by Schering during normal business
hours upon reasonable prior written notice; provided, however, that except with
respect to (i) Improved Active Compounds, (ii) Active Compounds, and (iii)
Preliminary Compounds of the same Chemotype as such Improved Active Compounds or
Active Compounds, NeoGenesis shall not provide Schering with access to any
chemical structures or structural data.

          (b) NeoGenesis shall provide Schering with reasonably-detailed written
reports describing the results of the research performed pursuant to the
Screening Program including all Preliminary Compounds, Active Compounds and
Improved Active Compounds identified in the Screening Program but shall not
include any chemical structures or structural data with respect to any Compounds
which are not (i) Improved Active Compounds, (ii) Active Compounds, and (iii)
Preliminary Compounds of the same Chemotype as such Improved Active Compounds or
Active Compounds. Such reports shall be delivered to Schering at least quarterly
during the term of the Screening Program. In addition, with respect to each
Target, promptly following the completion of screening of the entire NeoMorph
Screening Library against such Target, NeoGenesis will deliver to Schering a
Preliminary Target Report (as defined in ATTACHMENT A) with respect to any and
all Preliminary Compounds identified during the Screening Program as having
activity with respect to such Target. Each Preliminary Target Report shall
include the binding affinities for all such Preliminary Compounds, as well as
any information generated by NeoGenesis with regard to Target specificities and
functional activities of such Preliminary Compounds. NeoGenesis shall also
provide Schering with a Final Target Report (as defined in ATTACHMENT A) in
accordance with the provisions of Paragraph 4 of ATTACHMENT A. NeoGenesis shall
also provide Schering with reports at least one (1) week prior to each Steering
Committee Meeting detailing the results of any Lead Compound optimization
activities performed by NeoGenesis pursuant to Section 2.2(b) and ATTACHMENT A,
which reports shall include the chemical structures and binding affinities of
all Derivative Compounds contained in NeoMorph Focused Libraries prepared by
NeoGenesis based upon such Lead Compound(s) and other information generated by
NeoGenesis with respect thereto.

     2.6  STEERING COMMITTEE.

     (a) Promptly after the Effective Date, the parties shall establish a joint
committee (the "STEERING COMMITTEE") having oversight responsibility for the
day-to-day

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       14

<Page>

management and performance of the Screening Program. The Steering Committee
shall consist of six (6) members, three (3) members to be appointed by each
of NeoGenesis and Schering. Each party shall notify the other party of the
names and contact information for its members of the Steering Committee, and
thereafter may with notice to the other substitute any of its members serving
on the Steering Committee. Each member of the Steering Committee will have
one vote and all decisions of the Steering Committee will be by unanimous
agreement. The quorum for Steering Committee meetings shall be two, provided
there is at least one member from each of NeoGenesis and Schering present.
The Steering Committee will render decisions by unanimous vote.

          (b) The Steering Committee shall be responsible for the management and
conduct of the Screening Program and shall in particular: (i) consider, review
and amend the Screening Program from time to time in such manner as may be
appropriate; (ii) monitor progress of the Screening Program; (iii) report
regularly to the management of both parties upon the progress of the Screening
Program; and (iv) be the initial medium for transfer of information between the
parties. Schering shall keep the Steering Committee reasonably informed of the
status of Schering's activties with respect to the discovery and development of
Licensed Products against each Target.

          (c) During the term of the Screening Program, the Steering Committee
shall hold meetings as mutually agreed by the parties (but in no event less
quarterly) to review the Screening Program. The first meeting of the Steering
Committee shall be held within forty-five (45) days of the Effective Date and
shall be held in Cambridge, MA. Thereafter, meetings may be held by telephone or
video conference if requested by either party in writing to the other, PROVIDED
THAT the parties shall meet in person at least four (4) times per year during
the term of the Screening Program. Minutes of all meetings setting forth
decisions of the Steering Committee relative to the Screening Program shall be
prepared by the host party and circulated to both parties within fifteen (15)
days after each meeting, but minutes shall not become official until approved
and countersigned by both parties (which approval the parties shall use
reasonable efforts to give within thirty (30) days of receipt of such minutes).

          (d) In the event that the Steering Committee is unable to reach
agreement, the issue in dispute shall be referred to an "OVERSIGHT COMMITTEE"
consisting of the Executive Vice President, Discovery Research of the
Schering-Plough Research Institute (an Affiliate of Schering) and NeoGenesis'
Chief Executive Officer, or their respective designees, for resolution. If the
disagreement is not resolved by the Oversight Committee within thirty (30) days,
then Schering shall have the right to make the final decision on such matter;
PROVIDED, that in the event and to the extent that any dispute concerns whether
or not budgeted FTE funding for the Screening Program has been expended in
accordance with the provisions of this Agreement such matter shall be resolved
using the procedure specified in Section 9.1.

     2.7  SELECTED COMPOUNDS.

          (a) From time to time during the term of this Agreement, Schering may
designate, by written notice to NeoGenesis, one or more Active Compounds and/or
Improved

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

Active Compounds identified by screening of the NeoMorph Screening Libraries
pursuant to Section 2.2 as Selected Compounds; provided, that at any given time
Schering may not designate Active Compounds and Improved Active Compounds
representing more than [*] different Chemotypes against a given Target from the
NeoMorph Screening Library. The parties acknowledge and agree that the foregoing
limitation does not apply to the NeoMorph Focused Libraries. [*] Selected
Compounds that Schering may designate from the NeoMorph Focused Libraries. With
respect to each Target, Schering shall use diligent efforts to identify and
designate at least one Selected Compound within [*] following Schering's receipt
of the Final Target Report for all screening against such Target in accordance
with Section 2.5(b) and ATTACHMENT A. In the event that the Schering does not
designate any Selected Compounds with respect to such Target, then upon
expiration of the applicable [*] period, Schering's right to designate Selected
Compounds with respect to such Target shall expire. If the NeoMorph Screening
Library is subsequently re-screened against a given Target pursuant to Section
2.1(e) and new Active Compounds and/or Improved Active Compounds are identified
as a result of such re-screening, then to the extent Schering's right to
designate Selected Compounds against such Target has previously expired,
Schering shall have a renewed right to designate Selected Compounds arising from
such re-screening on the same terms as set forth above.

          (b) Effective upon the date of receipt by NeoGenesis of notice from
Schering, pursuant to Section 2.7(a) that one or more Active Compounds and/or
Improved Active Compounds have been designated as Selected Compounds, NeoGenesis
grants to Schering an exclusive option to obtain the exclusive license provided
for in Article 3 with respect to such Selected Compounds and related Derivative
Compounds (including without limitation any Compounds contained in a NeoMorph
Focused Library prepared based upon such Selected Compound). The masking of the
Selected Compound(s) (and any Preliminary Compounds, Active Compounds and
Improved Active Compounds of the same Chemotype(s) as such Selected Compound(s))
from the NeoMorph Screening Library in accordance with Section 2.3 shall be
maintained during the applicable Option Period (as defined below). In addition,
within [*] following receipt of notification from Schering identifying Selected
Compounds, NeoGenesis shall amend ATTACHMENT B to identify any applicable
NeoGenesis Patent Rights not previously identified to Schering. The "OPTION
PERIOD" with respect to each Selected Compound identified pursuant to Section
2.7(a), shall extend until the later of: (i) the [*] anniversary of the
expiration of the Screening Program for the applicable Target, or (ii) in the
event that Schering is conducting an active internal medicinal chemistry
research program to identify Derivative Compounds based upon such Selected
Compound (as documented with written notice to NeoGenesis), a period of [*]
following the termination of such medicinal chemistry program. For purposes of
this Section 2.7(b), Schering shall be deemed to be conducting an active
medicinal chemistry program if at least [*] working full time on the design and
discovery of Derivative Compounds with respect to a given Selected Compound.
Schering shall provide NeoGenesis with written certification, [*] every [*],
during the performance of such medicinal chemistry program for purposes of
monitoring the expiration of the Option Period.

          (c) Schering shall have the right to exercise the option granted to it
under Section 2.7(b) with respect to one or more Selected Compounds (and related
Derivative Compounds, including without limitation any Compounds contained in a
NeoMorph Focused

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       16
<Page>

Library prepared based upon such Selected Compound) at any time prior to the
expiration of the applicable Option Period, by providing written notice to
NeoGenesis to that effect. The exclusive licenses granted to Schering pursuant
to Article 3 with respect to such Selected Compounds (and related Derivative
Compounds, including without limitation any Compounds contained in a NeoMorph
Focused Library prepared based upon such Selected Compound) shall become
effective upon NeoGenesis' receipt of such notice, and Schering shall pay the
applicable license fee under Section 4.2 to NeoGenesis within five (5) business
days of such notice. As of such date of such notice, the masking of the
applicable Selected Compound(s) (and related Derivative Compounds, including
without limitation any Compounds contained in a NeoMorph Focused Library
prepared based upon such Selected Compound), as well as any Preliminary
Compounds, Active Compounds and Improved Active Compounds of the same Chemotype
as such Selected Compound, from the NeoMorph Screening Library in accordance
with Section 2.3 shall become permanent, and during the term of this Agreement
NeoGenesis shall continue take such other steps as are reasonably necessary to
ensure that information with regard to the Selected Compounds and the relevant
Active Compounds, Improved Active Compounds and Preliminary Compounds of the
same Chemotype as such Selected Compounds are no longer available or accessible
to any third party.

          (d) In the event that Schering fails to exercise its option rights
with respect to one or more Selected Compounds prior to the expiration of the
applicable Option Period, then upon expiration of the Option Period Schering's
option right shall expire with respect to the applicable Selected Compound(s),
the licenses provided for in Article 3 with respect to such Selected Compound(s)
shall be void and of no further force or effect, and NeoGenesis shall be free to
unmask such Selected Compound(s) in the NeoMorph Screening Library.

          (e) In the event that during the applicable Option Period, one or more
Selected Compounds with respect to a given Target become Designated Compounds
and Schering has not, as of the effective date of such designation, exercised
the option and paid the license fee due under section 4.2 with respect to
Selected Compounds against such Target, then the license fee shall be paid
concurrently with the milestone payment due upon designation of such Designated
Compounds in accordance with Section 2.8.

          (f) Schering shall not begin screening any Selected Compound or
related Derivative Compounds against any biological targets other than Targets
until such time as it has exercised its option in accordance with Section 2.7(c)
and paid the applicable licensee fee.

     2.8  PRODUCT DEVELOPMENT.

          (a) During the term of this Agreement, Schering shall, at its expense,
conduct a research and development program to evaluate Selected Compounds and
Derivative Compounds as potential candidates for commercial development as
Licensed Products. Such efforts may include the performance of further medicinal
chemical research based upon such Selected Compounds and Derivative Compounds,
as well as biological, pharmacokinetic and toxicology studies and other
preclinical research activities. Schering shall have sole discretion

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       17
<Page>

over the scope of such research and development program, and the selection of
which Selected Compounds and Derivative Compounds will be the focus of such
activities.

          (b) Schering shall notify NeoGenesis in writing in the event that
Schering, in its sole discretion (based on Schering's good faith evaluation of
the satisfaction of the applicable Success Criteria by such Selected Compound or
Derivative Compound), decides to proceed with a development program for any
Selected Compounds or Derivative Compounds as suitable candidates for drug
development (thereafter, each a "DESIGNATED COMPOUND"). A Selected Compound or
Derivative Compound will be deemed to be a Designated Compound upon the earlier
of that date on which (i) Schering (or its Affiliate) formally approves
proceeding with full development of such Compound, or (ii) Schering (or its
Affiliate) initiates IN VIVO toxicology trials necessary, and meeting U.S. FDA
(or corresponding European or Japanese) standards, for obtaining approval for
use of such Compound in human clinical trials, unless Schering sooner designates
such Selected Compound or Derivative Compound as a Designated Compound with
notice to NeoGenesis. Upon Schering's designation of a Designated Compound,
Schering shall thereafter, at its expense, use Commercially Reasonable Efforts
to develop and commercialize Licensed Products incorporating the Designated
Compound in the Territory. Schering shall be solely responsible for determining
in which countries in the Territory to develop and commercialize each Licensed
Product, provided that it shall use Commercially Reasonable Efforts to obtain
Regulatory Approval and to market and sell each Licensed Product in the Major
Market Countries.

          (c) Subject to Schering's diligence obligations under this Agreement,
the Parties acknowledge and agree that all business decisions regarding
research, development and commercialization of Designated Compounds and Licensed
Products including, without limitation, decisions relating to the design,
development, manufacture, sale, price, distribution, marketing and promotion of
Licensed Products under this Agreement, and the decision of whether to develop a
particular Designated Compound, or to develop and commercialize a particular
Licensed Product, shall be within the sole discretion of Schering.

          (d) Schering shall have no quotas or other minimum diligence
obligations with regard to the number of Designated Compounds and/or Licensed
Products to be developed and commercialized hereunder. The parties acknowledge
and agree that so long as Schering is using Commercially Reasonable Efforts to
discover, develop and commercialize [*] Licensed Product in the Territory,
Schering shall be deemed to be in compliance with its diligence obligations
under this Agreement.

     2.9 COMMERCIALIZATION OF LICENSED PRODUCTS. With respect to each Licensed
Product developed and commercialized by Schering, or its designated Affiliates,
under this Agreement, Schering shall be solely responsible, at its sole expense,
for all aspects of the development and commercialization of the Licensed Product
in the Territory, including, without limitation:

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       18
<Page>

     (i)  the manufacture of Designated Compounds and Licensed Products in
          accordance with the applicable Regulatory Approvals, laws, Good
          Laboratory Practices and Good Manufacturing Practices;

     (ii)  preparation, filing, obtaining, maintaining and supporting, in its
           own name or that of its designated Affiliate, with the appropriate
           regulatory authorities of all regulatory approvals, authorizations,
           permits and licenses (including, without limitation, all Regulatory
           Approvals) that are necessary to conduct clinical studies of Licensed
           Products and/or to manufacture, import, distribute, market and sell
           Licensed Products;

     (iii) the reporting all adverse events associated with any Licensed Product
           to the appropriate regulatory authorities in accordance with
           applicable laws, rules and regulations in the Territory; and

     (iv)  the distribution, marketing, promotion and sale of Licensed Products.

Following the expiration of the Screening Program, Schering shall provide
NeoGenesis with semi-annual reports summarizing the status of Schering's
development and commercialization activities with respect to each Licensed
Product being developed under this Agreement. In addition, Schering shall notify
NeoGenesis in writing upon the filing of each application for Regulatory
Approval of a Licensed Product in the Territory.

     2.10 DILIGENCE EXCEPTIONS. All of Schering's diligence obligations
hereunder with respect to each Licensed Product being developed or
commercialized hereunder are expressly conditioned upon the continuing absence
of any adverse condition or event which warrants a delay in commercialization of
the Licensed Product due to an adverse condition or event relating to the safety
or efficacy of such Licensed Product or unfavorable pricing, pricing
reimbursement, labeling or lack of regulatory approval, and Schering shall have
no obligation to develop or market any such Licensed Product so long as in
Schering's reasonable opinion any such condition or event exists.

     2.11 THIRD PARTY LICENSES. Schering shall be solely responsible for (a)
obtaining any and all licenses from third parties necessary or desirable to
develop or commercialize any Licensed Product and (b) any and all consideration
payable with respect to such licenses. The decision as to whether or not to
obtain any such third party licenses relating to Licensed Products, and the
negotiation and acceptance of the terms and conditions for any such licenses,
shall be within the sole discretion and control of Schering, and nothing herein
shall be construed as obligating Schering to obtain any such third party
licenses.

     2.12 COMPLIANCE WITH LAW. Schering shall be responsible for ensuring that
all activities related to the development and commercialization of Licensed
Products conducted by or on its behalf are performed in compliance with all
applicable laws, rules and regulations (including, but not limited to, those
related to occupational safety and health, public safety and

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

health, protecting the environment, the disposal of wastes, Good Clinical
Practices, Good Laboratory Practices and Good Manufacturing Practices, as
applicable).

3.   LICENSES; INTELLECTUAL PROPERTY RIGHTS

     3.1 LICENSE TO LICENSED PRODUCTS. NeoGenesis hereby grants to Schering, and
Schering hereby accepts, an exclusive (even as to NeoGenesis), right and license
in the Territory and within the Field under the NeoGenesis Patent Rights and to
use the NeoGenesis Know-How to make, have made, use, distribute, promote,
market, offer for sale, sell, import and export Licensed Products. The licenses
granted to Schering under this Section 3.1 include the right to grant
sublicenses to Affiliates or third parties in accordance with the provisions of
Section 3.3. Schering shall mark or have marked all containers or packages of
Licensed Products that are the subject of the license granted under this Section
3.1 in accordance with the patent marking laws of the jurisdiction in which such
Licensed Products are manufactured, used or sold. For purposes of clarity and
avoidance of doubt, it is acknowledged that the exclusive licenses granted
hereunder shall not be construed as encompassing Compounds other than Selected
Compounds (and Active Compounds, Improved Active Compounds and Preliminary
Compounds of the same Chemotype as such Selected Compounds), Derivative
Compounds and Designated Compounds.

     3.2 LICENSE TO COMPOUNDS. NeoGenesis hereby grants to Schering, and
Schering hereby accepts, an exclusive (even as to NeoGenesis), right and license
in the Territory and within the Field under the NeoGenesis Patent Rights and to
use the NeoGenesis Know-How to research, develop, make, have made, import,
export and use the Selected Compounds (and Active Compounds, Improved Active
Compounds and Preliminary Compounds of the same Chemotype as such Selected
Compounds), Designated Compounds and Derivative Compounds, for research purposes
and to develop Licensed Products. The licenses granted to Schering under this
Section 3.2 include the right to grant sublicenses to Affiliates or third
parties in accordance with the provisions of Section 3.3. Schering shall mark or
have marked all containers or packages of Selected Compounds Derivative
Compounds and Designated Compounds that are the subject of the license granted
under this Section 3.1 in accordance with the patent marking laws of the
jurisdiction in which such Selected Compounds, Derivative Compounds and
Designated Compounds are manufactured, used or sold.

     3.3 SUBLICENSING. Schering's shall have the right to grant sublicenses
under this Agreement to third parties and/or Affiliates; provided that all such
sublicenses shall be consistent with the terms and conditions of this Agreement,
and in particular shall include provisions to ensure that such sublicense is
subject to the obligations set forth in Section 3.1(last sentence), 4.4, 4.5,
4.6, 4.7 and 8.3(b) (last sentence) of this Agreement. Schering shall remain
responsible to NeoGenesis for all of its sublicensees financial and other
obligations under this Agreement. Schering's sublicensees shall have no further
right to grant sublicenses, and any sublicense granted by Schering under this
Agreement shall not be assigned, transferred or otherwise conveyed by the
sublicensee to any third party, as a matter of law or through any action by
sublicensee, without the prior written consent of NeoGenesis.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       20
<Page>

     3.4  RETAINED RIGHTS.

          (a) Title to the NeoGenesis Know-How and NeoGenesis Patent Rights
shall at all times remain vested in NeoGenesis, and this Agreement does not
convey to Schering any ownership rights or other interest in any NeoGenesis
Know-How or NeoGenesis Patent Rights, by implication, estoppel or otherwise,
except for those rights and licenses expressly granted under this Agreement.

          (b) Title to the Schering Know-How and Schering Patent Rights shall at
all times remain vested in Schering, and this Agreement does not convey to
NeoGenesis any ownership rights or other interest in any Schering Know-How or
Schering Patent Rights, by implication, estoppel or otherwise, except for the
rights and licenses expressly granted under this Agreement.

          (c) The parties acknowledge and agree that notwithstanding the
exclusive licenses granted to Schering hereunder, with respect to the NeoGenesis
Know-How and NeoGenesis Patent Rights, NeoGenesis shall retain the right to
continue to use its NeoMorph Screening Library to screen target proteins (other
than Targets) for third parties; PROVIDED that NeoGenesis complies with all of
its obligations with respect to the masking of Preliminary Compounds, Active
Compounds, Improved Active Compounds and Selected Compounds from the NeoMorph
Screening Library.

     3.5  INVENTIONS.

          (a) Title to and ownership of all Inventions directly related to (i)
Selected Compounds, Derivative Compounds, Designated Compounds and Licensed
Products, or the manufacture or use thereof, or (ii) Targets provided to
NeoGenesis by Schering, in each case regardless of inventorship, as well as
those Inventions subject to Section 3.5(b)(ii), shall be the sole property of
Schering (hereinafter "SCHERING INVENTIONS") and are included in Schering
Know-How and/or Schering Patent Rights, as the case may be. NeoGenesis hereby
assigns and agrees to assign to Schering all of NeoGenesis' right, title and
interest in such Schering Inventions; such assignment to take effect with
respect to particular Selected Compounds (and related Derivative Compounds,
Designated Compounds and Licensed Products) upon the date NeoGenesis receives
notice from Schering pursuant to Section 2.7(c) that Schering has decided to
exercise its option to exclusively license the Selected Compounds and related
Derivative Compounds; and NeoGenesis shall use Commercially Reasonable Efforts
to perfect such assignment (at Schering's expense). Title to and ownership of
all Inventions directly related to the NeoMorph Screening Library, ALIS
screening technology or QSCD (regardless of inventorship), as well as those
Inventions subject to Section 3.5(b)(i) (hereinafter "NEOGENESIS INVENTIONS"),
shall be the sole property of NeoGenesis and are included in NeoGenesis Know-How
and/or NeoGenesis Patent Rights, as the case may be. Schering hereby assigns and
agrees to assign to NeoGenesis, all of Schering's right title and interest (if
any) in such NeoGenesis Inventions and Schering shall use Commercially
Reasonable Efforts to perfect such assignment (at the NeoGenesis' expense).

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       21
<Page>

          (b) Title to and ownership of all other Inventions arising from the
Screening Program and which are not covered by Section 3.5(a) shall be
determined as follows:

          (i)   Inventions made solely by one or more employees or agents of
                NeoGenesis shall be the sole property of NeoGenesis are
                NeoGenesis Inventions and are included in NeoGenesis Know-How
                and/or NeoGenesis Patent Rights, as the case may be.

          (ii)  Inventions made solely by one or more employees or agents of
                Schering shall be the sole property of Schering, are Schering
                Inventions, and are included in Schering Know-How and/or
                Schering Patent Rights, as the case may be.

          (iii) Inventions made jointly by one or more employees or agents of
                NeoGenesis and one or more employees or agents of Schering shall
                be the joint property of NeoGenesis and Schering (hereinafter
                "JOINT INVENTIONS").

In determining each party's contribution to Inventions arising under this
Agreement, inventorship shall be determined in accordance with United States
patent law.

     3.6  PATENT PROTECTION FOR INVENTIONS. Each of NeoGenesis and Schering
shall promptly disclose to the other knowledge of any Inventions arising in
connection with the Screening Program. Responsibility for the preparation,
filing, prosecution and maintenance of any patent applications and patents
claiming such Inventions shall be determined based upon ownership of the
Inventions and shall be handled in accordance with the provisions of this
Section 3.6. Within forty five (45) days following disclosure of any
Invention(s), the parties shall classify such Invention as a Schering Invention,
a NeoGenesis Invention or a Joint Invention and shall update ATTACHMENT C to add
such Invention and reflect such classification.

          (a) NeoGenesis shall have the right and responsibility to prepare,
file, prosecute, and maintain all patent applications and patent within the
NeoGenesis Patent Rights throughout the Territory at NeoGenesis sole expense,
including, without limitation, those with respect to NeoGenesis Inventions.
NeoGenesis shall have sole discretion as to all such activities with regard to
the NeoGenesis Patent Rights. NeoGenesis shall keep Schering currently advised
as to the status of all patents and patent applications with respect to the
NeoGenesis Patent Rights and shall supply Schering promptly with copies of all
patents, patent applications, substantive patent office actions, substantive
responses received or filed in connection with such applications. Schering may
offer comments and suggestions with respect to the matters that are the subject
of this Section 3.6(a) and NeoGenesis agrees to consider such comments and
suggestions; PROVIDED that nothing herein shall obligate NeoGenesis to adopt or
follow such comments or suggestions. In the event that NeoGenesis elects not to
file for patent protection for any NeoGenesis Inventions or elects not to
continue to prosecute or maintain a patent or patent application under the
NeoGenesis Patent Rights it shall notify Schering of such decision at least
forty-five (45) days prior to the due date of any action or payment due with
respect thereto.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       22
<Page>

Schering shall have the right, but not the obligation to assume the
responsibility therefor at its own cost and expense.

          (b) Schering and NeoGenesis, acting through the Steering Committee,
shall select and retain patent counsel mutually acceptable to each of them for
the purpose of preparing, prosecuting, issuing and maintaining appropriate
patent applications concerning Joint Inventions. NeoGenesis, in consultation
with Schering, shall be primarily responsible for the preparation, filing
(including foreign filing decisions), prosecution and maintenance of such patent
applications and patents relating to Joint Inventions. NeoGenesis shall furnish
or have furnished to Schering copies of documents relevant to the same and
provide Schering with the opportunity to review and comment on patent decisions
made by patent counsel. Any disagreements between NeoGenesis and Schering with
respect to preparation, filing, prosecution, issuance and maintenance matters
will be discussed and resolved to their mutual satisfaction using the procedures
specified in Section 9.1, if necessary; PROVIDED, that to the extent that any
disagreement regards only the costs associated with a particular proposed
action, NeoGenesis may assume responsibility for such costs and the requirement
that the parties mutually agree upon resolution of the matter shall not apply.
Each party shall be responsible for fifty percent (50%) of all expenses
associated with the preparation, filing, prosecution, issuance and maintenance
of patents or other intellectual property protection for Joint Inventions. In
the event that either party elects not to pursue a particular action with
respect to which the parties disagree regarding costs, the other party shall
have the right to assume such costs and to have such action taken; PROVIDED
FURTHER that the non-paying party's licenses hereunder shall exclude any
intellectual property rights that are the subject of such action (e.g., patent
coverage in a particular country) unless and until such party reimburses the
other party for one-half (50%) of the costs of such action.

          (d) Schering shall have the sole right, but not the obligation, to
file, prosecute, and maintain, at Schering's sole expense, each of the Schering
Patent Rights throughout the Territory. Upon request, and at Schering's expense,
NeoGenesis will provide Schering with reasonable assistance to prepare, file,
prosecute, maintain and defend the Schering Patent Rights, and will take all
steps necessary to enable Schering to perfect its rights and title to the
Schering Patent Rights with respect to any Schering Inventions. Reasonable
assistance shall include, without limitation, providing Schering any data and
information relating to such Schering Inventions and access to the NeoGenesis
employees who are inventors of such Schering Inventions, as well as causing the
execution of any patent assignment or other documents.

     3.7  ENFORCEMENT. Each party shall promptly notify the other of its
knowledge of any actual or potential infringement of the NeoGenesis Patent
Rights, the Schering Patent Rights or any Joint Inventions.

          (a) NeoGenesis shall be solely responsible for defense and enforcement
of NeoGenesis Know-How and NeoGenesis Patent Rights. Schering shall be solely
responsible for the defense and enforcement of Schering Know-How and Schering
Patent Rights. In the event that either party recovers any sums in such
litigation by way of damages or in settlement thereof, such party shall have the
right to retain all such sums; PROVIDED that any recovery of ordinary

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

damages by Schering to the extent based upon third party sales of products that
infringe upon Compound Patent Rights shall be deemed to be Net Sales and
Schering shall pay NeoGenesis an amount calculated in accordance with Section
4.4 to reimburse NeoGenesis for royalties due on lost sales of Licensed Product
represented by such ordinary damages; PROVIDED FURTHER that this allocation
shall not apply with respect to special or punitive damages, and that Schering
shall be entitled to deduct all litigation costs incurred by it in connection
therewith from such settlement or award prior to calculating such royalties.

          (b) Schering shall have the first option to pursue any enforcement or
defense of any patents claiming Joint Inventions within the Field and the
Territory ("JOINT PATENT RIGHTS"); PROVIDED, that Schering pays all costs and
expenses related thereto. Schering shall have three (3) months from the date it
receives notice of such infringement to obtain a discontinuance of such
infringement or bring suit against the third party infringer. Schering shall
keep NeoGenesis reasonably informed of the status of such activities. NeoGenesis
shall provide reasonable assistance to Schering in any suit for infringement of
a Joint Patent Right brought by Schering against a third party, and shall have
the right to consult with Schering and to participate in and be represented by
independent counsel in such litigation at its own expense. For purposes of this
Section 3.7(b), reasonable assistance shall mean providing Schering reasonable
access to information, materials and NeoGenesis personnel which Schering
reasonably determines is necessary to enable Schering to conduct the suit.
Schering shall periodically reimburse NeoGenesis for its out-of-pocket costs
(excluding the costs of retaining independent counsel) incurred in cooperating
with Schering. Schering shall incur no liability to NeoGenesis as a consequence
of such litigation or any unfavorable decision resulting therefrom, including
any decision holding any of the Joint Patent Rights invalid or unenforceable. In
the event that Schering recovers any sums in such litigation by way of damages
or in settlement thereof, Schering shall have the right to retain all such sums;
PROVIDED that any recovery of ordinary damages to the extent based upon third
party sales of products that infringe upon the Joint Patent Rights shall be
deemed to be Net Sales and Schering shall pay NeoGenesis an amount calculated in
accordance with Section 4.4 to reimburse NeoGenesis for royalties due on lost
sales of Licensed Product represented by such ordinary damages; PROVIDED FURTHER
that this allocation shall not apply with respect to special or punitive damages
and that Schering shall be entitled to deduct all litigation costs incurred by
it in connection therewith from such settlement or award prior to calculating
such royalties.

          (c) If, after the expiration of the three (3) month period specified
in Section 3.6(b), Schering has not overcome the allegation of infringement,
obtained a discontinuance of such infringement, or brought suit against the
third party infringer, then, provided such infringement is substantial,
NeoGenesis shall have the right, but not the obligation, to bring suit against
such infringer under the Joint Patent Right, provided that NeoGenesis shall bear
all the expenses of such suit. Schering shall provide reasonable assistance to
NeoGenesis in any suit for infringement of a Joint Patent Right brought by
NeoGenesis against a third party, and shall have the right to consult with
NeoGenesis and to participate in and be represented by independent counsel in
such litigation at its own expense. For purposes of this Section 3.6(c),
reasonable assistance shall mean providing NeoGenesis reasonable access to
information, materials and Schering personnel which NeoGenesis reasonably
determines is necessary to enable NeoGenesis

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       24
<Page>

to conduct the suit. NeoGenesis shall periodically reimburse Schering for its
out-of-pocket costs (excluding the costs of retaining independent counsel)
incurred in cooperating with NeoGenesis. NeoGenesis shall incur no liability to
Schering as a consequence of such litigation or any unfavorable decision
resulting therefrom, including any decision holding any of the Joint Patent
Rights invalid or unenforceable. In the event that NeoGenesis recovers any sums
in such litigation by way of damages or in settlement thereof, NeoGenesis shall
have the right to retain all such sums.

          (d) Each party shall immediately give written notice to the other
of any certification of which it becomes aware filed pursuant to the
Waxman-Hatch Act (21 U.S.C. Section 355(b)(2)(A), or Section
355(j)(2)(A)(vii)), or any amendment or successor statute thereto, at least
fourteen (14) days prior to expiration of the forty five (45) day period set
forth in 21 U.S.C. Section 355(c)(3)(c) (or any amendment or successor
statute thereto).

          3.8 LIST OF NEOGENESIS PATENT RIGHTS. The NeoGenesis Patent Rights
exclusively licensed to Schering pursuant to Sections 3.1 and 3.2 shall be
listed in ATTACHMENT B, which shall be amended from time to time during the term
of this Agreement to reflect additions or changes to the NeoGenesis Patent
Rights in accordance with Section 2.7. For the avoidance of doubt, to the extent
that ATTACHMENT B is not updated to include any NeoGenesis Patent Rights that
are directly related to any Selected Compounds (and Active Compounds and
Improved Active Compounds of the same Chemotype as such Selected Compounds),
Designated Compounds, Derivative Compounds and/or Licensed Products within the
scope of an exclusive license granted to Schering under Sections 3.1 and 3.2,
NeoGenesis agrees that it shall not have any action against Schering in relation
thereto and shall automatically amend ATTACHMENT B to include such NeoGenesis
Patent Rights.

     4.   CONSIDERATION

          4.0 ADDITIONAL PAYMENT OBLIGATIONS. The parties acknowledge that
Schering's payment obligations as set forth in Sections 4.1, 4.2, 4.3 and 4.4 of
this Agreement are in addition to the payment obligations of Schering-Plough
Ltd. set forth in Sections 4.1, 4.2, 4.3 and 4.4 of the International Agreement.

          4.1 RESEARCH FUNDING. In consideration for the performance of the
Screening Program and activities related thereto by NeoGenesis, Schering shall
pay to NeoGenesis research funding during the term of the Screening Program at
the rate of [*] term of the Screening Program. Such payments constitute [*]
payment for FTEs at a rate of [*] per year per FTE, with [*] of such funding to
be paid by Schering-Plough Ltd. under the terms of the International Agreement.
The amount of such funding shall be based upon the actual number of FTEs
assigned by NeoGenesis to work on the Screening Program pursuant to Section
2.2(f), it being understood that except as otherwise agreed by the parties in
writing, research funding shall be paid based upon [*] FTEs. Research funding
shall be payable in equal quarterly installments during the term of the
Screening Program, with the first such payment due within [*] after the
Effective Date and each successive payment due quarterly in advance on the first
day of each calendar quarter starting on October 1, 2001. It is understood and
agreed by the parties that first

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       25
<Page>

two research funding payments due under this Agreement [*] represents payment
for work performed by NeoGenesis in connection with the Screening Program during
the entire 2001 calendar year, including activities performed during the period
extending from January 1, 2001 until the Effective Date. In the event that the
term of the Screening Program is extended, the FTE rate payable under this
Section 4.1 in each such extension year shall be increased by the CPI (as
defined below). If Schering is unwilling to provide funding for such documented
cost increases and the parties are unable to resolve such funding matter to
their mutual satisfaction within forty five (45) days then the Screening Program
shall not be extended for such extension year. If in any quarterly funding
period, actual expenditures by NeoGenesis with respect to FTE's exceed the
amount budgeted for the period, the overrun will be carried forward for the next
period and paid for from the next payment(s); PROVIDED, that Schering payment
obligations for any year of the Screening Program shall not exceed the budgeted
amount for such year unless Schering has agreed to fund additional FTE work
beyond that budgeted for such year by means of a written amendment to this
Agreement approved in writing by the parties. For purposes of this Section 4.1,
"CPI" means the Consumer Price Index for [*], as published by the Bureau of
Labor Statistics of the United States Department of Labor. In the event that the
Bureau of Labor Statistics ceases to publish the CPI or substantially changes
its content or format in a manner that precludes its further use hereunder,
Schering and NeoGenesis shall substitute therefor another comparable measure
published by an agreed-upon source.

     4.2  LICENSE FEES/EQUITY PURCHASE.

          (a) In partial consideration for the licenses and other rights granted
to Schering hereunder, Schering shall pay to NeoGenesis a license fee of [*]
with respect to each Target for which one or more Selected Compounds are
designated pursuant to Section 2.7. Each such license fee shall be payable
within [*] after the effective date of the licenses to such Selected Compounds,
as provided under Section 2.7(b). The license fee shall be payable [*],
irrespective of the number of Selected Compounds, Designated Compounds or
Licensed Products which may be identified and/or developed with respect thereto.
Payment of any license fees under this Section 4.2(a) shall be made concurrently
with payment of the corresponding license fees under Section 4.2(a) of the
International Agreement.

          (b) Schering agrees to subscribe for and purchase, and NeoGenesis
agrees to authorize and issue to Schering, an aggregate five million dollars and
thirty-seven cents ($5,000,000.37) worth of Series E (non-voting) Preferred
Stock, $.001 par value per share, at a price of five and 97/100's dollars
($5.97) per share. Such equity investment shall be made pursuant to a separate
Series E Preferred Stock Purchase Agreement containing mutually acceptable terms
(the "Stock Purchase Agreement"), which is attached hereto as ATTACHMENT F. Such
equity subscription shall be made within thirty (30) days following the
Effective Date unless the parties agree to extend the time for the consummation
of such subscription.

          (c) Effective as of the first anniversary of the Effective Date and
subject to the applicable laws rules and regulations that restrict the ability
of NeoGenesis to permit purchases of shares in connection with its initial
public offering ("IPO"), including any Securities and Exchange Commission
regulations, Schering shall have the option, exercisable in its sole

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       26
<Page>

discretion, to purchase from NeoGenesis, and in such event NeoGenesis shall sell
to Schering, additional shares of NeoGenesis common stock having an aggregate
value of five million dollars ($5,000,000). Such option may be exercised solely
in connection with NeoGenesis' IPO and shall be exercised at a price per share
for such Common Stock equal to the price at which such shares are offered to the
public in such initial public offering. The option set forth in this Section
4.2(c) shall expire and be of no further force or effect if: (i) NeoGenesis does
not complete an IPO by the third anniversary of the Effective Date or (ii) this
Agreement has been terminated prior to the completion of NeoGenesis' IPO.

     4.3  MILESTONES. In partial consideration for the licenses and other rights
granted to Schering hereunder, Schering shall pay to NeoGenesis the following
payments upon the occurrence of the indicated milestone event.

          (a) with respect to any Designated Compound (and any Licensed Products
based upon such Designated Compound) which is being developed based upon
activity with respect to a specific Target, and was discovered as a result of
optimization of one or more Lead Compounds by NeoGenesis pursuant to Section
2.2(b):

          (i)   [*] upon designation of such Designated Compound pursuant to
                Section 2.8;

          (ii)  [*] upon initiating treatment of the first patient in a Phase I
                clinical trial for the applicable Licensed Product under an
                approved IND (or its equivalent);

          (iii) [*] upon initiating treatment of the first patient in a Phase
                III clinical trial for the applicable Licensed Product;

          (iv)  [*] upon filing and acceptance of the first NDA (or its European
                or Japanese equivalent) for the applicable Licensed Product; and

          (v)   [*] upon receipt of the first Regulatory Approval for the
                applicable Licensed Product in a Major Market Country.

          (b) with respect to any Designated Compound (and any Licensed Products
based upon such Designated Compound) which is being developed based upon
activity with respect to a specific Target, but was not discovered as a result
of optimization of one or more Lead Compounds by NeoGenesis pursuant to Section
2.2(b):

          (i)   [*] upon designation of such Designated Compound pursuant to
                Section 2.8;

          (ii)  [*] upon initiating treatment of the first patient in a Phase I
                clinical trial for the applicable Licensed Product under an
                approved IND (or its equivalent);

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

          (iii) [*] upon initiating treatment of the first patient in a Phase
                III clinical trial for the applicable Licensed Product;

          (iv)  [*] upon filing and acceptance of the first NDA (or its European
                or Japanese equivalent) for the applicable Licensed Product; and

          (v)   [*] upon receipt of the first Regulatory Approval for the
                applicable Licensed Product in a Major Market Country.

          (c) All payments made to NeoGenesis by Schering pursuant to Section
4.3(a) or (b) shall be due within thirty (30) days after the achievement of the
corresponding milestone and shall be nonrefundable and not creditable against
other amounts due to NeoGenesis. The payments provided for under this Section
4.3 shall only be payable once upon the first achievement of the indicated
milestone with respect to Designated Compound and/or Licensed Product developed
against a particular Target and no additional payments shall be due on
subsequent or repeated achievement of the same milestone for another Designated
Compound and/or Licensed Product developed against the same Target. No
milestones shall be payable under this Section 4.3 with respect to (i) any
compounds or products other than Designated Compounds and Licensed Products, or
(ii) any Designated Compounds or Licensed Products being developed based upon
[*].

          (d) In the event that Schering ceases all clinical development for a
Designated Compound/Licensed Product (a "Discontinued Product") for which one or
more milestones have been paid pursuant to this Section 4.3, no payment shall be
due under this Section 4.3 with respect to the achievement of the same
milestone(s) with respect to the another Designated Compound or Licensed Product
discovered or developed against the same Target as the Discontinued Product (a
"Back-up Product"). In the event that the Back-up Product achieves milestones
which were not previously achieved by the relevant Discontinued Product, such
milestone payments will be paid in accordance with this Section 4.3.

     4.4  ROYALTIES. In partial consideration for the licenses and other rights
granted to Schering hereunder, Schering shall pay royalties to NeoGenesis based
upon Net Sales of Licensed Products in the Territory.

          (a) The royalties payable to NeoGenesis on Net Sales of Licensed
Products in the Territory by Schering, its Affiliates and sublicensees, shall be
determined as follows:

          (i)   [*] of Net Sales of Licensed Products in the Territory where the
                Designated Compound in such Licensed Product was discovered as a
                result of optimization of one or more Lead Compounds by
                NeoGenesis pursuant to Section 2.2(b); or

          (ii)  [*] of Net Sales of Licensed Products in the Territory where the
                Designated Compound in such Licensed Product was not discovered
                as a

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       28
<Page>

               result of optimization of one or more Lead Compounds by
               NeoGenesis pursuant to Section 2.2(b); or

          (iii) [*] of Net Sales of Licensed Products in the Territory where the
                Designated Compound in such Licensed Product is a Derivative
                Compound derived from an Selected Compound identified through
                Schering's screening of a Selected Compound against a target
                other than the specific Target(s) for which the Selected
                Compound was screened by NeoGenesis.

          (b) Starting with the First Commercial Sale of each Licensed Product
in the Territory, Schering shall provide NeoGenesis with quarterly reports of
Net Sales by country of each Licensed Product in the Territory. Each such
quarterly report shall be provided to NeoGenesis not later than sixty (60) days
following the close of the relevant calendar quarter, (i.e., following each
March 31, June 30, September 30 and December 31). Concurrently with the making
of such reports, Schering shall pay to NeoGenesis royalties due for such period
at the rates specified in Section 4.4(a). The report due for the quarter ending
December 31 of each year shall also include the aggregate royalties due
NeoGenesis for the entire year.

          (c) Schering's obligation to pay royalties with respect to each
Licensed Product shall expire on a country-by-country basis upon the later of
(i) the expiration (or revocation or complete rejection) of the last to expire
(or to be revoked or to be completely rejected) of any NeoGenesis Patent Right
and/or Compound Patent Right having a Valid Claim covering such Licensed Product
in the country, or (ii) ten (10) years from the First Commercial Sale of the
Licensed Product in such country. No royalties shall accrue on the disposition
of any Licensed Product in reasonable quantities by Schering, its Affiliates or
its sublicenses at no charge as samples (promotional or otherwise) or as
donations (for example, to non-profit institutions or government agencies for a
non-commercial purpose) or for clinical studies.

     4.5  REMITTANCE.

          (a) All royalties, milestone and other payments required under this
Article 4 shall be made by bank wire transfer in United States dollars in
immediately available funds to an account designated by NeoGenesis. Royalties
shall be deemed payable by the entity making the Net Sales from the country in
which earned in local currency and subject to foreign exchange regulations then
prevailing. Royalty payments shall be made in United States dollars to the
extent that free conversion to United States dollars is permitted. The rate of
exchange to be used in any such conversion from the currency in the country
where such Net Sales occurs shall be in accordance with the policy set forth in
ATTACHMENT D attached hereto.

          (b) In the event that any payment due NeoGenesis under this Agreement
is not made when due, the amount due shall accrue interest beginning on the
fifth day following the final date on which such payment was due, calculated at
the annual rate equal to two percent (2%) above the prime interest rate reported
in the WALL STREET JOURNAL for the due date, calculated

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       29
<Page>

from the due date until paid in full. Such payment when made shall be
accompanied by all interest so accrued.

          (c) If at any time legal restrictions or prohibitions imposed by
national or international authority prevent the conversion of the local currency
and such currency cannot be removed from such country such that prompt
remittance by Schering of any royalties owed by Schering to NeoGenesis in
respect of sales in such country is prevented, the parties shall consult with a
view to finding a prompt and acceptable solution, and Schering or its designated
Affiliates will make payment through any means as NeoGenesis may lawfully direct
at no additional out-of-pocket expense to Schering.. Notwithstanding the
foregoing, if royalties in any country cannot be remitted to NeoGenesis for any
reason within three (3) months after the end of the calendar quarter during
which they are earned, then Schering shall be obligated to pay NeoGenesis in the
local currency of such country and shall deposit the relevant royalties in a
bank account in such country designated by NeoGenesis and in the name of
NeoGenesis.

     4.6 RECORDS. Schering, its Affiliates and sublicensees shall keep and
maintain complete, true and accurate books of account and records (prepared in
accordance with United States Generally Accepted Accounting Principles,
consistently applied) sufficient to determine the amounts of Net Sales and any
royalty payments due with respect thereto. All such books and records shall be
maintained in accordance with Schering's records retention policies consistently
applied but for a period of at least thirty six (36) months from the date of
each payment of royalties.

     4.7 INSPECTION. Upon prior written notice Schering and its Affiliates
shall, within a period not to exceed forty-five (45) days, permit an independent
certified public accounting firm of nationally recognized standing selected by
NeoGenesis and reasonably acceptable to Schering, at NeoGenesis' expense, to
have access during regular business hours to examine pertinent books and records
of Schering and its Affiliates necessary to verify the accuracy of the royalty
reports and payments by Schering hereunder. The examination shall be limited to
pertinent books and records for any calendar year ending not more than
twenty-four (24) months prior to the date of such request. Such inspection right
shall not be exercised more than once in any calendar year. The accounting firm
employees shall sign confidentiality agreements reasonably acceptable to
Schering as a condition precedent to their inspection. Schering may designate
competitively sensitive information which such auditor may not disclose to
NeoGenesis; PROVIDED, HOWEVER, that such designation shall not encompass the
auditor's conclusions. The accounting firm shall disclose to NeoGenesis only
whether the royalty reports are correct or incorrect and the specific details
concerning any discrepancies. No other information shall be provided to
NeoGenesis. In the event that the accounting firm correctly concludes that a
variation or error has occurred resulting in an underpayment of royalties by
Schering of five percent (5%) or more of the amount actually due for the period
covered by the inspection, Schering shall pay to NeoGenesis in addition to such
underpayment, the costs relating to the inspection, within thirty (30) days of
receipt of an invoice for such amounts. Any overpayment of royalties by Schering
discovered through such audit shall be fully creditable against royalties
subsequently due hereunder. Schering shall include in each sublicense granted by
it pursuant to this Agreement a provision requiring the sublicensee to make
reports to Schering, to keep and maintain records of sales made

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       30
<Page>

pursuant to such sublicense and to grant access to such records by NeoGenesis'
independent accountant to the same extent required of Schering under this
Agreement. Upon expiration of the twenty-four (24) month period immediately
following the receipt by NeoGenesis of Schering's fourth quarter royalty report
for a given calendar year, the calculation of royalties payable with respect to
such year shall be binding and conclusive upon NeoGenesis, and Schering, its
Affiliates and its sublicensees shall be released from any liability or
accountability with respect to royalties for such year, except for instances of
fraud or other intentional misconduct.

     4.8 TAXES. If at any time, any jurisdiction within the Territory requires
the withholding of income taxes or other taxes imposed upon payments set forth
in this Article 4, Schering shall make such withholding payments as required and
subtract such withholding payments from the payments to be made to NeoGenesis as
set forth in this Article 4, or if applicable, NeoGenesis will promptly
reimburse Schering or its designee(s) of the amount of such withholding payments
that are not subtracted from the payments made to NeoGenesis as set forth in
this Article 4. Schering shall provide NeoGenesis with documentation of such
withholding and payment in a manner that is satisfactory for purposes of
reporting to the U.S. Internal Revenue Service. Any withholdings paid when due
hereunder shall be for the account of NeoGenesis. Withholding payments made by
Schering pursuant to this Section 4.8 shall be made based upon financial
information provided to Schering by NeoGenesis, and to the extent that such
information is incorrect, NeoGenesis shall be liable for any deficiency, and any
fine, assessment or penalty imposed by any taxing authority in the Territory for
any deficiency in the amount of any such withholding or the failure to make such
withholding payment. If Schering is required to pay any such deficiency, or any
fine, assessment or penalty for any such deficiency, NeoGenesis shall promptly
reimburse Schering for such payments.

5.   CONFIDENTIALITY

     5.1 PUBLICITY. Each of the parties hereto agrees not to disclose to any
third party the existence or the terms of this Agreement without the prior
written consent of the other party hereto. Notwithstanding the foregoing, the
parties may agree upon an initial press release to announce the execution of
this Agreement, together with a corresponding Q&A outline for use in responding
to inquiries about the Agreement. In the event of such agreed upon press
release, each party may thereafter disclose to third parties the specific
information contained in such press release and Q&A without the need for further
approval by the other party. Nothing in this Section 5.1 shall prohibit a party
from making such disclosures to the extent required under applicable federal or
state securities laws or any rule or regulation of any nationally recognized
securities exchange. In such event, however, the disclosing party shall use good
faith efforts to notify and consult with the other party prior to such
disclosure and, where applicable, shall diligently seek confidential treatment
to the extent such treatment is available under applicable securities laws.

     5.2  CONFIDENTIALITY.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       31
<Page>

          (a)  Confidential Information received by one party (the "RECEIVING
PARTY") from the other party (the "DISCLOSING PARTY") in connection with this
Agreement will be used by the Receiving Party solely for the performance of the
Screening Program or as otherwise expressly permitted by this Agreement. All
Confidential Information will be received and held in confidence by the
Receiving Party, and shall not be disclosed to any third party without the prior
written consent of the Disclosing Party. Each party acknowledges that, except as
expressly set forth herein, it will not obtain any rights of any sort in or to
the Confidential Information of the Disclosing Party as a result of such
disclosure.

          (b)  The Receiving Party will restrict disclosure of the Disclosing
Party's Confidential Information to those of the Receiving Party's and its
Affiliates' employees, officers, directors, consultants and agents to whom it is
necessary to disclose such Confidential Information in connection with the
performance of its obligations under this Agreement. The Receiving Party shall
use all reasonable efforts, which shall be at least fully commensurate with
those employed by the Receiving Party for the protection of its own Confidential
Information, to protect the Confidential Information of the Disclosing Party.

          (c)  The confidentiality and use restrictions set forth in this
Article 5 shall not apply to Confidential Information to the extent such
information:

               (i)   was already known to the Receiving Party, other than under
                     an obligation of confidentiality, at the time of
                     disclosure;

               (ii)  was generally available to the public or otherwise part of
                     the public domain at the time of its disclosure to the
                     Receiving Party;

               (iii) became generally available to the public or otherwise part
                     of the public domain after its disclosure and other than
                     through any act or omission of the Receiving Party in
                     breach of this Agreement;

               (iv)  was independently developed by the Receiving Party without
                     the aid, application or use of the Disclosing Party's
                     Confidential Information, as demonstrated by documented
                     evidence prepared contemporaneously with such independent
                     development; or

               (v)   was subsequently lawfully disclosed to the Receiving Party,
                     other than under a duty of confidentiality, by a third
                     party that had the right to make such disclosure.

          (d)  Each party hereto may use or disclose Confidential Information
disclosed to it by the other party to the extent (i) such use or disclosure is
reasonably necessary and permitted in the exercise of the rights granted
hereunder in filing or prosecuting patent applications and prosecuting or
defending litigation, (ii) such disclosure is reasonably required to be made to
any institutional review board of any entity conducting clinical trials with
Designated

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       32
<Page>

Compound(s) and/or Licensed Product(s), or to any governmental or other
regulatory agency, in order to gain approval to conduct clinical trials or to
market Designated Compound(s) and/or Licensed Products, (iii) such disclosure is
required by law, regulation, rule, act or order of any governmental authority,
court, or agency, or is made in connection with submitting required information
to tax or other governmental authorities, or (iv) such disclosure or use is
reasonably required in conducting clinical trials, or making a permitted
sublicense or otherwise exercising license rights expressly granted to it by the
other party pursuant to the terms of this Agreement; in each case, provided that
if the Receiving Party is required to make any such disclosure of the Disclosing
Party's Confidential Information, other than pursuant to a confidentiality
agreement, it will give reasonable advance notice to the Disclosing Party of
such disclosure and, except to the extent inappropriate in the case of patent
applications, will use its reasonable diligent efforts to secure confidential
treatment of such Confidential Information in consultation with the Disclosing
Party prior to its disclosure (whether through protective orders or otherwise)
and disclose only the minimum necessary to comply with such requirements.

          (e)  Following the termination of this Agreement, or at any time upon
written request by the Disclosing Party, the Receiving Party shall promptly
return to the Disclosing Party all of the Disclosing Party's Confidential
Information, including all copies thereof, in its possession; provided that the
Receiving Party's legal counsel may retain one (1) copy of the Disclosing
Party's Confidential Information in a secure location solely for the purpose of
determining its obligations under this Agreement.

     5.3  PUBLICATION. Each of Schering and NeoGenesis acknowledges the other
party's interest in publishing its results to obtain recognition within the
scientific community and to advance the state of scientific knowledge. Each
party also recognizes the mutual interest in obtaining valid patent protection
and in protecting business interests and trade secret information. Consequently,
either party, its Affiliates, employees or consultants wishing to make a
publication relating to the results of the Screening Program shall deliver to
the other party a copy of the proposed written publication or an outline of an
oral disclosure at least sixty (60) days prior to submission for publication or
presentation. For purposes of this Agreement, the term "publication" shall
include, without limitation, abstracts and manuscripts for publication, slides
and texts of oral or other public presentations, and texts of any transmission
through any electronic media, any computer access system such as the internet,
world wide web, or similar medium. The reviewing party shall have the right to
(i) propose modifications to the publication for patent reasons, trade secret
reasons or business reasons or (ii) delay the publication or presentation in
order to protect patentable information. If the reviewing party requests a
delay, the publishing party shall delay submission or presentation for a period
not to exceed eighteen (18) months from the filing date of the first patent
application covering the information contained in the proposed publication, or
shall modify such Publication to eliminate such patentable information. If the
reviewing party requests modifications to the publication, the publishing party
shall edit such publication to prevent disclosure or trade secret or proprietary
business information prior to submission of the publication or presentation.

6.   REPRESENTATIONS AND WARRANTIES.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       33
<Page>

     6.1  REPRESENTATIONS AND WARRANTIES OF EACH PARTY. Each of NeoGenesis
and Schering hereby represents, warrants and covenants to the other party
hereto as follows:

          (a)   it is a corporation or entity duly organized and validly
existing under the laws of the state or other jurisdiction of its incorporation
or formation;

          (b)  the execution, delivery and performance of this Agreement by such
party has been duly authorized by all requisite corporate action;

          (c) it has the power and authority to execute and deliver this
Agreement and to perform its obligations hereunder;

          (d) the execution, delivery and performance by such party of this
Agreement and its compliance with the terms and provisions hereof does not and
will not conflict with or result in a breach of any of the terms and provisions
of or constitute a default under (i) a loan agreement, guaranty, financing
agreement, agreement affecting a product or other agreement or instrument
binding or affecting it or its property; (ii) the provisions of its charter or
operative documents or bylaws; or (iii) any order, writ, injunction or decree of
any court or governmental authority entered against it or by which any of its
property is bound;

          (e) except for the governmental and regulatory approvals required to
market the Licensed Product(s), the execution, delivery and performance of this
Agreement by such party does not require the consent, approval or authorization
of, or notice, declaration, filing or registration with, any governmental or
regulatory authority and the execution, delivery or performance of this
Agreement will not violate any law, rule or regulation applicable to such party;

          (f) this Agreement has been duly authorized, executed and delivered
and constitutes such party's legal, valid and binding obligation enforceable
against it in accordance with its terms subject, as to enforcement, to
bankruptcy, insolvency, reorganization and other laws of general applicability
relating to or affecting creditors' rights and to the availability of particular
remedies under general equity principles; and

          (g) it shall comply with all applicable material laws and regulations
relating to its activities under this Agreement.

     6.2  NEOGENESIS' REPRESENTATIONS. NeoGenesis hereby represents, warrants
and covenants to Schering as follows:

          (a) to the best of NeoGenesis' knowledge, as of the Effective Date,
NeoGenesis is the sole and exclusive owner of the NeoMorph Screening Library,
the NeoGenesis Patent Rights and the NeoGenesis Know-How free and clear of all
liens, charges and encumbrances and no other person, corporate or other private
entity, or governmental entity or subdivision thereof, has or shall have any
claim of ownership with respect thereto;

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       34
<Page>

          (b) as of the Effective Date it has the full right, power and
authority to grant all of the right, title and interest in the licenses and
other rights granted to Schering under this Agreement;

          (c) to the best of NeoGenesis' knowledge, as of the Effective Date the
NeoMorph Screening Library, NeoGenesis Patent Rights and NeoGenesis Know-How,
and the use thereof in performance of the Screening Program as contemplated
hereunder, do not infringe on any intellectual property rights owned or
possessed by any third party;

          (d) during the term of this Agreement, NeoGenesis shall not grant or
attempt to grant any licenses, options or other rights to any third party that
are contrary to or otherwise inconsistent with the licenses and other rights
granted to Schering hereunder;

          (e) as of the Effective Date there are no claims, judgments or
settlements against or owed by NeoGenesis or pending or, to the best of
NeoGenesis' knowledge, threatened claims or litigation against NeoGenesis
relating to the NeoMorph Screening Library, NeoGenesis Patent Rights and
NeoGenesis Know-How;

          (f) as of the Effective Date, it is in compliance in all material
respects with any agreements with third parties, and during the term of this
Agreement (i) it will use diligent efforts not to diminish the rights under the
NeoGenesis Patent Rights and NeoGenesis Know-How granted to Schering hereunder,
including without limitation, by not committing or permitting any actions or
omissions which would cause the breach of any agreements between itself and
third parties which provide for intellectual property rights applicable to the
performance of the Screening Program, and (ii) it will provide Schering promptly
with notice of any such alleged breach; and

          (g) during the term of this Agreement it will not use in any capacity,
in connection with any activities to be performed under this Agreement, any
individual who has been debarred pursuant to the United States Food, Drug and
Cosmetic Act.

     6.3  SCHERING'S REPRESENTATIONS. Schering hereby represents, warrants and
covenants to NeoGenesis as follows:

          (a)  during the term of this Agreement it will not use in any
capacity, in connection with any services to be performed under this Agreement,
any individual who has been debarred pursuant to the United States Food, Drug
and Cosmetic Act;

          (b)  to the best of Schering's knowledge, as of the Effective Date it
is the sole and exclusive owner or licensee of the Schering Patent Rights and
the Schering Know-How, all of which is free and clear of any liens, charges and
encumbrances, and no other person, corporate or other private entity, or
governmental entity or subdivision thereof, has or shall have any claim of
ownership with respect thereto;

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       35
<Page>

          (c) to the best of Schering's knowledge, as of the Effective Date it
is the owner of the Targets and any other tangible materials to be provided to
NeoGenesis hereunder for use in the Screening Program;

          (d) to the best of Schering's knowledge, as of the Effective Date, the
use of the Targets in performance of the Screening Program as contemplated
hereunder, does not infringe a valid and enforceable claim of any issued U.S.
patent owned or possessed by any third party; and

          (e) as of the Effective Date, there are no claims, judgments or
settlements against or owed by Schering or pending or, to the best of Schering's
knowledge, threatened claims or litigation against Schering relating to the
Schering Patent Rights and Schering Know-How.

     6.4  DISCLAIMER.

          (a) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS 6.1-6.3,
NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER EXPRESS OR
IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY WARRANTY
AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL PROPERTY
RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR A
PARTICULAR PURPOSE WITH RESPECT TO THE NEOMORPH SCREENING LIBRARY, THE NEOMORPH
FOCUSED LIBRARIES, QSCD, THE COMPOUNDS, THE ACTIVE COMPOUNDS, THE IMPROVED
ACTIVE COMPOUNDS, THE SELECTED COMPOUNDS, THE DESIGNATED COMPOUNDS, THE TARGETS,
THE LICENSED PRODUCTS, THE NEOGENESIS KNOW-HOW, THE SCHERING KNOW-HOW, THE
SCOPE, VALIDITY OR ENFORCEABILITY OF THE NEOGENESIS PATENT RIGHTS OR THE
SCHERING PATENT RIGHTS, OR SUCH PARTY'S OBLIGATIONS UNDER THIS AGREEMENT.

          (b) THE REPRESENTATIONS AND WARRANTIES OF EACH OF NEOGENESIS AND
SCHERING EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY
CLAIM OR DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT
PROVIDED IN SECTIONS 7.2-7.3.

7.   INDEMNIFICATION.

     7.1 INDEMNIFICATION BY SCHERING. Schering shall indemnify, defend and hold
harmless NeoGenesis and its Affiliates, and each of its and their respective
employees, officers, directors and agents from and against any and all
liability, loss, claims, damage, cost, and expense (including reasonable
attorneys' fees) arising out of or in connection with third party claims
relating to (i) the discovery, development, manufacture, use, testing,
marketing, sale or

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       36
<Page>

other disposition of Designated Compounds and/or Licensed Products by or on
behalf of Schering or its Affiliates or sublicensees, (ii) performance of the
Screening Program by Schering, (iii) the use of any and all Targets with respect
to which screening or other research activities are conducted in the Screening
Program, or (iv) any breach by Schering of its representations and warranties
under this Agreement, except, in each case, to the extent such liability, loss,
claims, damage, cost or expense is caused by the negligence or willful
misconduct of NeoGenesis, its Affiliates, or any of their respective employees,
officers, directors or agents.

     7.2 INDEMNIFICATION BY NEOGENESIS. NeoGenesis shall indemnify, defend and
hold harmless Schering and its Affiliates, and each of its and their respective
employees, officers, directors and agents from and against any and all
liability, loss, claims, damage, cost, and expense (including reasonable
attorneys' fees) arising out of or in connection with third party claims
relating to (i) the performance of the Screening Program by NeoGenesis, except
to the extent directly related to the use of Targets provided by Schering, (ii)
any breach of NeoGenesis' contractual obligations to third parties, or (iii) any
breach by NeoGenesis of its representations and warranties made under this
Agreement, except, in each case, to the extent such liability, loss, claims,
damage, cost, and expense is caused by the negligence or willful misconduct of
Schering, its Affiliates, or any of their respective employees, officers,
directors or agents.

     7.3 PROCEDURE. As a condition to the indemnification provided for under
Sections 7.1 and 7.2, the indemnified party shall promptly notify the party from
whom indemnification is sought (the "INDEMNIFYING PARTY") in writing of any
claim or suit; PROVIDED, that failure to give such notice shall not relieve
Indemnifying Party of its indemnification obligations under this Article 7,
except to the extent such failure actually and materially prejudices the rights
of Indemnifying Party to defend against such claim or suit. The Indemnifying
Party shall have the right to assume the defense of any suit or claim related to
the liability if it has assumed responsibility for the suit or claim in writing;
however, if in the reasonable judgment of the indemnified party, such suit or
claim involves an issue or matter which could have a materially adverse effect
on the business operations or assets of the indemnified party, the indemnified
party may retain control of the defense or settlement thereof by providing
written notice of such effect to the Indemnifying Party, but in no event shall
such action or notice be construed as a waiver of any indemnification rights
that the indemnified party may have at law or in equity. If the Indemnifying
Party defends the suit or claim, the indemnified party may participate in (but
not control) the defense thereof at its sole cost and expense. If Indemnifying
Party elects to compromise or defend a claim that is the subject of this Article
7, it shall notify the indemnified party of its decision within thirty (30) days
after delivery of the notice described above (or sooner if the nature of the
third party claim requires). If Indemnifying Party elects not to defend the
indemnified party or fails to notify the indemnified party of its election as
provided in this Section 7.3, the indemnified party may pay, compromise or
settle such claim (subject to the provisions of Section 7.5) and the indemnified
party shall be free to pursue such remedies as may be available under applicable
law to recover from Indemnifying Party.

     7.4 LIMITATIONS ON LIABILITY. With respect to any claim by one party
against the other arising out of the performance or failure of performance of
the other party under this Agreement, the parties expressly agree that the
liability of such party to the other party for such

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       37
<Page>

breach shall be limited under this Agreement or otherwise at law or equity to
direct damages only and in no event shall a party be liable for punitive,
exemplary or consequential damages; PROVIDED that this limitation shall not
apply to the extent arising under third party claims which are subject to
indemnification under Section 7.1 or Section 7.2.

     7.5 SETTLEMENTS. Neither party may settle a claim or action related to a
liability, loss, claims, damage, cost or expense arising in connection with this
Agreement without the consent of the other party, which consent shall not be
unreasonably withheld, if such settlement would impose any monetary obligation
on the other party or require the other party to submit to an injunction or
otherwise limit the other party's rights under this Agreement. Any payment made
by a party to settle any such claim or action shall be at its own cost and
expense; PROVIDED, that in the event and to the extent that an indemnified party
enters into a settlement of a matter with respect to which it believes it is
entitled to indemnification under this Article 7 after the other party has
refused to assume the defense of such matter, the provisions of this Section 7.5
shall not constitute a waiver of such party's right to seek remedies from the
other party concerning such matter.

     7.6 INSURANCE. Each party acknowledges and agrees that during the term of
this Agreement it shall maintain adequate insurance and/or a self-insurance
program for liability insurance, including products liability and contractual
liability insurance, to cover such party's obligations under this Agreement.
Each party shall provide the other party with evidence of such insurance and/or
self-insurance program, upon request.

8.   TERM AND TERMINATION

     8.1 TERM. This Agreement shall take effect as the Effective Date and shall,
unless sooner terminated in accordance with Section 8.2 or Section 9.5(a),
expire on a Licensed Product-by -Licensed Product and country-by-country basis
upon the later of: (i) the expiration of the last-to-expire of the NeoGenesis
Patent Rights having a Valid Claim covering the Licensed Product in such
country, or (ii) ten (10) years following the First Commercial Sale of the
Licensed Product in such country. Upon expiration of this Agreement with respect
to a Licensed Product in a given country, the licenses granted to Schering
hereunder with respect to such Licensed Product in such country shall become
fully paid, royalty-free, irrevocable licenses.

     8.2  TERMINATION.

          (a) Schering shall have the right to terminate this Agreement, with or
without cause at any time following the first anniversary of the Effective Date
upon one hundred and eighty (180) days written notice.

          (b) During the term of the Screening Program, either party may
terminate the Screening Program and this Agreement (i) upon thirty (30) days
written notice to the other party if the other party fails to pay any amounts
properly due and owing under this Agreement, unless such amount is paid prior to
the expiration of such thirty (30) day period, or (ii) upon ninety (90)

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       38
<Page>

days written notice to the other party if the other party commits a material
breach of this Agreement (other than non-payment), unless such breach is cured
within the ninety (90) day notice period, or if such breach is not capable of
being cured within ninety (90) days unless such party during such ninety (90)
day period initiates actions reasonably expected to cure the breach and
thereafter diligently proceeds to cure the breach.

          (c) Following completion of the Screening Program, either party may
terminate this Agreement (i) upon thirty (30) days written notice to the other
party if the other party fails to pay any amounts properly due and owing under
this Agreement, unless such amount is paid prior to the expiration of such
thirty (30) day period, or (ii) upon ninety (90) days written notice to the
other party if the other party commits a material breach of this Agreement
(other than non-payment), unless such breach is cured within the ninety (90) day
notice period, or if such breach is not capable of being cured within ninety
(90) days unless such party during such ninety (90) day period initiates actions
reasonably expected to cure the breach and thereafter diligently proceeds to
cure the breach. Notwithstanding the foregoing, in the event that the
non-payment or breach is related to a Licensed Product, any such termination
shall be effective only with respect to such Licensed Product and this Agreement
shall remain in full force and effect with respect to any other Licensed
Products being developed and commercialized by Schering under this Agreement.

     (d) This Agreement may be terminated by either party upon the filing or
institution of bankruptcy, reorganization, liquidation or receivership
proceedings, or upon an assignment of a substantial portion of the assets for
the benefit of creditors by the other party, or in the event a receiver or
custodian is appointed for such party's business, or if a substantial portion of
such party's business is subject to attachment or similar process; provided,
however, that in the case of any involuntary bankruptcy proceeding such right to
terminate shall only become effective if the proceeding is not dismissed within
sixty (60) days after the filing thereof.

     8.3  EFFECT OF TERMINATION.

          (a) Upon termination of this Agreement pursuant to Section 8.2: (i)
NeoGenesis will terminate all tasks then in process in an orderly manner, as
soon as practical and in accordance with a schedule agreed to by Schering and
NeoGenesis; (ii) NeoGenesis shall deliver to Schering all materials developed
through the termination of this Agreement; (iii) Schering shall pay NeoGenesis
any monies due and owing NeoGenesis up to the time of termination for services
actually performed (including all work-in process), and (iv) within thirty (30)
days following termination (including expiration) of this Agreement, NeoGenesis
shall deliver to Schering a reasonably-detailed written report describing the
results of the research performed up to the date of such termination. In
addition, upon termination (including expiration) of this Agreement each party
shall return to the other party or certify in writing to the other party that it
has destroyed all Confidential Information of the other party in its possession.

          (b) The licenses granted by NeoGenesis under Article 3 shall survive
any expiration or termination of the Screening Program or the termination of
this Agreement with respect to any Designated Compound or Licensed Product for
which the applicable service fees

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       39
<Page>

and milestone fees and royalties have been paid (when due in accordance with the
terms of this Agreement) and Schering shall continue to have the right to
develop, have developed, make, have made, use, distribute, offer for sale,
import, export and sell Licensed Products relating to such Designated Compounds;
PROVIDED that Schering continues to pay NeoGenesis milestone fees and royalties
as required by Sections 4.3 and 4.4 and complies with Sections 4.5-4.8. In the
event the licenses granted to Schering under Article 3 terminates for any
reason, each of Schering's sublicensees at such time shall continue to have the
rights and license set forth in their sublicense agreements, PROVIDED such
sublicensee agrees in writing that NeoGenesis is entitled to enforce all
relevant provisions directly against such sublicensee.

          (c) Nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of any termination.
Schering's liability for any charges, payments or expenses due to NeoGenesis
that accrued prior to the termination date shall not be extinguished by
termination, and such amounts (if not otherwise due on an earlier date) shall be
immediately due and payable on the termination date.

          (d) Termination of this Agreement by either party pursuant to Section
8.2 or 9.5(a) hereof shall constitute termination of the International Agreement
under the corresponding provisions thereof.

     8.4 SURVIVAL. Articles 1, 5, 6, 7 and 9 and Sections 2.2(b), 2.2(c),
2.2(g), 2.5, 3.4, 3.5, 3.6, 3.7, 4.6, 4.7, 4.8 and 8.3(a-c), and the second and
third sentences of Section 2.1(c), shall survive any termination or expiration
of this Agreement.

9.   GENERAL PROVISIONS.

     9.1 DISPUTE RESOLUTION. Any controversy or dispute that arises under or
relates to this Agreement (with the exception to disputes relating to the
performance of the Screening Program which are governed by the terms of Section
2.6(d)) shall be referred to the Oversight Committee (as defined in Section
2.6(d)) for resolution. If the Oversight Committee is unable to resolve the
dispute within thirty (30) days, the dispute shall be resolved by binding
arbitration pursuant to the provisions of Schedule 9.1 (attached hereto).
Nothing herein shall prevent the parties from settling any dispute by mutual
agreement at any time.

     9.2 GOVERNING LAW. This Agreement shall be governed and construed in
accordance with the laws of the State of New York without regard for any
conflict of laws rule or provision thereof that would result in the application
of the substantive laws of any other jurisdiction. Notwithstanding the
foregoing, the parties (and the arbitrators) shall use United States (Federal)
patent and copyright laws for purposes of governing and construing Sections 3.5,
3.6 or 3.7 of this Agreement. The United Nations Convention on Contracts for the
International Sale of Goods shall not apply to the transactions contemplated by
this Agreement.

     9.3 AMENDMENT AND WAIVER. This Agreement may only be modified or amended by
a written instrument signed by authorized representatives of each party. No
provision of or right

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       40
<Page>

under this Agreement shall be deemed to have been waived by any act or
acquiescence on the part of either party, its agents or employees, but only by
an instrument in writing signed by an authorized officer of each party. No
waiver by either party of any breach of this Agreement by the other party shall
be effective as to any other breach, whether of the same or any other term or
condition and whether occurring before or after the date of such waiver.

     9.4  INDEPENDENT CONTRACTORS. Each party represents that it is acting on
its own behalf as an independent contractor and is not acting as an agent for or
on behalf of any third party. This Agreement and the relations hereby
established by and between Schering and NeoGenesis do not constitute a
partnership, joint venture, franchise, agency or contract of employment. Neither
party is granted, and neither party shall exercise, the right or authority to
assume or create any obligation or responsibility on behalf of or in the name of
the other party or its Affiliates. NeoGenesis shall be solely responsible for
compensating all its personnel and for payment of all related FICA, workers'
compensation, unemployment and withholding taxes.

     9.5  ASSIGNMENT. (a) This Agreement, and any of a party's rights and
obligations under this Agreement, may not be assigned, delegated, sold,
transferred, sublicensed (except as otherwise provided herein) or otherwise
disposed of, by operation of law or otherwise, to any third party without the
prior written consent of the other party; PROVIDED, that either party may assign
this Agreement to an Affiliate or in connection with the transfer or sale of all
or substantially all of its assets related to the division or the subject
business, or in the event of its merger or consolidation or change in control or
similar transaction PROVIDED, FURTHER, that in each instance the assignee
expressly assumes all obligations imposed on the assigning party by this
Agreement in writing. This Agreement shall be binding upon, and inure to the
benefit of, each party, its Affiliates, and its permitted successors and
assigns. Each party shall be responsible for the compliance by its Affiliates
with the terms and conditions of this Agreement.

          (b) In the event that any (i) third party or "group" (within the
meaning of Section 13(d) or 14(d) of the Exchange Act of 1934, as amended) other
than the current officers and directors of NeoGenesis or Schering, as the case
may be, has acquired, directly or indirectly, the beneficial ownership, by way
of merger, consolidation or otherwise of 50% of the voting power of NeoGenesis
or Schering, as the case may be, on a fully-diluted basis or (ii) the sale,
lease or transfer of all or substantially all of the assets of NeoGenesis or
Schering to any third party or group not controlled directly or indirectly by
such party (each, a "CHANGE IN CONTROL") during the term of the Screening
Program causes either party's rights and obligations hereunder to pass to any
third party, the other party shall have the right to terminate the Screening
Program and this Agreement upon written notice within thirty (30) days of
receipt of actual knowledge of such Change of Control, without providing the
party that is the subject of such Change in Control any opportunity to cure.
Thereafter, such party shall also have the right to terminate this Agreement if
the assignee of the party that is the subject of such Change in Control does not
provide the writing required under Section 9.5(a). In addition, if the
beneficial ownership (in the manner described in Section 9.5(b)(i)-(ii)) of more
than fifty percent (50%) of the voting or income interest in NeoGenesis or
Schering, as applicable, on a fully diluted basis, is acquired by a third party
or group that is reasonably regarded as a competitor of the other party, such
determination being made with reference to the products and services that such
third party then

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       41
<Page>

markets or for which it has made regulatory submissions with the FDA or an
equivalent Regulatory Authority in another Major Country or for which it has
publicly announced its intention to do either of the foregoing, the other party
shall have the right, but not the obligation, to terminate the Screening Program
with six (6) months notice to the party being acquired.

     9.6 NOTICES. Any notice required or permitted to be given or sent under
this Agreement shall be hand delivered or sent by express delivery service or
certified or registered mail, postage prepaid, or by facsimile transmission
(with written confirmation copy by registered first-class mail) to the parties
at the addresses and facsimile numbers indicated below.

     If to NeoGenesis, to:

                          NeoGenesis Drug Discovery, Inc.
                          840 Memorial Drive
                          Cambridge, Massachusetts 02139
                          Attention:  Satish Jindal, President and CSO
                          Fax:  (617) 868-1515

     If to Schering, to:

                          Schering Corporation
                          2000 Galloping Hill Road
                          Kenilworth, New Jersey  07033
                          Attention: Vice President, Business Development
                          Facsimile No.: (908) 298-7366

                with copies to:

                     Schering Corporation
                     2000 Galloping Hill Road
                     Kenilworth, New Jersey  07033
                     Attention: Law Department - Staff Vice-President, Licensing
                     Facsimile No.: (908) 298-2739

Any such notice shall be deemed to have been received on the earlier of the date
actually received or the date five (5) days after the same was posted or sent.
Either party may change its address or its facsimile number by giving the other
party written notice, delivered in accordance with this Section 9.6.

     9.7  PROVISIONS FOR INSOLVENCY.

          (a) All rights and licenses granted under or pursuant to this
Agreement by NeoGenesis to Schering are, for all purposes of Section 365(n) of
Title 11 of the United States Code ("TITLE 11"), licenses of rights to
"intellectual property" as defined in Title 11. NeoGenesis

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       42
<Page>

agrees during the term of this Agreement to create and maintain current copies
or, if not amenable to copying, detailed descriptions or other appropriate
embodiments, to the extent feasible, of all such intellectual property. If a
case is commenced by or against NeoGenesis under Title 11, then, unless and
until this Agreement is rejected as provided in Title 11, NeoGenesis (in any
capacity, including debtor-in-possession) and its successors and assigns
(including, without limitation, a Title 11 Trustee (as defined therein)) shall,
as Schering may elect in a written request, immediately upon such request:

          (i)  perform all of the obligations provided in this Agreement to be
               performed by NeoGenesis including, where applicable and without
               limitation, providing to Schering portions of such intellectual
               property (including embodiments thereof) held by NeoGenesis and
               such successors and assigns or otherwise available to them; or

          (ii) provide to Schering all such intellectual property (including all
               embodiments thereof) held by NeoGenesis and such successors and
               assigns or otherwise available to them.

          (b)  If a Title 11 case is commenced by or against NeoGenesis, and
this Agreement is rejected as provided in Title 11, and Schering elects to
retain its rights hereunder as provided in Title 11, then NeoGenesis (in any
capacity, including debtor-in-possession) and its successors and assigns
(including, without limitation, a Title 11 Trustee) shall provide to Schering
all such intellectual property (including all embodiments thereof) held by
NeoGenesis and such successors and assigns, or otherwise available to them,
immediately upon Schering's written request. Whenever NeoGenesis or any of its
successors or assigns provides to Schering any of the intellectual property
licensed hereunder (or any embodiment thereof) pursuant to this Section 9.7,
Schering shall have the right to perform the obligations of NeoGenesis hereunder
with respect to such intellectual property, but neither such provision nor such
performance by Schering shall release NeoGenesis from any such obligation or
liability for failing to perform it.

          (c) All rights, powers and remedies of Schering provided herein are in
addition to and not in substitution for any and all other rights, powers and
remedies now or hereafter existing at law or in equity (including, without
limitation, Title 11). In the event of the commencement of a Title 11 case by or
against NeoGenesis, Schering, in addition to the rights, power and remedies
expressly provided herein, shall be entitled to exercise all other such rights
and powers and resort to all other such remedies as may now or hereafter exist
at law or in equity (including, without limitation, Title 11) in such event. The
parties agree that they intend the foregoing Schering rights to extend to the
maximum extent permitted by law, including, without limitation, for purposes of
Title 11:

          (i)  the right of access to any intellectual property (including all
               embodiments thereof) of NeoGenesis, or any third party with whom
               NeoGenesis contracts to perform an obligation of NeoGenesis under
               this Agreement, and, in the case of the third party, which is
               necessary for the development,

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       43
<Page>

               registration, manufacture and marketing of Designated Compounds
               and/or Licensed Products; and

          (ii) the right to contract directly with any third party described in
               (i) to complete the contracted work.

     9.8 SEVERABILITY. In the event any provision of this Agreement shall for
any reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof. The parties agree that they will negotiate in good faith to
replace any provision hereof so held invalid, illegal or unenforceable with a
valid provision which is as similar as possible in substance to the invalid,
illegal or unenforceable provision.

     9.9 CAPTIONS. Captions of the sections and subsections of this Agreement
are for reference purposes only and do not constitute terms or conditions of
this Agreement and shall not limit or affect the meaning or construction of the
terms and conditions hereof.

     9.10 ENTIRE AGREEMENT. This Agreement (including the Attachments or
Schedules hereto) constitutes the entire understanding of the parties with
respect to the transactions and matters contemplated hereby and supersedes all
previous communications, representations, agreements and understandings, whether
written or verbal, relating to the subject matter hereof. No representations,
inducements, promises or agreements, whether oral or otherwise, between the
parties not contained in this Agreement shall be of any force or effect.

     9.11 RULES OF CONSTRUCTION. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of
this Agreement shall not be construed against either party by reason of the
extent to which such party or its professional advisors participated in the
preparation of this Agreement.

     9.12 COUNTERPARTS. This Agreement may be executed in multiple counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

     9.13 FORCE MAJEURE. Failure of any party to perform its obligations under
this Agreement (except the obligation to make payments when properly due) shall
not subject such party to any liability or place them in breach of any term or
condition of this Agreement to the other party if such failure is due to any
cause beyond the reasonable control of such non-performing party ("FORCE
MAJEURE"), unless conclusive evidence to the contrary is provided. Causes of
non-performance constituting force majeure shall include, without limitation,
acts of God, fire, explosion, flood, drought, war, riot, sabotage, embargo,
strikes or other labor trouble, failure in whole or in part of suppliers to
deliver on schedule materials, equipment or machinery, interruption of or delay
in transportation, a national health emergency or compliance with any order or
regulation of any government entity acting with color of right. The party
affected shall promptly notify the other party of the condition constituting
force majeure as defined herein and shall exert reasonable efforts to eliminate,
cure and overcome any such causes and to resume

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       44
<Page>

performance of its obligations with all possible speed; provided that nothing
herein shall obligate a party to settle on terms unsatisfactory to such party
any strike, lockout or other labor difficulty, any investigation or other
proceeding by any public authority or any litigation by any third party. If a
condition constituting force majeure as defined herein exists for more than
ninety (90) consecutive days, the parties shall meet to negotiate a mutually
satisfactory resolution to the problem, if practicable. If the parties cannot in
good faith reach a satisfactory resolution to the problem within sixty (60) days
of meeting, the matter shall be referred to binding arbitration pursuant to
Section 9.1.

     9.14 FURTHER ASSURANCES. Each party agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives.

NEOGENESIS DRUG DISCOVERY, INC.                    SCHERING CORPORATION

By: /s/ Satish Jindal                              By: /s/ David Poorvin
    --------------------------                         ----------------------
Satish Jindal                                      David Poorvin, Ph.D.
President and CSO                                  Vice President

Date: August 2, 2001                               Date: August 2, 2001
      ------------------------                           --------------------

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       45
<Page>

                                  ATTACHMENT A

                                SCREENING PROGRAM

The Screening Program to be performed by NeoGenesis with respect to the Targets
will screen up to [*] Compounds contained in the NeoGenesis NeoMorph Screening
Library against each Target using the protocol described below.

1. Schering will provide NeoGenesis with approximately [*] of each of the
purified functionally-active Target proteins. Control experiments will be
performed with each of the Targets to determine screening characteristics in
NeoGenesis' ALIS protocols. Follow-up control experiments will be performed
using Schering ligands (if available) to validate the retention of binding
activity of the Targets. Written Standard Operating Procedures ("SOPS") will be
established by the Steering Committee for ALIS screening based on the preceding
experiments.

2. Using the SOPs, NeoGenesis will perform ALIS screening of the NeoMorph
Screening Library against each Target. The ALIS screening will be carried out to
identify Target-specific Compounds that bind to the Schering Target with binding
affinities less than [*] micromolar (Kd < [*]), or such other binding affinity
threshold for a specific Target as shall be agreed upon by the parties in
writing (each, a Preliminary Compound as defined in Section 1.36).

3. NeoGenesis will deliver to Schering [*] of each of the discrete Preliminary
Compounds. Schering will evaluate the activity of these discrete compound(s) in
a Target-based functional assay and/or secondary assay and will notify
NeoGenesis of any such Preliminary Compound(s) which has demonstrated activity
in the Target-based functional assays (each, an Active Compound as defined in
Section 1.1) within [*] after completion of such assays and not later than [*]
after the discrete compounds are delivered by NeoGenesis. NeoGenesis will
prepare a report for all Preliminary Compound(s) that details the binding
affinities of such Preliminary Compound(s) (each, a "PRELIMINARY TARGET
REPORT"). NeoGenesis will deliver such Preliminary Target Report when it
delivers the discrete compounds.

4. Following identification of Active Compounds by Schering, NeoGenesis will
disclose to Schering the structures of all Active Compounds and Preliminary
Compounds of the same Chemotype. At the direction of the Steering Committee,
NeoGenesis will perform initial optimization of such Active Compounds to obtain
compounds with binding affinities of [*] micromolar or less (Kd < [*]) (each, an
Improved Active Compound as defined in Section 1.21) and NeoGenesis will provide
Schering with [*] of discrete Improved Active Compounds. Schering will evaluate
the activity of these discrete compound(s) in a Target-based functional assay
and/or secondary assay and will notify NeoGenesis of any such Improved Active
Compound(s) which has demonstrated activity in the Target-based functional
assays within [*] after completion of such assays and not later than [*] after
the discrete Improved Active Compounds are delivered by NeoGenesis. NeoGenesis
will prepare a report for all Improved Active Compound(s) that details the
chemical structures, binding affinities and competition analysis data for such
Improved Active Compound(s) (each, a "FINAL TARGET REPORT").

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       46
<Page>

NeoGenesis will deliver such Final Target Report when it delivers the discrete
Improved Active Compounds. In the event and to the extent that the Steering
Committee determines that the aggregate amount of initial optimization
activities performed by NeoGenesis pursuant to this Paragraph 4 will adversely
effect the ability of NeoGenesis to perform initial screening activities for the
Targets that are the subject of the Screening program during a particular
funding period, the Screening Committee may determine that Schering rather than
NeoGenesis should perform certain optimization activities.

5. Schering will select those Improved Active Compounds with respect to each
Target that have demonstrated activity in the Target-based functional assay
and/or secondary assay and that it considers worthy of further study or
optimization as Selected Compounds in accordance with Section 2.7 of the
Agreement. In addition, those Selected Compounds which are to be optimized by
NeoGenesis as Lead Compounds pursuant to Section 2.2(b) of the Agreement will
also be identified by Schering at the time it designates Selected Compounds for
the applicable Target.

6. At the request of Schering in accordance with Section 2.2(b), NeoGenesis will
perform medicinal chemistry optimization on each Lead Compound.

                                       LIST OF ACCEPTED TARGETS

                  1.   [*]

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       47
<Page>

                                  ATTACHMENT B
                            NEOGENESIS PATENT RIGHTS

                  [TO BE SUPPLIED BY NEOGENESIS AS APPLICABLE]

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       48
<Page>

                                  ATTACHMENT C
                                   INVENTIONS

                          [TO BE SUPPLIED AS DEVELOPED]

                                  ATTACHMENT D

                        BOOKKEEPING EXCHANGE RATE POLICY

                                     PURPOSE

To provide general guidelines for the establishment and communication of current
bookkeeping exchange rates by Corporate Treasury to divisions and subsidiaries.

                                   APPLICATION

Applies to Schering-Plough Corporation, its divisions and all subsidiaries.

                                     POLICY

ESTABLISHMENT OF RATES

The current bookkeeping exchange rates will be determined monthly by S-P
Corporate Treasury. The rates will be based on:

     o    The market rates for selling foreign currencies in New York on the
          morning of the 25th of each month; the 31st in December; or
     o    In thinly traded currencies the local rate established in that country
          for buying U.S. dollars.

If the 25th occurs on a holiday, Saturday or Sunday, the rates used are those of
the last business day prior to the 25th. If for any reason a rate established is
significantly different from the rate prevailing locally, the Chief Financial
Officer of the subsidiary should promptly telex Corporate Treasury.

NOTIFICATION

Rates will be communicated to subsidiaries on the last day of each accounting
period by Corporate Treasury (1st workday of ensuing year at year-end). The
communication will advise each subsidiary of all Corporate wide current rates,
regardless of whether or not they have changed from the prior accounting period.

As there is no January closing, January rates will not be issued and December
rates will remain in effect until the February month-end closing.

RECORDKEEPING OF RATES

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       49
<Page>

At the beginning of each year, a worksheet will be sent to all subsidiaries by
Corporate Treasury. Each subsidiary will maintain a monthly record of all
exchange rates throughout the Corporate system which may affect its accounting
transactions and reporting.

The worksheet lists all countries in which subsidiaries are located and for each
country gives:

     1.   The cable code (based on country abbreviation) so as to identify the
          country for which there is a change in exchange rate.
     2.   The average exchange rate used in the Operating Plan for the current
          year and
     3.   The exchange rate established as of the end of the previous year.
          Twelve columns are provided for the subsidiary to record changes in
          exchange rates from communication received each month.

QUOTING OR RATES

To conform with practices generally prevailing in each country, and to avoid any
confusion, ALL exchange rates will be quoted in terms of the number of foreign
currency units per U.S. dollar. This means that for those foreign currency units
that are valued at more than one U.S. dollar, the exchange rates are quoted as a
decimal of the foreign currency unit.

For example, the pound sterling plan rate is quoted as (pound).571 per U.S.
dollar rather than U.S.$1.75 per pound sterling.

Exchange rates are generally quoted as follows:

     o    In THREE decimals for currencies with less than one unit per U.S.
          dollar (e.g., UK .571)
     o    In TWO decimals for those with one or more but less than ten units
          (e.g., France 5.70)
     o    In ONE decimal for those with ten or more but less than 100 units
          (e.g., Austria 12.0) and
     o    With NO decimals for those with 100 or more units (e.g. Italy 1270)

Rates will be quoted in more than three digits only when necessary to conform to
rates required for official purposes locally or when the exchange rate exceeds
1,000 (e.g., Italy 1270). If the rate exceeds 1,000, it should be rounded to
three significant digits (e.g., rate of 4633 would be shown as 4630).

                                 RESPONSIBILITY

The Corporate Treasury Department will:

     A.   Distribute the Current Bookkeeping Exchange rate Worksheet at the
          beginning of each year to all divisions and subsidiaries.
     B    Establish and communicate the Current Bookkeeping Exchange rate as
          stated in the above policy.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       50
<Page>

The chief financial officer of each subsidiary will maintain monthly records of
communicated exchange rates.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       51
<Page>

                                  ATTACHMENT E

                               DISPUTE RESOLUTION

(a) SCOPE. Subject to and in accordance with the terms of this Agreement and
this Schedule 9.1, all differences, disputes, claims or controversies arising
out of or in any way connected or related to this Agreement, whether arising
before or after the expiration of the term of this Agreement, and including,
without limitation, its negotiation, execution, delivery, enforceability,
performance, breach, discharge, interpretation and construction, existence,
validity and any damages resulting therefrom or the rights, privileges, duties
and obligations of the parties under or in relation to this Agreement (including
any dispute as to whether an issue is arbitrable) shall be referred to binding
arbitration in accordance with the rules set forth herein and of the American
Arbitration Association, as in effect at the time of the arbitration. The time
frames set forth herein shall control the timing of the arbitration procedure.

(b) PARTIES TO ARBITRATION. For the purposes of each arbitration under this
Agreement, Schering shall constitute one party to the arbitration and NeoGenesis
shall constitute the other party to the arbitration.

(c) NOTICE OF ARBITRATION. A party requesting arbitration hereunder (the
"REQUESTING PARTY") shall give a notice of arbitration to the other party (the
"NON-REQUESTING PARTY") containing a concise description of the matter submitted
for arbitration (a "NOTICE OF ARBITRATION"). Notice of Arbitration shall be
delivered to the other party in accordance with Section 9.6 of the Agreement.

(d) RESPONSE. The Non-Requesting Party must respond in writing within thirty
(30) days of receiving a Notice of Arbitration with an explanation responding to
each issue raised, including references to the relevant provisions of the
Agreement. The Non-Requesting Party may add additional issues to be submitted to
arbitration by including a description of such issue in the response.

(e) MEETING. Within fifteen (15) days of receipt of the response from the
Non-Requesting Party pursuant to Paragraph (d), the parties shall meet and
discuss in good faith options for resolving the dispute. The Requesting Party
must initiate the scheduling of this resolution meeting. Each party shall make
available appropriate personnel to meet and confer with the other party during
such fifteen (15) day period.

(f) SELECTION OF ARBITRATOR. Any and all disputes that cannot be resolved
pursuant to Paragraphs (c), (d) and (e) shall be submitted to an arbitrator (the
"ARBITRATOR") to be selected by mutual agreement of the parties. The Arbitrator
shall be a retired judge of a state or federal court, to be chosen from a list
of such retired judges to be prepared jointly by the parties within fifteen (15)
days following the response, with each party entitled to submit the names of
three such retired judges for inclusion in the list, provided that to the extent
the dispute involves issues of

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       52
<Page>

patent law the parties shall limit such list to judges retired from federal
courts having jurisdiction over patent law issues; PROVIDED FURTHER, that in the
event a dispute relates to matters that are the subject Section 3.4, 3.5 or 3.6
such judge shall be a retired federal judge with expertise in patent law. Upon
completion of the list, the parties shall decide within ten (10) days thereafter
which of the retired judges will be selected as the Arbitrator. No Arbitrator
appointed or selected hereunder shall be an employee, director or shareholder
of, or otherwise have any current or previous relationship with, any party or
its respective Affiliates. If the parties fail to agree on the selection of the
Arbitrator within the allotted time frame, the Arbitrator shall be designated by
the then President of the American Arbitration Association.

(g) POWERS OF ARBITRATOR. The Arbitrator may determine all questions of law and
jurisdiction (including questions as to whether a dispute is arbitrable) and all
matters of procedure relating to the arbitration, except that the Arbitrator
shall be bound by the time frames set forth herein in connection with such
arbitration. The Arbitrator shall have the right to grant legal and equitable
relief (including injunctive relief) and to award costs (including reasonable
legal fees and costs of arbitration) and interest. The Arbitrator is not
permitted to award punitive, exemplary or any similar damages.

(h) ARBITRATION PROCEDURE. The arbitration shall take place in the City and
State of New York at such place and time, consistent with the time frames set
forth herein, as the Arbitrator may fix for the purpose of hearing the evidence
and representations that the parties may present. The arbitration proceedings
shall be conducted in the English language. The law applicable to the
arbitration shall be the law of the State of New York.

(i) DISCOVERY AND HEARING. During the meeting referred to in Paragraph (e), the
parties shall negotiate in good faith the scope and schedule of discovery,
relating to depositions, document production and other discovery devices, taking
into account the nature of the dispute submitted for resolution. If the parties
are unable to reach agreement as to the scope and schedule of discovery, the
Arbitrator may order such discovery as it deems necessary. The parties and the
Arbitrator must adhere to the following schedule: (1) all discovery shall be
completed within forty-five (45) days from the date of the selection of the
Arbitrator, and (2) the arbitration hearing shall commence within fifteen (15)
days after completion of such discovery. At the arbitration hearing, the parties
may present testimony (either live witness or deposition), subject to
cross-examination, and documentary evidence. To the extent practicable taking
into account the nature of the dispute submitted for resolution and the
availability of the Arbitrator, the hearing shall be conducted over a period not
to exceed ten (10) consecutive calendar days, with each party entitled to one
half of the allotted time.

(j) WITNESS LISTS. At least twenty (20) calendar days prior to the date set for
the hearing, each party shall submit to each other party and the Arbitrator a
list of all documents on which such party intends to rely in any oral or written
presentation to the Arbitrator and a list of all witnesses, if any, such party
intends to call at such hearing and a brief summary of each witness' testimony.
Each party shall be given the opportunity to depose any such designated
witnesses not already deposed during the discovery phase. At least five (5)
calendar days prior to the hearing, each party must submit to the Arbitrator and
serve on each other party a proposed findings of fact

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       53
<Page>

and conclusions of law on each issue to be resolved. Following the close of
hearings, the parties may each submit such post-hearing briefs to the Arbitrator
addressing the evidence and issues to be resolved as may be required or
permitted by the Arbitrator. No later than fifteen (15) calendar days after
hearing the representations and evidence of the parties, the Arbitrator shall
make its determination in writing and deliver one copy to each of the parties.

(k) CONFIDENTIALITY. The arbitration proceedings shall be confidential and,
except as required by law, no party shall make, or instruct the Arbitrator to
make, any public announcement with respect to the proceedings or decision of the
Arbitrator without the prior written consent of the other party. The existence
of any dispute submitted to arbitration and the award of the Arbitrator shall be
kept in confidence by the parties and the Arbitrator, except as required in
connection with the enforcement of such award or as otherwise required by law.

(l) AWARDS AND APPEAL. Subject to the provisions of this Schedule 9.1, the
decision of the Arbitrator shall be final and binding upon the parties in
respect of all matters relating to the arbitration, the conduct of the parties
during the proceedings, and the final determination of the issues in the
arbitration. There shall be no appeal from the final determination of the
Arbitrator to any court, except in the case of fraud or bad faith on the part of
the Arbitrator or any party to the arbitration proceeding in connection with the
conduct of such proceedings. Judgment upon any award rendered by the Arbitrator
may be entered in any court having jurisdiction thereof.

(m) COSTS OF ARBITRATION. The costs of any arbitration hereunder shall be borne
by the parties in the manner specified by the Arbitrator in its determination.

(n) PERFORMANCE OF THE AGREEMENT. During the pendency of the arbitration
proceedings, the parties shall continue to fully perform their respective
obligations under the Agreement; PROVIDED that if the matter which is the
subject of such arbitration proceeding is a matter relating to Schering's
development of Designated Compounds and/or Licensed Products, then the matter
shall be performed by Schering, in its sole discretion; and if the matter which
is the subject of such arbitration proceeding is a matter relating to payment
for the Screening Program services, then the Screening Program shall be
performed by NeoGenesis in its sole discretion. For purposes of this Paragraph
(n) the term "pendency of the arbitration proceeding" shall mean the period
starting on the date on which arbitration proceedings are commenced by a party
in accordance with Paragraph (c) of this Schedule 9.1 and ending on the date on
which the Arbitrator delivers its final determination in writing to the parties.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       54
<Page>

                                  ATTACHMENT F
                            STOCK PURCHASE AGREEMENT

                             SUBSCRIPTION AGREEMENT

                                                                  July ___, 2001

NeoGenesis Drug Discovery, Inc.
840 Memorial Drive
Cambridge, Massachusetts 02139

         Re:  Private Placement (the "OFFERING") of 3,517,588 shares of
              Series E Convertible Preferred Stock, $.001 par value per share
              (the "SHARES" OR "SERIES E CONVERTIBLE PREFERRED STOCK") AT A
              PRICE OF $5.97 PER SHARE

Gentlemen:

     1.   SUBSCRIPTION. Subject to the terms and conditions hereof, the
undersigned (the "SUBSCRIBER") hereby irrevocably subscribes for and agrees at
the Closing to purchase for $5.97 per share the number of Shares set forth on
the signature page of this Agreement. The Shares to be purchased by Subscriber
hereunder shall have the rights, restriction, privileges and preferences of
Series E Convertible Preferred Stock, as expressly set forth in the Third
Amended and Restated Certificate of Incorporation of NeoGenesis Drug Discovery,
Inc., a copy of which is attached hereto and is herein incorporated by reference
and made a part hereof.

     2.   CLOSING/TENDER OF CONSIDERATION. Subject to the terms and conditions
of this Agreement, the Subscriber hereby tenders to the Company by wire transfer
of immediately available funds to an account to be specified by the Company the
amount of five million dollars and thirty-seven cents ($5,000,000.37) (the
"CLOSING"). At the Closing, subject to the terms and conditions of this
Agreement, the Company will deliver to the Subscriber certificates representing
the number of Shares to be sold and purchased pursuant to Section 1, in proper
form for transfer to Subscriber and dated as of the date of the Closing.

     3.   ACKNOWLEDGEMENTS, REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE
SUBSCRIBER. The Subscriber understands and acknowledges that the Shares are
being offered and sold under one or more of the exemptions from the registration
provided for in Section 4(2) of the Securities Act of 1933, as amended (the
"SECURITIES ACT"), including Regulation D promulgated thereunder, and any
applicable state securities laws. The Subscriber is purchasing the Shares
without being offered or furnished any formal offering literature or prospectus.
The Subscriber understands that this transaction has not been reviewed and
approved by the Securities and Exchange Commission (the "SEC") or by any state
regulatory authority. All documents pertaining to this investment have been made
available to the Subscriber and its representatives, and the books and records
of the Company are available upon reasonable notice for inspection by the
Subscriber during reasonable business hours at the Company's principal place of
business.

          3.1  SUITABILITY. The Subscriber confirms that it understands and has
     fully considered the risks of this investment and understands that (i) this
     investment is suitable only for an

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       55
<Page>

     investor who is able to bear the economic consequences of losing its entire
     investment, (ii) the purchase of the Shares is a speculative investment
     which involves a high degree of risk, and (iii) there are substantial
     restrictions on the transferability of, and there will be no immediate
     public market for, the Shares, and accordingly, it may not be possible for
     it to liquidate its investment in case of emergency. The Subscriber's
     overall commitment to investments which are not readily marketable is not
     disproportionate to the undersigned's net worth and the Subscriber's
     investment in the Company will not cause such overall commitment to become
     excessive.

          3.2  LACK OF LIQUIDITY. The Subscriber confirms that it is able (i) to
     bear the economic risk of this investment, and (ii) to hold the Shares for
     an indefinite period of time. The Subscriber has sufficient liquid assets
     so that the illiquidity associated with this investment will not cause any
     undue financial difficulties or affect the undersigned's ability to provide
     for its current needs and possible financial contingencies, and that its
     commitment to all speculative investments is reasonable in relation to its
     net worth and annual income. The Subscriber qualifies as an "accredited
     investor" pursuant to Regulation D under the Securities Act and has
     executed the Registration D Qualification Statement attached hereto as
     EXHIBIT A.

          3.3  KNOWLEDGE AND EXPERIENCE. The Subscriber has such knowledge and
     experience in financial and business matters that it is capable of
     evaluating the merits and risks of this investment and of making an
     informed investment decision.

          3.4  ACCESS TO MANAGEMENT. The Subscriber confirms that, in making its
     decision to purchase the Shares, it has relied solely upon independent
     investigations made by it, and that it has been given the opportunity to
     ask questions of, and to receive answers from, management and other persons
     acting on behalf of the Company concerning the Company and the terms and
     conditions of the Offering.

          3.5  INVESTMENT INTENT. The Shares are being acquired by the
     undersigned solely for its own personal account, for investment purposes
     only, and not with a view to, or in connection with, any resale or
     distribution thereof. The Subscriber has no contract, undertaking,
     understanding, agreement or arrangement, formal or informal, with any
     person to sell, transfer or pledge to any person the Shares for which it
     hereby subscribes, or any part thereof, or any interest therein or any
     rights thereto. The Subscriber has no present plans to enter into any such
     contract, undertaking, agreement or arrangement. The Subscriber must bear
     the economic risk of the investment for an indefinite period of time
     because the Shares have not been registered under the Securities Act and
     applicable state securities laws and, therefore, cannot be sold unless they
     are subsequently registered under the Securities Act and applicable state
     securities laws or unless an exemption from such registration is available.

          3.6 RESTRICTIVE LEGEND. The Subscriber consents to the placement of a
     restrictive legend on the certificates for the Shares as required by
     applicable securities laws.

          3.7  LOCK-UP AGREEMENT FOR PUBLIC OFFERING. In connection with any
     public offering of equity securities of the Company, the Subscriber agrees
     not to sell, pledge, transfer or otherwise dispose of, or grant any option
     or purchase right with respect to, any shares of capital stock then owned
     by it and not otherwise offered in any public offering, or engage in any
     short sale, hedging transaction or other derivative security transaction
     involving the Shares, or any other Shares of common stock of the Company
     held by it, for such period of time commencing thirty (30) days prior to
     the proposed effective date of such public offering until such period of
     time following such public offering as the Company and the managing
     underwriter of such public

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       56
<Page>

     offering deem necessary in order to ensure a stable and orderly trading
     market, provided however, that the period of time following such public
     offering shall not exceed one hundred and eighty (180) days.

          4.   REPRESENTATIONS, WARRANTS AND COVENANTS OF THE COMPANY. By its
     acceptance of this subscription, the Company hereby acknowledges,
     represents and warrants to the Subscriber as follows:

               4.1 ORGANIZATION. The Company is a corporation duly organized,
          validly existing and in good standing under the laws of the State of
          Delaware and has all requisite corporate power and authority to own
          and lease its properties, to carry on its business as presently
          conducted and as proposed to be conducted and to carry out the
          transactions contemplated hereby. The Company is qualified as a
          foreign corporation in all jurisdictions wherein the character of the
          property owned or leased or the nature of the activities conducted by
          it makes such qualification necessary.

               4.2 CAPITALIZATION. The Company has a total authorized
          capitalization consisting of Thirty Eight Million Three Hundred Eighty
          Thousand Seven Hundred Ninety (38,380,790) shares, of which (i) Twenty
          Four Million Twenty One Thousand Six Hundred Forty Five (24,021,645)
          shares are designated as Common Stock, and (ii) Fourteen Million Three
          Hundred Fifty Nine Thousand One Hundred Forty Five (14,359,145) shares
          are designated as preferred stock, $.001 par value per share, of which
          (A) One Million Two Hundred Fifty Thousand (1,250,000) are designated
          Series A Convertible Preferred Stock, (B) Five Hundred Thirty Thousand
          Two Hundred Five (530,205) are designated Series B Convertible
          Preferred Stock, (C) Four Million Four Hundred Thirty Seven Thousand
          Eight Hundred Sixty Five (4,437,865) are designated Series C
          Convertible Preferred Stock, (D) Four Million Six Hundred Twenty Three
          Thousand Four Hundred Eighty Seven (4,623,487) are designated Series D
          Convertible Preferred Stock and (E) Three Million Five Hundred
          Seventeen Thousand Five Hundred Eighty Eight (3,517,588) are
          designated Series E Convertible Preferred Stock. Immediately prior to
          the Closing, the issued and outstanding capital stock of the Company
          shall consist of 5,466,375 shares of Common Stock, 1,250,000 shares of
          Series A Convertible Preferred Stock, 530,205 shares of Series B
          Convertible Preferred Stock, 4,241,055 shares of Series C Convertible
          Preferred Stock, 4,623,487 shares of Series D Convertible Preferred
          Stock and 2,680,067 shares of Series E Convertible Preferred Stock.

               4.3 AUTHORIZATION OF AGREEMENT. The execution, delivery and
          performance of this Agreement by the Company has been duly authorized
          by all requisite corporate action, and this Agreement constitutes the
          legal, valid and binding obligation of the Company, enforceable
          against it in accordance with its terms. The execution, delivery and
          performance by the Company of this Agreement will not violate any
          provision of law, any order of any court or other agency of
          government, the organizational documents or By-Laws of the Company, or
          any provision of any indenture, agreement or other instrument by which
          the Company, or its respective properties or assets are bound or
          affected, or conflict with or result in a breach of or constitute
          (with due notice or lapse of time of both) a default under any such
          indenture, agreement or other instrument, or result in the creation or
          imposition of any lien, charge or encumbrance of any nature whatsoever
          upon any of the properties or assets of the Company.

               4.4 OFFEREES. The offer, sale and issuance of the Shares in
          conformity with the terms of the Agreement constitute transactions
          exempt from Section 5 of the Securities Act and from any applicable
          state qualification or registration requirements.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       57

<Page>

               4.5 NO CONSENT OR APPROVAL REQUIRED. (i) No consent of any person
          and (ii) except for approvals required under state securities or blue
          sky laws, no consent, approval or authorization of, or declaration to
          or filing with, any governmental or regulatory authority is required
          for the valid authorization, execution and delivery by the Company of
          this Agreement, or for the valid authorization, issuance and delivery
          of the Shares to the Subscriber pursuant to this Agreement other than
          those consents, approvals, authorizations, declarations or filing
          which have been obtained or made, as the case may be.

          5.   SURVIVAL OF ACKNOWLEDGMENTS REPRESENTATIONS, WARRANTIES AND
COVENANTS. The Subscriber agrees that the acknowledgements, representations,
warranties and covenants made in Section 3 hereof shall survive any purchase by
it of the Shares, as well as, investigation made by it or any acceptance or
rejection of this subscription. The Company agrees that the representations,
warranties and covenants made in Section 4 hereof shall survive for twelve
months subsequent to the date hereof.

          6.   AGREEMENT NOT TRANSFERABLE. The Subscriber understands that it
may not transfer or assign this Agreement or any of its rights hereunder.

          7.   EXECUTION OF FURTHER DOCUMENTATION. The Subscriber agrees to
execute any and all further documents necessary or advisable, in the sole
discretion of the Company, in connection with its proposed purchase of the
Shares.

          8.   IRREVOCABILITY OF SUBSCRIPTION. The Subscriber agrees that it may
not cancel, terminate or revoke this Agreement, which Agreement shall be binding
upon the Subscriber's successors and assigns.

          9.   COMPANY COVENANTS.

               9.1  The Company covenants and agrees that, from the date of the
          Closing under this Subscription Agreement and thereafter so long as
          the Subscriber owns at least 500,000 shares of Series E Convertible
          Preferred Stock, it will provide to the Subscriber within ninety (90)
          days after the end of each fiscal year of the Company, a copy of the
          financial statements for such year for the Company, including therein
          a balance sheet of the Company as of the end of such fiscal year and
          statements of income and stockholder's equity and of cash flows of the
          Company for such fiscal year.

               9.2 The covenant set forth above in 9.1 shall be of no further
          force or effect upon the closing of any public offering of equity
          securities of the Company.

          10.  MISCELLANEOUS.

               10.1 All notices or other communications given or made hereunder
          shall be in writing, and shall be delivered by hand or mailed by
          overnight mail, registered or certified mail, return receipt
          requested, postage prepaid, to the Subscriber or to the Company, at
          the respective addresses set forth herein.

               10.2 This Agreement shall be governed by and construed in
          accordance with the laws of the State of Delaware, without giving
          effect to the conflict of law principles thereof.

               10.3 This Agreement constitutes the entire agreement among the
          parties hereto with respect to the subject matter hereof, and may be
          amended only by a written agreement executed by the party to be bound
          thereby.

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       58
<Page>

                   SIGNATURE PAGE FOR SUBSCRIPTION AGREEMENT

Dated:  July ___, 2001

                                            SCHERING CORPORATION

                                            By:
                                               --------------------------------
                                               Name:
                                               Title:

Number of Shares subscribed for:            837,521

Total Amount of Subscription:               $5,000,000.37

Tax I.D. No.:
                                            -----------------------------------
Address:                                    2000 Galloping Hill Road
                                            Kenilworth, New Jersey 07033

         ACCEPTED by the Company this _____ day of July 2001

                                            NEOGENESIS DRUG DISCOVERY,
                                            INC.

                                            By:
                                               --------------------------------
                                               Allen H. Michels
                                               Chief Executive Officer

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       59
<Page>

                                    EXHIBIT A

                         NEOGENESIS DRUG DISCOVERY, INC.
                      REGULATION D QUALIFICATION STATEMENT

     (A) The undersigned qualifies as an "accredited investor" pursuant to
Regulation D under the Securities Act of 1933 as a result of its status as
(check the appropriate descriptions) [If you are NOT an Accredited Investor
please so indicate on the signature line below]:

___    1.     a natural person whose individual net worth, or joint net worth
              with his or her spouse, exceeds $1,000,000;

___    2.     a natural person who had an individual income in excess of
              $200,000 in each of the two most recent years, or joint income
              with his or her spouse in excess of $300,000 in each of those
              years, and who reasonably expects an income of the same level in
              the current year;

___    3.     a bank as defined in Section 3(a)(2) of the Securities Act of 1933
              or savings and loan association or other institution as defined in
              Section 3(a)(S)(A) of the Securities Act of 1933, whether acting
              in its individual or fiduciary capacity;

___    4.     a broker or dealer registered pursuant to Section 15 of the
              Securities Exchange Act of 1934;

___    5.     an insurance company as defined in Section 2(13) of the
              Securities Act of 1933;

___    6.     an investment company registered under the Investment Company Act
              of 1940 or a business development company as defined in Section 2
              (a)(48) of the Investment Company Act of 1940;

___    7.     a small business investment company licensed by the U.S. Small
              Business Administration under Section 301(c) or (d) of the Small
              Business Investment Act of 1958;

___    8.     an employee benefit plan within the meaning of Title I of the
              Employee Retirement Income Security Act of 1974, if any of the
              following apply:

       ___    a.  the employee benefit plan has total assets in excess of
                  $5,000,000; or

       ___    b.  the investment decision is made by a plan fiduciary, as
                  defined in Section 3(21) of such Act, which is either a bank,
                  savings and loan association, insurance company, or registered
                  investment adviser; or

       ___    c.  the plan is a self-directed plan in which the investment
                  decisions are made solely by persons who are accredited
                  investors. (Please put an "*" in the appropriate
                  description(s) to indicate how the person(s) making
                  investment decisions are "accredited");

___    9.     a private business development company as defined in Section 202
              (a)(22) of the Investment Advisers Act of 1940;

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       60

<Page>

___    10.    a charitable, educational, religious or other not-for-profit
              organization described in Section 501(c)(3) of the Internal
              Revenue Code with total assets in excess of $5,000,000 and not
              formed for the specific purpose of acquiring the securities
              offered;

___    11.    a corporation, Massachusetts or similar business trust, or
              partnership with total assets in excess of $5,000,000 and not
              formed for the specific purpose of acquiring the securities
              offered;

___    12.    a trust with total assets greater than $5,000,000 not formed for
              the purpose of acquiring the securities offered whose purchase is
              directed by a person who has such knowledge and experience in
              financial and business matters that he is capable of evaluating
              the merits and risks of the investment;

___    13.    an entity in which all of the equity owners are "accredited
              investors" under any one or more of the categories specified in
              subparagraphs 1 through 12 above.

       (B)    IF THE UNDERSIGNED IS A CORPORATION, PARTNERSHIP OR TRUST (CHECK
              1. OR 2.):

___    1.     it was not organized or reorganized for the purpose of making an
              investment in NeoGenesis Drug Discovery, Inc. or

___    2.     if it was organized or reorganized for the purpose of making an
              investment in NeoGenesis Drug Discovery, Inc., the number of
              investors in the undersigned (all of whom are accredited
              investors) is  (Each such investor should complete and execute
              its own Regulation D Qualification Statement.)

       (C)    The undersigned's state of residence is ______________________.

CHECK IF APPLICABLE:                   ____ I AM NOT AN ACCREDITED INVESTOR

                                       SCHERING CORPORATION

Dated:  July ___, 2001                 Signature:
                                                 -----------------------------
                                       Name:
                                            ----------------------------------
                                       Title:
                                             ---------------------------------

*= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       61<Page>

                                                                   Exhibit 10.14

                             CONFIDENTIAL TREATMENT

                                    AGREEMENT
This Agreement (AGREEMENT) is entered into as of August 30, 2001 (EFFECTIVE
DATE) between NeoGenesis Drug Discovery, Inc., a Delaware corporation
(NEOGENESIS), and Tularik Inc. (TULARIK), a Delaware corporation, and sets forth
the terms and conditions that will apply to the provision by NeoGenesis to
Tularik of certain screening and analysis services.

                                   BACKGROUND
Tularik is interested in identifying potential pharmaceutical products for
treatment of certain human diseases and wishes to identify compounds that
exhibit a high degree of chemical binding and functional activity to specific
protein targets. NeoGenesis has certain technology and know-how, including
screening processes and libraries of mass-encoded small molecule compounds,
relating to the identification, discovery, validation and optimization of novel
compounds which may be useful for development of novel therapeutics employing
targets implicated in a disease process. The parties wish to pursue a
collaborative screening process to identify compounds exhibiting a high degree
of chemical binding activity to targets designated by Tularik from among the
NeoGenesis libraries of mass-encoded small molecule compounds and which have
activity in bioassays or functional assays. The terms and conditions set forth
below shall govern the performance of such collaborative effort.

1.   DEFINITIONS.

1.1 DEFINED TERMS. Capitalized terms used in this Agreement and not otherwise
defined herein shall have the meaning set forth below.

     AFFILIATE means with respect to either party, any Person that, directly or
indirectly, is controlled by, controls or is under common control with such
party. For purposes of this definition only, "CONTROL" means, with respect to
any Person, the direct or indirect ownership of more than fifty percent (50%) of
the voting or income interest in such Person or the possession otherwise,
directly or indirectly, of the power to direct the management or policies of
such Person.

     ALIS means the Automated Ligand Identification System, an automated,
ultra-high throughput ligand selection system proprietary to NeoGenesis that is
used to identify multiple classes of chemical ligands against a target protein.

     APPLICABLE LAWS means all applicable laws, statutes, regulations and
ordinances, including without limitation the FD&C Act.

     COMMERCIALLY REASONABLE EFFORTS means (i) with respect to any objective by
any party, commercially reasonable, diligent, good faith efforts to accomplish
such objective as such party would normally use to accomplish a similar
objective under similar circumstances; and (ii) with respect to any objective
relating to the development or Commercialization of any Product or Shared
Product by any party, efforts and resources normally used by such party with
respect to a product owned by such party or to which such party has similar
rights which is of similar market potential at a similar stage in the
development or life of such product, taking into account issues of safety,
efficacy, product profile, the competitiveness of the marketplace, the
proprietary position of the product, the regulatory structure involved,
profitability of the product and other relevant commercial factors.

     COMMERCIALIZATION means any and all activities of importing, exporting,
marketing, promoting, distributing, offering for sale and selling a Product or
Shared Product or Independent Product. When used as a verb, COMMERCIALIZE means
to engage in Commercialization.

     CONFIDENTIAL INFORMATION means any proprietary or confidential information
of either party (including but not limited to all Tularik Intellectual Property
and all NeoGenesis Intellectual Property) disclosed to the other party pursuant
to this Agreement, except any portion thereof which: (i) is known to the
receiving party, as evidenced by the

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

<Page>

receiving party's prior written records, before receipt thereof under this
Agreement; (ii) is disclosed to the receiving party by a third person who is
under no obligation of confidentiality to the disclosing party hereunder with
respect to such information and who otherwise has a right to make such
disclosure; (iii) is or becomes generally known in the public domain through no
fault of the receiving party; or (iv) is independently developed by the
receiving party, as evidenced by the receiving party's written records, without
access to such information.

     CONTROL OR CONTROLLED means, with respect to any intellectual property
right, the possession (whether by ownership or license) by a party or an
Affiliate thereof of the ability to grant to the other party access or a license
as provided herein under such item or right without violating the terms of any
agreement or other arrangements between such party or its Affiliate and any
third party existing before, or acquired after, the Effective Date.

     COST OF GOODS means the cost of manufacturing the Designated Selected
Compound or Product or the Designated Shared Compound or Shared Product or
Independent Compound or Independent Product in bulk or finished form (including
samples) calculated in accordance with GAAP. Cost of Goods shall include: (a)
the Cost of Manufacture for Designated Selected Compounds and Products or the
Designated Shared Compounds and Shared Products or the Independent Compounds and
Independent Products manufactured by either party or the amount paid for
Designated Selected Compounds and Products or the Designated Shared Compounds
and Shared Products manufactured or the Independent Compounds and Independent
Products by a third party; and (b) the net cost or credit of any value-added
taxes or duties actually paid or utilized in respect of the Designated Selected
Compounds and Products or the Designated Shared Compounds and Shared Products or
the Independent Compounds and Independent Products.

     COST OF MANUFACTURE means the fully-allocated cost of manufacturing
Designated Selected Compounds and Products or Designated Shared Compounds and
Shared Products or the Independent Compounds and Independent Products
(calculated in accordance with GAAP), including the direct and indirect cost of
any raw materials, packaging materials and labor (including the cost of employee
benefits) utilized in such manufacturing (including formulating, filling,
finishing, labeling and packaging, as applicable) plus factory overhead costs
(fixed and variable) allocated to the relevant Designated Selected Compound,
Product, Designated Shared Compound, Shared Product, Independent Compound or
Independent Product in accordance with normal accounting practices for all
products manufactured in the applicable facility.

     DERIVATIVE COMPOUNDS means any analogs, homologs or isomers of a Designated
Screening Compound, a Designated Shared Compound and/or an Independent Compound,
as applicable.

     DESIGNATED COMPOUNDS means Designated Screening Compounds and Designated
Shared Compounds.

     DEVELOPMENT shall mean the development of any Shared Product occurring from
and after the filing of an IND, through and including approval of an NDA and any
other Regulatory Approvals required for the Manufacture and Commercialization of
such Shared Product in a country. Development shall not include Pre-Clinical
Development activities.

     DEVELOPMENT COSTS shall mean all costs and expenses reasonably resulting
directly from the Pre-Clinical Development of any Designated Shared Compound or
Development of any Shared Product, as well as Overhead costs of the functions
that directly support such Pre-Clinical Development or Development (as
calculated in accordance with GAAP and using the same allocation methods that
the party incurring such costs uses throughout its operations, but in all events
excluding General Corporate Overhead), all as specified in the Development Plan
and the Development Budget. DEVELOPMENT COSTS shall include, without limitation:
(i) the Cost of Goods for the Designated Shared Compound used in such
Pre-Clinical Development or Shared Product used in such Development (including
early batches of the Shared Product for use in obtaining Regulatory Approval, to
the extent not re-used later in commercial sales); (ii) direct costs for third
party professional Pre-Clinical Development or Development services, including
without limitation toxicology studies or clinical studies performed by third
parties; (iii) direct charges for materials (including without limitation
chemicals, animals and lab supplies); (iv) labor and materials

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       1
<Page>

costs and fees incurred in connection with securing Regulatory Approvals; (v)
labor and materials costs for the Development of the Manufacturing process for
Shared Products and scale-up of such process; and (vi) the costs of FTEs
dedicated to the foregoing activities.

     DIRECT ADMINISTRATIVE EXPENSES means the costs of invoicing, tracking and
administering rebate and chargeback programs and product returns and of
establishing and maintaining contracts with managed care organizations and
governmental purchasers.

     DISTRIBUTION COSTS means the costs of distributing and shipping the Shared
Product and samples to wholesalers, distributors, physicians and customers
(including costs of returns) and costs of collection. In the event that such
costs cannot be calculated on a Shared Product-by-Shared Product basis, such
costs shall be calculated by multiplying: (i) the aggregate distribution costs
incurred by the party's pharmaceutical business for all pharmaceutical products
that shall be calculated correspondingly according to the formula set forth in
this paragraph; by (ii) a fraction, (x) the numerator of which is the Net Sales
for such Shared Product; and (y) the denominator of which is the total net sales
of all pharmaceutical products of the party's pharmaceutical business that shall
be calculated correspondingly according to the formula for Net Sales under this
Agreement.

     EXPENSES shall mean expenses incurred by a party to the extent allocable to
the Commercialization of Shared Products in all countries in the Territory,
calculated in accordance with GAAP. EXPENSES shall include, without limitation,
the following: (a) the Cost of Goods; (b) Pre-Launch Expenses; (c) Distribution
Costs; (d) Selling and Promotion Expenses; (e) Third Party Royalties; (f)
Post-Regulatory Approval Clinical Studies Expenses; (g) Direct Administrative
Expenses; (h) Recall Expenses; and (i) Other Allowable Expenses.

     FDA means the United States Food and Drug Administration, or any successor
thereto.

     FD&C ACT means the United States Federal Food, Drug and Cosmetic Act of
1938 and applicable regulations promulgated thereunder, as amended from time to
time.

     FIELD means all preventative, therapeutic and diagnostic uses in humans.

     FIRST COMMERCIAL SALE of product(s) means any transfer for value in an
arms'-length transaction to an independent third party distributor, agent or end
user in a country within the Territory after obtaining all necessary Regulatory
Approvals as may be necessary for such transfer in such country.

     FORCE MAJEURE means any event beyond the control of the parties, including,
without limitation, power outages, fire, flood, riots, strikes, epidemics, war
(declared or undeclared and including the continuance, expansion or new outbreak
of any war or conflict now in existence), embargoes and governmental actions or
decrees.

     FTE means the equivalent of a full time (12) months (including normal
vacations, sick days and holidays) work of a person, carried out by one or more
employees or agents of a party.

     FTE RATE means an amount not to exceed [*] per FTE per year.

     GAAP shall mean United States Generally Accepted Accounting Principles,
consistently applied.

     GENERAL CORPORATE OVERHEAD shall mean all expenses that are not primarily
associated with research, Pre-Clinical Development or Development functions of
either party. Such expenses include salaries and benefits of executive officers
(unless primarily involved in research, Pre-Clinical Development or Development
activities), administrative support for such officers, and all costs of the
finance, purchasing, legal (including both in-house and outside counsel),
business development and corporate development functions of both parties. In the
event that such costs cannot be calculated on a Designated Shared
Compound-by-Designated Shared Compound or Shared Product-by-Shared Product
basis, such costs shall be calculated by multiplying: (i) the aggregate general
corporate overhead incurred by the party's pharmaceutical business for all
pharmaceutical products that shall be calculated

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

correspondingly according to the formula set forth in this paragraph; by (ii) a
fraction, (x) the numerator of which is the Net Sales for such Shared Product;
and (y) the denominator of which is the total net sales of all pharmaceutical
products of the party's pharmaceutical business that shall be calculated
correspondingly according to the formula for Net Sales under this Agreement.

     GOOD CLINICAL PRACTICES means the then current standards for clinical
trials for pharmaceuticals, as set forth in the FD&C Act and such standards of
good clinical practice as are required by the European Union and other
Regulatory Authorities in countries in which the relevant product is intended to
be sold, to the extent such standards are not in contravention with United
States Good Clinical Practices.

     GOOD LABORATORY PRACTICES or GLP means the then current standards for
laboratory activities for pharmaceuticals, as set forth in the FD&C Act and such
standards of good laboratory practice as are required by the European Union and
other Regulatory Authorities in countries in which the relevant product is
intended to be sold, to the extent such standards are not in contravention with
United States Good Laboratory Practices.

     GOOD MANUFACTURING PRACTICES means the current standards for the
manufacture of pharmaceuticals, as set forth in the FD&C Act and such standards
of good manufacturing practice as are required by the European Union and other
Regulatory Authorities in countries in which the relevant product is intended to
be sold, to the extent such standards are not in contravention with United
States Good Manufacturing Practices.

     IND means an investigational new drug application, as defined in the FD&C
Act, or any equivalent document filed with the FDA and necessary for beginning
clinical trials of any product in humans or any application or other
documentation filed with any Regulatory Authority of a country other than the
United States prior to beginning clinical trials of any product in humans in
that country.

     INVENTION(S) means discoveries, inventions, know-how, trade secrets,
techniques, methodologies, modifications, improvements, works of authorship,
designs and data (whether or not protectable under patent, copyright, trade
secrecy or similar laws).

     MAJOR COUNTRY mean the United States, the United Kingdom, France, Germany
or Japan, as the case may be.

     MANUFACTURING means any and all activities involved in the production of a
Designated Screening Compound, a Designated Shared Compound or an Independent
Compound (and Derivative Compounds thereof) or a Product or a Shared Product or
a Independent Product to be developed and/or Commercialized under this
Agreement. When used as a verb, MANUFACTURE means to engage in Manufacturing.

     MARKETING, ADVERTISING AND EDUCATION EXPENSES means the costs of public
relations, advertising, promotion and marketing of the Shared Product through
any means (including agency fees, advertisements, marketing management,
promotional literature, market research, symposia, exhibits and direct mail) and
the costs of educating physicians and customers about use of the Shared Product.
In the event that such costs cannot be calculated on a Shared Product-by-Shared
Product basis, such costs shall be calculated by multiplying: (i) the aggregate
marketing, advertising and education expenses incurred by the party's
pharmaceutical business for all pharmaceutical products that shall be calculated
correspondingly according to the formula set forth in this paragraph; by (ii) a
fraction, (x) the numerator of which is the Net Sales for such Shared Product;
and (y) the denominator of which is the total net sales of all pharmaceutical
products of the party's pharmaceutical business that shall be calculated
correspondingly according to the formula for Net Sales under this Agreement.

     A MEDICINAL CHEMISTRY EFFORT begins, in the case of a Designated Screening
Compound, following the synthesis by Tularik of more than [*] of a Designated
Screening Compound provided by NeoGenesis, and, in the case of a Designated
Shared Compound, following the synthesis by the parties (as determined by the
Steering Committee) of more than a [*] of a Designated Shared Compound provided
by NeoGenesis.

     NDA means a new drug application as defined in the FD&C Act and the
non-U.S. equivalent thereof.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

     NEOGENESIS INTELLECTUAL PROPERTY means, individually and collectively, (a)
all Inventions that are conceived, discovered, developed, generated, created,
made or reduced to practice or tangible medium of expression solely by employees
or consultants of NeoGenesis at any time prior to the Effective Date, or after
the Effective Date if such Inventions are not based upon or related to the
performance of the Program; (b) any tangible materials provided by NeoGenesis to
Tularik for use in the conduct of the Program, together with, where applicable,
any analogs, derivatives, fragments, progeny, sub-cellular constituents or
expression products thereof; and (c) the NeoMorph Screening Library, ALIS and
QSCD. The term NeoGenesis Intellectual Property, HOWEVER, does not include any
techniques, methodologies, know-how, information and data which is, as of the
Effective Date, or later becomes, generally available to the public, other than
such techniques, methodologies, know-how, information and data included in
NeoGenesis Patent Rights.

     NEOGENESIS PATENT RIGHTS means those (a) patents and patent applications
covering NeoGenesis Intellectual Property and Program Intellectual Property
owned by or licensed to NeoGenesis that are Controlled by NeoGenesis at any time
during the term of this Agreement; and (b) all divisionals, continuations,
continuations-in-part, reissues, extensions, supplementary protection
certificates and foreign counterparts thereof. NeoGenesis shall list all
NeoGenesis Patent Rights on ATTACHMENT D, which will be updated by NeoGenesis no
less frequently than quarterly during the term of this Agreement.

     NEOMORPH CHEMISTRY means the process, proprietary to NeoGenesis, of forming
libraries and sub-libraries of discrete compounds by coupling a broad set of
diverse cores with diverse sets of building blocks employing proprietary
mass-coding algorithms.

     NEOMORPH FOCUSED LIBRARIES means those compounds synthesized by NeoGenesis
based upon Selected Compounds identified by Tularik.

     NEOMORPH SCREENING LIBRARY means the entire collection of libraries
consisting of mass-encoded small molecule organic compounds owned by NeoGenesis
and developed with NeoMorph Chemistry, comprising approximately ten million
(10,000,000) different compounds.

     NET SALES means, with respect to any Product, Shared Product or Independent
Product, the aggregate gross amount received by Tularik, its Affiliates or any
of its sublicensees (in the case of a Product), by the parties, their Affiliates
or any of their sublicensees (in the case of a Shared Product) or by the
Independent Party, its Affiliates or any of its sublicensees (in the case of an
Independent Product) from unrelated third party distributors or agents (in each
case, who are not sublicensees), or end users in the Territory for the sale or
transfer for value of the applicable Product or Shared Product or Independent
Product LESS deductions for (a) trade, quantity and cash discounts and rebates
allowed to and taken by customers, (b) refunds, chargebacks and any other
allowances actually paid to or taken by customers, (c) amounts separately and
actually credited to customers for Product or Shared Product or Independent
Product returns, credits or allowances, (d) rebates actually paid or credited to
any governmental agency (or branch thereof) or to any third party payor,
administrator or contractee, (e) discounts mandated by, or granted to meet the
requirements of, applicable state, provincial or federal law, paid or credited
to a wholesaler, purchaser, third party or other contractee including required
chargebacks and retroactive price reductions, (f) special outbound packing,
transportation, freight, handling, postage charges and other charges such as
insurance relating thereto that are separately billed to the customer or prepaid
and (g) sales, excise, value added, turnover, use and other like taxes or
customs duties paid and any other governmental charges, excluding net income
tax, imposed upon the sale of the applicable Product or Shared Product or
Independent Product. The amounts of any deductions taken pursuant to clauses
(a)-(g) shall be determined from books and records maintained in accordance with
GAAP. Net Sales shall not include revenue received by a party (or any of its
Affiliates) from transactions with an Affiliate, where the Product or Shared
Product or Independent Product in question will be resold to an independent
third-party distributor or agent (in each case, who is not a sublicensee) or end
user by the Affiliate where such revenue received by the Affiliate from such
resale is included in Net Sales. Revenue received by a party (or any of its
Affiliates) from transactions with an Affiliate, where the Product or Shared
Product or Independent Product in question is used by the

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       4
<Page>

Affiliate solely for such Affiliate's internal purposes shall also be included
in Net Sales at a price equal to the fair market value of such transfer(s).

In the event the applicable Product or Shared Product or Independent Product is
sold as part of a combination product, or as part of a bundled product or as
part of a delivery system, the Net Sales from the combination product, bundled
product or delivery system, for the purposes of determining royalty payments,
shall be determined by multiplying the Net Sales (as defined above) of the
combination product by the fraction, A/(A+B) where A is the average sale price
of the Product or Shared Product or Independent Product when sold separately in
finished form and B is the average sale price of the other product(s) or system
sold separately in finished form or where A+B is the average sale price of the
product(s) and the delivery system together, as the case may be. In the event
that such average sale price cannot be determined for both the product and such
other product(s) or system in combination, Net Sales for purposes of determining
royalty payments shall be calculated by multiplying the Net Sales of the
combination products by the fraction C/(C+D) where C is the party's Cost of
Goods of the Product or Shared Product or Independent Product and D is the
party's cost of goods for the other product(s) or system, determined in
accordance with the method of accounting normally employed by such party in
computing cost of goods.

     OTHER ALLOWABLE EXPENSES means any costs incurred by the parties (i) in
obtaining and enforcing intellectual property rights relating to Shared
Products, included in the NeoGenesis Patent Rights, Tularik Patent Rights,
NeoGenesis Intellectual Property, Tularik Intellectual Property, Program Patent
Rights and Program Intellectual Property, (ii) in defending against any third
party claim of infringement of such third party's intellectual property rights
or of property damage or injury or death to persons arising out of or relating
to the Manufacturing, use, sale, offer for sale or import of Shared Products and
(iii) as set forth in Section 4A.24.

     OVERHEAD shall mean facilities costs (including rent, depreciation,
utilities, insurance, taxes, repairs and maintenance), freight and
communications expenses, supervisory costs and costs of administrative support,
but shall not include General Corporate Overhead. In the event that such costs
cannot be calculated on a Designated Shared Compound-by-Designated Shared
Compound or Shared Product-by-Shared Product basis, such costs shall be
calculated by multiplying: (i) the aggregate overhead incurred by the party's
pharmaceutical business for all pharmaceutical products that shall be calculated
correspondingly according to the formula set forth in this paragraph; by (ii) a
fraction, (x) the numerator of which is the Net Sales for such Shared Product;
and (y) the denominator of which is the total net sales of all pharmaceutical
products of the party's pharmaceutical business that shall be calculated
correspondingly according to the formula for Net Sales under this Agreement.

     PERSON means any individual, corporation, association, partnership (general
or limited), joint venture, trust, estate, limited liability company, limited
liability partnership, unincorporated organization, government (or any agency or
political subdivision thereof) or other legal entity or organization, other than
NeoGenesis or Tularik.

     PHASE I CLINICAL TRIALS means any human clinical trials, the principal
purpose of which is a preliminary determination of safety of a Product, Shared
Product or Independent Product, as the case may be, for its intended use in
healthy individuals or patients to support its continued testing in similar
clinical trials prescribed by the relevant Regulatory Authorities.

     PHASE II CLINICAL TRIALS means any human clinical trials for which a
Primary Endpoint is a preliminary determination of safety, biological activity,
efficacy or dose ranges of a Product, Shared Product or Independent Product, as
the case may be, in patients with the disease target being studied as required
by the relevant Regulatory Authorities.

     PHASE III CLINICAL TRIALS means any safety and/or efficacy clinical studies
of any Product, Shared Product or Independent Product, as the case may be, in
human patients with the disease target being studied to determine safety and
efficacy of such Product, Shared Product or Independent Product, as the case may
be, in patients as required by the relevant Regulatory Authorities.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       5
<Page>

     POST-REGULATORY APPROVAL CLINICAL STUDIES EXPENSES means the cost of
conducting clinical trials conducted after Regulatory Approval of Shared
Products in a country, costs of monitoring adverse drug reactions, cost of
handling quality control complaints, costs associated with maintaining the
regulatory approval of Shared Products and reasonably allocable regulatory
affairs group overhead costs.

     PRE-CLINICAL DEVELOPMENT means all aspects of all activities (including,
but not limited to: medicinal chemistry, cytotoxicity and target specificity,
chemical development/scale-up; formulation; stability; non-GLP, GLP, acute and
chronic toxicity studies; pharmacokinetics; absorption, distribution, metabolism
and excretion (ADME) studies; and safety pharmacology) that will be undertaken
with respect to a Designated Shared Compound or Independent Compound or
Derivative Compound thereof, as the case may be, that are necessary or desirable
to enable the filing of an IND for a Shared Product or Independent Product based
upon or incorporating such Designated Shared Compound or Independent Compound or
Derivative Compound thereof, including the preparation and filing of an IND.

     PRE-LAUNCH EXPENSES means direct costs, specifically allocable to the
Shared Products, incurred prior to commencement of sales of the Shared
Product including advertising, education, sales force training, Phase IIIb
clinical trials, trademark selection, filing and enforcement costs and
includes the Marketing, Advertising and Education Expenses.

     PRIMARY ENDPOINT means, with respect to a Phase II Clinical Trial, the
point at which positive statistical significance has been achieved with respect
to the primary endpoint specified in the protocol for such trial.

     PRODUCT(S) means any product: (a) made up of, comprising or containing a
Designated Screening Compound or a Derivative Compound thereof; and (b) the
development, manufacture, use or sale of which, absent the license granted to
Tularik under Section 3.1 OR the rights assigned to Tularik under Section 3.2(d)
of this Agreement, would infringe the NeoGenesis Intellectual Property or
NeoGenesis Patent Rights or which make use of any Program Patent Rights with
respect to which NeoGenesis, its employees or agents is an inventor (as
determined under U.S. patent laws.).

     PROGRAM means the Screening Program and the activities undertaken in
connection with Section 4A with respect to Designated Shared Compounds,
Derivative Compounds thereof, Shared Products, Independent Compounds, Derivative
Compounds thereof and Independent Products.

     PROGRAM INTELLECTUAL PROPERTY means, individually and collectively, all
Inventions that are conceived, created, discovered, developed, generated, made
or reduced to practice or tangible medium of expression: (a) solely by one or
more employees or consultants of NeoGenesis at any time if such Inventions are
based upon or related to the performance of the Program; (b) jointly by one or
more employees or consultants of NeoGenesis and one or more employees or
consultants of Tularik at any time if such Inventions are based upon or related
to the performance of the Program; or (c) solely by one or more employees or
consultants of Tularik at any time if such Inventions are based upon or related
to the performance of the Program. Program Intellectual Property will be listed
in ATTACHMENT B, which shall be amended from time-to-time to include new Program
Intellectual Property, in accordance with Section 3.3.

     PROGRAM PATENT RIGHTS means (a) those patents and patent applications
covering Program Intellectual Property and (b) all divisionals, continuations,
continuations-in-part, reissues, extensions, supplementary protection
certificates and foreign counterparts thereof.

     QSCD means Quantized Surface Complimentary Diversity, a model proprietary
to NeoGenesis, pursuant to which discrete chemical compliments to the surfaces
of a Target are defined.

     R&D PROGRAM means on a Designated Screening Compound-by-Designated
Screening Compound and country-by-country basis the activities Tularik deems
necessary or desirable to be undertaken in connection with the research and
development of such Designated Screening Compound with the goal of obtaining
Regulatory Approval for a Product in such country (regardless of the country in
which such activities are conducted).

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       6
<Page>

     RECALL EXPENSES means expenses associated with any Shared Product recall or
any FDA (or its foreign equivalent) mandated communication relating to a
potential recall of any Shared Product.

     REGULATORY APPROVALS means, for any country in the Territory, those
authorizations by the appropriate Regulatory Authority(ies) required for the
Manufacture, importation, marketing, promotion, pricing and sale of the
Product(s) or Shared Product(s) in such country.

     REGULATORY AUTHORITY means any national, supra-national, regional, state or
local regulatory agency, department, bureau, commission, council or other
governmental entity in the Territory, including, without limitation, the FDA.

     SCREENING PROGRAM means the screening program described in paragraphs 1-10
of ATTACHMENT A as the same may be amended by mutual written agreement of the
parties acting through the Steering Committee; but subject to the limitation
specified in Section 2.7(b)(i).

     SCREENING TARGETS means Targets selected by Tularik for which the screening
fee described in Section 4.2, the success payment described in Section 4.3, the
milestone payments described in Section 4.4 and the royalties described in
Section 4.5 are due from Tularik to NeoGenesis as specified in Section 4.

     SELLING AND PROMOTION EXPENSES means direct costs, specifically allocable
to a Shared Product, incurred for the sale (including costs of sales forces,
sales force incentives specific to a Shared Product, customer targeting, call
reporting and other monitoring/tracking costs, training of sales force and other
regional sales management) and the promotion (including costs of promotional
literature, symposia, industry trade shows, exhibits and direct mail) of a
Shared Product and which are not also characterized as Marketing, Advertising
and Education Expenses. In the event that such costs cannot be calculated on a
Shared Product-by-Shared Product basis, such costs shall be calculated by
multiplying: (i) the aggregate selling and promotion expenses incurred by the
party's pharmaceutical business for all pharmaceutical products that shall be
calculated correspondingly according to the formula set forth in this paragraph;
by (ii) a fraction, (x) the numerator of which is the Net Sales for such Shared
Product; and (y) the denominator of which is the total net sales of all
pharmaceutical products of the party's pharmaceutical business that shall be
calculated correspondingly according to the formula for Net Sales under this
Agreement.

     SHARED PRODUCT(S) means any product made up of, comprising or containing a
Designated Shared Compound or a Derivative Compound thereof. SHARED PRODUCTS
shall not include Products.

     SHARED PRODUCT LOSSES means in any calendar year the excess, if any, by
which Expenses exceed Net Sales.

     SHARED PRODUCT PROFITS means in any calendar year the excess, if any, by
which Net Sales exceed Expenses.

     SHARED TARGETS means Targets proposed by Tularik and approved by NeoGenesis
for which no screening fee, success payments, milestones or royalties are due.
Instead, NeoGenesis and Tularik shall contribute equally to the further
research, Pre-Clinical Development and Development of compounds active against
Shared Targets, and all costs related to such activities in respect of such
Shared Targets, and NeoGenesis and Tularik shall share equally in the proceeds
of any resulting product(s), as described in Section 4A.

     SUBLICENSE REVENUES means revenues or other consideration received from
such sublicensee as consideration for the grant of such sublicense, less the
expenses directly attributable to supplying goods and services to such
sublicensees to enable their practice of such sublicenses (excluding all amounts
received for the purchase of an equity interest in, or as a loan to, a party, in
each case at the fair market value thereof.)

     SUBSTANTIAL COMPETITION means market penetration in a country with respect
to a Product by one or more third parties with a product with the same active
ingredient, which market penetration, with respect to such Product, cumulatively
amounts to more than [*] market share of all products containing the same active
ingredient determined on a per unit basis in such country during a calendar
year.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       7
<Page>

     SUCCESS CRITERIA means that Tularik identifies at least one Designated
Screening Compound as set forth in Section 2.8 or elects to participate in the
Pre-Clinical Development of at least one Designated Shared Compound as set forth
in Section 4A.2, on each of at least two (2) Targets included in the Proof of
Concept Stage, and each such Designated Compound must show activity such that
Tularik initiates (in the case of a Designated Screening Compound) or the
parties (in the case of a Designated Shared Compound) initiate a Medicinal
Chemistry Effort with respect to such Designated Compound.

     TARGET means a specific protein target(s) selected or proposed by Tularik,
as applicable, for which NeoGenesis will perform the Screening Program. A Target
may be either a Screening Target or a Shared Target. An Excluded Target is not a
Target for purposes of this Agreement until such time, if any, as it becomes a
Screening Target or a Shared Target.

     TERRITORY means all the countries of the world.

     THIRD PARTY ROYALTIES means any consideration approved by the Steering
Committee and paid to third parties pursuant to Section 4A.13.

     TULARIK INTELLECTUAL PROPERTY means, individually and collectively, (a) all
Inventions that are conceived, discovered, developed, generated, created, made
or reduced to practice or tangible medium of expression solely by employees or
consultants of Tularik at any time prior to the Effective Date, or after the
Effective Date, if such Inventions are not based upon or related to the
performance of the Program; (b) any tangible materials provided by Tularik to
NeoGenesis for use in the conduct of the Program, together with, where
applicable, any analogs, derivatives, fragments, progeny, sub-cellular
constituents or expression products thereof; (c) the Targets or the uses
thereof; and (d) the functional and/or secondary assays provided by Tularik
under the Program. The term Tularik Intellectual Property, HOWEVER, does not
include any techniques, methodologies, know-how, information and data which is,
as of the Effective Date or later becomes, generally available to the public,
other than such techniques, methodologies, know-how, information and data
included in Tularik Patent Rights.

     TULARIK PATENT RIGHTS means (a) those patents and patent applications
covering Tularik Intellectual Property and Program Intellectual Property owned
by or licensed to Tularik that are Controlled by Tularik at any time during the
term of this Agreement which relate to or otherwise would be infringed by the
performance of the Screening Program or the Development, Manufacture, use,
importation or sale of any Designated Shared Compound or Shared Product and, to
the extent permitted under Section 4A.15, Independent Compounds and Independent
Products and (b) all divisionals, continuations, continuations-in-part,
reissues, extensions, supplementary protection certificates and foreign
counterparts thereof.

     VALID CLAIM means (i) a claim of an unexpired and issued patent which has
not been found to be invalid or unenforceable by a court or other authority of
competent jurisdiction in the subject country in a decision which is
unappealable or not appealed; or (ii) a claim of a pending application, which
application, taking into consideration the earliest priority date, has not been
pending for more than five (5) years.

1.2 OTHER DEFINED TERMS. The following terms shall have the meanings set forth
in the section appearing opposite such term:

<Table>
<Caption>
        <S>                                    <C>
        AGREEMENT                              Recitals
        BANKRUPTCY CODE                        Section 3.1
        COMPLETION OF SCREENING                 Section 4.2
        CONVERTIBLE NOTE                       Section 4.1
        DESIGNATED SCREENING COMPOUND(S)       Section 2.8
        DESIGNATED SHARED COMPOUND(S)          Section 4A.2
        DEVELOPMENT BUDGET                     Section 4A.7
        DEVELOPMENT PLAN                       Section 4A.7
        DISCONTINUED COMPOUND(S)               Section 4A.3
        DISCRETE COMPOUND(S)                   ATTACHMENT A
</Table>

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       8
<Page>

<Table>
<Caption>
        <S>                                    <C>
        DISPUTE NOTICE                         Section 9.1
        EFFECTIVE DATE                         Recitals
        EXCLUDED TARGET                        Section 2.2
        EXPANDED COLLABORATION                 Section 2.1
        FINAL TARGET REPORT                    ATTACHMENT A
        GENERIC RIGHTS                         Section 3.2
        INDEMNIFIED PARTY(IES)                 Section 7.2
        INDEMNIFYING PARTY                     Section 7.2
        INDEPENDENT COMPOUND(S)                Section 4A.15
        INDEPENDENT PARTY                      Section 4A.15
        INDEPENDENT PRODUCT                    Section 4A.15
        IPO                                    Section 4.1
        LICENSED TECHNOLOGY                    Section 3.1
        LOSSES                                 Section 7.2
        MARKETING BUDGET                       Section 4A.23
        MARKETING PLAN                         Section 4A.23
        NEOGENESIS                             Recitals
        NON-PROPOSED COMPOUND(S)               Section 4A.4
        NON-PROPOSED COMPOUND INTERESTED PARTY Section 4A.4
        OVERAGE THRESHOLD                      Section 4A.8
        PRELIMINARY COMPOUND(S)                ATTACHMENT A
        PRIMARY ACTIVE COMPOUND(S)             ATTACHMENT A
        PROOF OF CONCEPT STAGE                 Section 2.1
        RE-ENGAGEMENT AMOUNT                   Section 4A.16
        RE-ENGAGEMENT EXPIRATION DATE          Section 4A.16
        RE-ENGAGEMENT NOTICE                   Section 4A.16
        SELECTED COMPOUND(S)                   ATTACHMENT A
        SELECTED SCREENING COMPOUND(S)         ATTACHMENT A
        SELECTED SHARED COMPOUND(S)            ATTACHMENT A
        SHARE OF LOSS                          Section 4A.17
        SHARE OF PROFIT                        Section 4A.17
        STEERING COMMITTEE                     Section 2.7
        TERMINATED COUNTRIES                   Section 4A.23
        TULARIK                                Recitals
</Table>

2.   SCREENING PROGRAM; R&D PROGRAM; COMMERCIALIZATION

2.1 PROOF OF CONCEPT STAGE; EXPANDED COLLABORATION STAGE. (a) The parties shall
conduct an initial program encompassing [*] Targets (the PROOF OF CONCEPT STAGE)
as described in Section 2.1(b). If the Proof of Concept Stage meets the Success
Criteria or if elected by Tularik upon Tularik's notice to NeoGenesis that
Tularik desires to initiate an expanded collaboration regardless of achievement
of the Success Criteria during the Proof of Concept Stage or as set forth in the
last sentence of Section 4.1(c), the parties shall expand such collaboration for
an additional three (3) years as described in Section 2.1(c) (the EXPANDED
COLLABORATION). The parties shall enter into the Expanded Collaboration or not
enter into the Expanded Collaboration, as the case may be, not later than [*]
after the date the Success Criteria are satisfied or, if the Success Criteria
are not satisfied, not later than [*] after the completion by NeoGenesis of the
Proof of Concept Stage.

     (b) During the Proof of Concept Stage, Tularik shall provide NeoGenesis
with [*] Targets for screening: [*] Screening Targets and [*] Shared Targets.
Screening and, if elected by Tularik or the Steering Committee, as applicable,
optimization for each Target that is the subject of the Proof of Concept Stage
shall be completed within [*] following delivery of each Target to NeoGenesis,
such delivery to occur within [*] of the Effective Date. The [*] Targets and
their designation as Screening Targets or Shared Targets are identified in
ATTACHMENT C.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       9
<Page>

     (c) During the Expanded Collaboration (if any), Tularik shall select [*]
Targets as Screening Targets for the Expanded Collaboration. In addition, for
every [*] Screening Targets selected for the Expanded Collaboration, Tularik
shall propose [*] Shared Target to become the subject of the Expanded
Collaboration (up to a maximum of [*] Shared Targets during the Expanded
Collaboration). Timing for the screening of Screening Targets and Shared Targets
in the Expanded Collaboration shall be mutually agreed upon, but each such
screening shall be completed within [*] of delivery of the relevant Target to
NeoGenesis by Tularik.

     (d) Notwithstanding any provision of this Agreement to the contrary,
Tularik shall not be permitted to screen more than [*] Screening Targets in the
aggregate that [*].

     (e) The Proof of Concept Stage will have a duration of [*]. If applicable,
the Expanded Collaboration will have a duration of an additional thirty six
(36)-month period. The duration of the Screening Program will equal the duration
of the Proof of Concept Stage, and, if applicable, the Expanded Collaboration.

2.2 DISCLOSURE OF TARGETS. During the Program, Tularik shall from time to time
disclose Screening Targets selected by Tularik and/or Shared Targets proposed by
Tularik to NeoGenesis in writing. Within [*] of each disclosure of a selected or
proposed Target by Tularik, NeoGenesis shall notify Tularik as to whether such
Target is an Excluded Target. If NeoGenesis does not serve such notice within
the specified period, such Target shall not be an Excluded Target. NeoGenesis
may deem a Target as an Excluded Target if on the date NeoGenesis receives such
selected or proposed Target disclosure from Tularik: (a) NeoGenesis is
contractually prohibited from performing the screening contemplated in this
Agreement on such Target, (b) NeoGenesis has received a request from a third
party to provide screening on such Target and NeoGenesis reasonably expects to
commence such screening within [*] for such third party, or (c) NeoGenesis has
previously conducted screening on such Target for another party (each, an
EXCLUDED TARGET). Excluded Targets shall [*] Screening Targets to be supplied by
Tularik during the Expanded Collaboration. Such Excluded Targets shall not,
however, at Tularik's option, [*] Screening Targets to be supplied during the
Expanded Collaboration. NeoGenesis will promptly notify Tularik if an Excluded
Target that was excluded pursuant to Section 2.2(b) does not become the subject
of screening at NeoGenesis within said [*] period Tularik may have such Excluded
Target deemed a Target with notice to NeoGenesis.

2.3 DELIVERY OF TARGET PROTEINS. Tularik shall deliver the Targets for the Proof
of Concept Stage as set forth in Section 2.1. In the Expanded Collaboration,
Tularik shall deliver to NeoGenesis for screening (a) Screening Targets selected
by Tularik within [*] of selection or (b) Shared Targets proposed by Tularik
that have been accepted by NeoGenesis within [*] following written acceptance by
NeoGenesis of such Shared Targets. Tularik shall provide Targets in the
quantities and formats specified in ATTACHMENT A. Tularik shall also provide
NeoGenesis at the time of delivery with a written description of the
concentration and volume of the Target. Tularik shall deliver the Targets FOB to
NeoGenesis' Cambridge, Massachusetts facility.

2.4 EXCLUSIVITY. Notwithstanding any other provision in this Agreement, any
Targets screened by NeoGenesis on behalf of Tularik during the Proof of Concept
Stage or the Expanded Collaboration, as either Screening Targets or Shared
Targets, shall not be screened for a third party or internally at NeoGenesis
(nor shall NeoGenesis research, develop, make, use or sell any products active
against such Targets) during the Screening Program and for a period of [*]
following completion of all work by NeoGenesis under the Screening Program with
respect to such Target. Notwithstanding the foregoing, NeoGenesis shall not
screen any Target proprietary to Tularik: (a) for a third party, except upon the
request of such third party and not as a result of any solicitation by
NeoGenesis with respect to any Target, for a period of [*] following completion
of all work by NeoGenesis under the Screening Program with respect to such
Target; or (b) internally at NeoGenesis for a period of [*] following completion
of all work by NeoGenesis under the Screening Program with respect to such
Target. It is understood and acknowledged by NeoGenesis that the restrictions
imposed by this Section 2.4 will operate independently of and in addition to any
patent rights that Tularik may hold in respect of any Target and that,
notwithstanding the preceding sentence, NeoGenesis shall not screen any Target
covered by patent rights owned or controlled by Tularik.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       10
<Page>

2.5 GRANT OF RESEARCH LICENSES. (a) Tularik hereby grants NeoGenesis a
nonexclusive, nontransferable, royalty-free license to use Tularik
Intellectual Property and Program Intellectual Property owned by Tularik
(including Tularik Patent Rights) solely for purposes of conducting the
Screening Program and performing NeoGenesis' obligations under the Screening
Program. NeoGenesis will not use Tularik Intellectual Property and Program
Intellectual Property owned by Tularik for any other purpose, without
Tularik's prior written permission and except as otherwise permitted by the
licenses granted in Sections 3.1 and 3.2(f). NeoGenesis shall not (i) grant,
or attempt to grant, a sublicense under this Section 2.5 to use Tularik
Intellectual Property or Program Intellectual Property owned by Tularik to
any Person without the express written consent of Tularik or (ii) modify the
Targets supplied by Tularik, including, without limitation, the making of any
derivatives, analogs, fragments or components thereof. In the event that
NeoGenesis does not consume all of the Targets supplied by Tularik in
performance of the Screening Program, NeoGenesis will upon completion of the
Screening Program with respect to each particular Target, return to Tularik
any quantities of such Target and any derivatives, analogs, fragments or
components thereof.

     (b) NeoGenesis hereby grants Tularik a nonexclusive, nontransferable,
royalty-free license to use NeoGenesis Intellectual Property and Program
Intellectual Property owned by NeoGenesis (including NeoGenesis Patent
Rights) solely for purposes of conducting the Screening Program, performing
Tularik's obligations under the Screening Program and identifying Designated
Compounds under Section 2.8. Tularik will not use NeoGenesis Intellectual
Property and Program Intellectual Property owned by NeoGenesis for any other
purpose, without NeoGenesis' prior written permission and except as otherwise
permitted by the licenses and assignments granted in Sections 3.1, 3.2(d),
3.2(e) and 3.2(i). Tularik shall not grant, or attempt to grant, a sublicense
under this Section 2.5 to use NeoGenesis Intellectual Property or Program
Intellectual Property owned by NeoGenesis to any Person without the express
written consent of NeoGenesis. In addition, Tularik shall not analyze the
structure of any Preliminary Compounds, Discrete Compounds or Primary Active
Compounds or otherwise seek to derive, independent of NeoGenesis, the
structure of such Preliminary Compounds, Discrete Compounds or Primary Active
Compounds until such time as Tularik designates Primary Active Compounds as
Selected Compounds in accordance with the procedure specified in ATTACHMENT A.

2.6 SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records
containing laboratory data generated in the course of the Screening Program to
enable it to furnish complete and accurate information to Tularik regarding the
Screening Program activities and results, including all Preliminary Compounds,
Primary Active Compounds and NeoMorph Focused Libraries identified in the
Screening Program and all Program Intellectual Property described in clauses (a)
or (b) of the Program Intellectual Property definition. All such written records
of NeoGenesis shall be open to inspection by Tularik during normal business
hours upon reasonable prior notice.

     (b) NeoGenesis shall provide Tularik with reasonably-detailed written
reports describing the results of the research performed pursuant to the
Screening Program including all Preliminary Compounds, Primary Active
Compounds and NeoMorph Focused Libraries identified in the Screening Program
and Program Intellectual Property described in clauses (a) or (b) of the
Program Intellectual Property definition. Such reports shall be delivered to
Tularik at least monthly during the Screening Program. Representatives of
NeoGenesis will make themselves reasonably available to discuss such reports
and the progress of the Screening Program. NeoGenesis will deliver a Final
Target Report (as defined in ATTACHMENT A) with respect to the Screening
Program work performed on each Target including a description of all the
Preliminary Compounds, Primary Active Compounds and NeoMorph Focused
Libraries identified during the Screening Program with respect to such Target.

2.7 STEERING COMMITTEE. (a) A Steering Committee (STEERING COMMITTEE) shall
be responsible for oversight of the Program. The Steering Committee shall
consist of four (4) members, two (2) members to be appointed by each of
NeoGenesis and Tularik, except as otherwise provided in Section 4A.7. Each
party may, with notice to the other, substitute any of its members serving on
the Steering Committee. The initial Tularik members shall be Tim Hoey and
Marc Labelle and the initial NeoGenesis members shall be Satish Jindal and
Huw Nash. Tularik shall have the right to appoint one of its members to be
the chairperson of the Steering Committee.

     (b) The Steering Committee shall be responsible for the management and
conduct of the Program and shall in particular: (i) consider, review and
amend ATTACHMENT A from time to time in such manner as may be appropriate;

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       11
<Page>

PROVIDED, that the Steering Committee may not amend ATTACHMENT A in a manner
that would conflict with the time period for designating Designated Screening
Compounds specified in Section 2.8 or the time period for designating Designated
Shared Compounds specified in Section 4A.1 or the obligations specified in the
last sentence of Section 2.5(b), in each case without the prior written
agreement of both Tularik and NeoGenesis; (ii) monitor progress of the Program;
(iii) report regularly to the management of both parties upon the progress of
the Program; (iv) be the conduit for transfer of information between the
parties; and (v) conduct such other activities as set forth in Section 4A.

     (c) The Steering Committee shall hold meetings as mutually agreed by the
parties (but in no event less than eight (8) times during the term of the
Screening Program if the parties enter into the Expanded Collaboration, unless
mutually agreed by the parties) to review the Program. The first meeting of the
Steering Committee shall be held within forty five (45) days of the Effective
Date and shall be held in Cambridge, Massachusetts. Thereafter, meetings may be
held by telephone or video conference, PROVIDED THAT the parties shall meet in
person at least two (2) times during the Screening Program. Minutes of all
meetings setting forth decisions of the Steering Committee relative to the
Program shall be prepared by the host party and circulated to both parties
within twenty five (25) days after each meeting, but minutes shall not become
official until approved by both parties (which approval the parties shall use
reasonable efforts to give within thirty (30) days of receipt of such minutes).

     (d) The quorum for Steering Committee meetings shall be two (2) members,
provided there is at least one member from each of NeoGenesis and Tularik
present. The Steering Committee will render decisions by unanimous vote.
Disagreements among the Steering Committee regarding the Program will be
resolved via good-faith discussions; PROVIDED, that in the event of a
disagreement that cannot be resolved within thirty (30) days after the date on
which the disagreement arose, the matter shall be referred to Tularik's Chief
Executive Officer and NeoGenesis's Chief Executive Officer or their respective
designees. Thereafter, if any such disagreement is not resolved within forty
five (45) days, then Tularik will have the right to make the final decision,
unless it is otherwise expressly provided in Section 4A that a particular
decision of the Steering Committee shall be unanimous.

2.8 DESIGNATED SCREENING COMPOUNDS. (a) Within [*] following the delivery of
Selected Screening Compounds to Tularik for a particular Screening Target in
accordance with ATTACHMENT A and completion of optimization, if any, performed
by NeoGenesis on Selected Screening Compounds for such Screening Target in
accordance with ATTACHMENT A, Tularik shall notify NeoGenesis whether it will
classify any Selected Screening Compounds or compounds arising out of
NeoGenesis' optimization (if any) for such Screening Target as candidates for
further research (each, a DESIGNATED SCREENING COMPOUND). If Tularik does not
identify any Designated Screening Compound(s) against a particular Screening
Target within such period, the license granted Tularik under Section 3.1 shall
terminate and be of no further force or effect solely with respect to Designated
Screening Compounds and/or Products against the applicable Screening Target, and
no further payment from Tularik shall be due with respect to such Screening
Target. If Tularik does identify any Designated Screening Compounds, such
Designated Screening Compounds will be subject to the license granted Tularik
under Section 3.1 and shall no longer be available to NeoGenesis or any third
party in any NeoGenesis compound library, including its NeoMorph Screening
Library, or in any other manner. Not more than [*] Designated Screening
Compounds per Screening Target may be taken from the Preliminary Compounds
(without optimization through NeoMorph Focused Library(ies)) and not more than a
total of [*] Designated Screening Compounds in the aggregate for all Screening
Targets may be taken from the Preliminary Compounds (without optimization
through NeoMorph Focused Library(ies)). Unless otherwise agreed by the parties,
there shall be [*] Designated Screening Compounds that may be taken from
NeoMorph Focused Library(ies); PROVIDED, all such Designated Screening Compounds
have [*]. In addition, Tularik may take up to [*] Designated Screening Compounds
per Screening Target from NeoMorph Focused Library(ies) which Designated
Screening Compounds [*].

     (b) Within [*] following receipt of notification from Tularik identifying
Designated Screening Compounds, NeoGenesis shall amend ATTACHMENT D to identify
any applicable NeoGenesis Patent Rights not previously identified to Tularik.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       12
<Page>

(c) Tularik shall have the right, with notice to NeoGenesis, to "undesignate"
those Designated Screening Compounds Tularik considers unsuitable for further
development. When a Designated Screening Compound is undesignated, Tularik shall
have the right to replace that compound with a new Designated Screening Compound
to the extent that such replacement compound is not otherwise subject to an
obligation to any third party; PROVIDED that Tularik returns such undesignated
compound to NeoGenesis upon the receipt of such replacement compound, any
restrictions with respect to such undesignated compound shall expire and
NeoGenesis shall be permitted to use such undesignated compound for any purpose
not otherwise prohibited by this Agreement or any patent rights owned or
Controlled by Tularik. Tularik may not: (i) undesignate any Designated Screening
Compound for which it has filed any patent applications covering such Designated
Screening Compound; (ii) undesignate more than [*] Designated Screening
Compounds per Screening Target; or (iii) undesignate more than (A) [*]
Designated Screening Compounds in the aggregate for all Screening Targets if the
parties do not enter into the Expanded Collaboration or (B) [*] Designated
Screening Compounds in the aggregate for all Screening Targets if the parties
enter into the Expanded Collaboration.

2.9 LIMITATIONS ON NEOGENESIS. Under no circumstances shall NeoGenesis disclose
any of the results (including without limitation any NeoMorph Focused
Library(ies) created during the Screening Program) or data arising out of the
Screening Program regarding the effectiveness or ineffectiveness of the
compounds in its compound libraries against all or any of the Targets to any
third party, or otherwise use such information for its own benefit or the
benefit of any third party, without Tularik's prior written consent; it being
understood that the use of the NeoMorph Screening Library may result in the
independent generation of results or data similar to the results or data
generated in the course of the Screening Program and that the use of such
independently generated results or data, if otherwise obtained and used in
accordance with Section 2.4 and the other provisions of the Agreement, shall not
constitute a breach of these obligations; PROVIDED FURTHER, that the obligations
of NeoGenesis to not make any Designated Compound available to NeoGenesis or any
third party in NeoGenesis' compound libraries, including its NeoMorph Screening
Library, shall operate independently of the foregoing exception. Subject to its
obligations under the Screening Program, nothing in the Agreement shall be
construed to prohibit Tularik, alone or with third parties, from performing
screening for compounds active against Targets, from performing any research and
development efforts with respect to such compounds or Targets or from making,
using or selling any products resulting from such research and development
efforts, without compensation or further obligation to NeoGenesis; PROVIDED,
that no NeoGenesis Intellectual Property or Program Intellectual Property owned
by NeoGenesis (including any intellectual property that is the subject of the
assignment set forth in Section 3.2(d)) is used in the development of such
products.

2.10 PRODUCT DEVELOPMENT. Tularik, [*], shall be responsible for and shall use
its Commercially Reasonable Efforts to conduct the R&D Program.

2.11 MANUFACTURE OF PRODUCT. Tularik, [*], shall be responsible for and shall
use its Commercially Reasonable Efforts to Manufacture any Products in
accordance with the Regulatory Approvals.

2.12 REGULATORY MATTERS. Tularik, [*], shall be responsible for the preparation
and filing, with the appropriate Regulatory Authorities, of all documents that
are necessary to conduct clinical studies of Products in connection with the R&D
Program. Tularik shall be responsible for and shall use Commercially Reasonable
Efforts to file Regulatory Approval applications and obtain applicable
Regulatory Approvals for at least one Product for each Screening Target in each
of the Major Countries. Simultaneously with the submission of each such
regulatory filing, Tularik shall notify NeoGenesis, in writing, that such
regulatory filing has been made. Tularik shall be responsible for reporting all
adverse events associated with any Product to the appropriate Regulatory
Authorities in accordance with Applicable Laws.

2.13 MARKETING AND SALE. Tularik, [*], shall be responsible for the
Commercialization of Products in the Territory and shall use its Commercially
Reasonable Efforts to Commercialize each Product in each of the Major Countries
in which it has obtained necessary Regulatory Approvals. Tularik shall be
responsible for establishing the price of each such Product sold by or on behalf
of it pursuant to this Agreement.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       13
<Page>

2.14 THIRD PARTY LICENSES. Tularik, [*], shall be responsible for obtaining any
and all licenses from third parties necessary or desirable to perform the R&D
Program and/or to Commercialize any Product.

2.15 COMPLIANCE WITH LAW. Tularik shall conduct the R&D Program and conduct its
Manufacturing operations, and each party shall conduct its activities under the
Program, in a safe and prudent manner, in compliance with all Applicable Laws
(including, but not limited to, those relating to occupational safety and
health, public safety and health, protecting the environment, the disposal of
wastes, Good Clinical Practices, Good Laboratory Practices and Good
Manufacturing Practices), and in compliance with all applicable provisions of
this Agreement. Each party shall obtain all necessary registrations and permits
pertaining to its activities contemplated by this Agreement.

2.16 PERIODIC REVIEW. Tularik and NeoGenesis shall periodically meet, at such
times and places as are mutually agreed upon, and in person or by telephone or
videoconference as mutually agreed upon, for Tularik to provide NeoGenesis with
an update on the status of the progress of Tularik's R&D Program and
Commercialization of each Product, PROVIDED, HOWEVER, that such meetings shall
occur no more than twice per calendar year unless the parties agree, in writing,
to meet more or less often. Tularik and NeoGenesis shall each be responsible for
its own expenses incurred in connection with attending such meetings.

3.   LICENSE; PROPRIETARY RIGHTS

3.1 GRANT OF LICENSE. (a) Subject to the terms and conditions of this Agreement,
NeoGenesis hereby grants to Tularik, and Tularik hereby accepts, a worldwide
right and license, without the right to sublicense (except as set forth in the
third sentence of this Section 3.1(a) with respect to Designated Screening
Compounds, Derivative Compounds thereof and Products), within the Territory, to
use (i) the NeoGenesis Intellectual Property and NeoGenesis Patent Rights and
(ii) the Program Intellectual Property owned by NeoGenesis, in each case with
application to the Field (collectively, the LICENSED TECHNOLOGY) to the extent
necessary or useful to research, develop, have developed, make, have made, use,
distribute, promote, market, offer for sale, sell, have sold, import and export
Designated Compounds, Derivative Compounds thereof, Products and Shared Products
and, to the extent permitted under Section 4A.15, Independent Compounds,
Derivative Compounds thereof and Independent Products. The foregoing license
shall be exclusive with respect to Designated Screening Compounds, Derivative
Compounds thereof and Products and co-exclusive (with NeoGenesis) with respect
to Designated Shared Compounds, Derivative Compounds thereof, Shared Products,
Independent Compounds and Independent Products. Tularik may grant sublicenses of
its rights under this Section 3.1(a) with respect to Designated Screening
Compounds, Derivative Compounds thereof and Products; PROVIDED that Tularik: (1)
obtains each sublicensee's written agreement to be subject to the same
obligations as is Tularik under Sections 2.15, 2.16, 3.1(d), 4.7, 4.8, 5.2 and
8.3(c) (last sentence) of this Agreement (or substantially identical provisions)
and (2) shall remain responsible for the performance of all of its obligations
under this Agreement, whether such obligations are performed by Tularik, its
Affiliates or any of its sublicensees.

     (b) Subject to the terms and conditions of this Agreement, Tularik hereby
grants to NeoGenesis, and NeoGenesis hereby accepts, a co-exclusive (with
Tularik), worldwide right and license, without the right to sublicense, within
the Territory, to use (i) the Tularik Intellectual Property and Tularik Patent
Rights and (ii) the Program Intellectual Property owned by Tularik, in each case
with application to the Field to the extent necessary or useful to research,
develop, have developed, make, have made, use, distribute, promote, market,
offer for sale, sell, have sold, import and export Designated Shared Compounds,
Derivative Compounds thereof and Shared Products and, to the extent permitted
under Section 4A.15, Independent Compounds, Derivative Compounds thereof and
Independent Products.

     (c) The licenses granted under this Section 3.1 shall be treated as a
license of rights to "intellectual property" (as defined in Section 101(56) of
Title 11 of the United States Code, as amended (the BANKRUPTCY CODE)) for
purposes of Section 365(n) of the Bankruptcy Code. The parties agree that the
party holding the license from the other party may elect to retain and may fully
exercise all of its rights and elections under the Bankruptcy Code, PROVIDED
that it abides by the terms of this Agreement.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       14
<Page>

     (d) Each party, as applicable, shall mark or have marked all containers or
packages of Products, Shared Products or Independent Products that are the
subject of the license granted under this Section 3.1 in accordance with the
patent marking laws of the jurisdiction in which such products are manufactured,
used or sold.

     (e) Unless sooner terminated in accordance with Section 8.2, the license
under Section 3.1(a) with respect to Designated Screening Compounds, Derivative
Compounds thereof and Products will remain in effect on a compound-by-compound,
Product-by-Product and country-by-country basis until the LATER OF: (i) the
expiration or revocation or complete rejection (in the case of a patent
application) of the last to expire or to be revoked or to be completely rejected
(in the case of a patent application) of the NeoGenesis Patent Rights (including
those NeoGenesis Patent Rights assigned to Tularik pursuant to Section 3.2(d))
covering the Designated Screening Compounds, Derivative Compounds thereof or
corresponding Products, as the case may be, in such country or (ii) in the case
of a particular Product, twelve (12) years following the First Commercial Sale
of such Product.

     (f) Subject to the next succeeding sentence and the provisions of Section
8.4, unless sooner terminated in accordance with Section 8.2, the licenses under
Sections 3.1(a) and 3.1(b) with respect to Designated Shared Compounds,
Derivative Compounds thereof, Shared Products, Independent Compounds, Derivative
Compounds thereof and Independent Products will remain in effect on a
compound-by-compound, product-by-product and country-by-country basis until the
earlier to occur of the first date on which: (i) Net Sales on Shared Products
and Independent Products, as the case may be, shall be reduced from a positive
number to zero; and (ii) neither party is then pursuing research, Pre-Clinical
Development or Development of the applicable Designated Shared Compound,
Derivative Compound thereof, Shared Product, Independent Compound, Derivative
Compound thereof or Independent Product, in each case using Commercially
Reasonable Efforts. If either party elects to terminate participation in the
Pre-Clinical Development or Development of any Designated Shared Compounds,
Derivative Compound thereof or Shared Product in accordance with Section 4A.14,
any license granted to the non-participating party with respect to the
applicable Designated Shared Compound, Derivative Compound thereof or Shared
Product shall terminate until such time (if any) as a party resumes
participation in the Pre-Clinical Development or Development of such Designated
Shared Compound, Derivative Compound thereof or Shared Product, in which case
such license shall revive and be of full force and effect with respect to such
Designated Shared Compound, Derivative Compound thereof or Shared Product until
terminated in accordance with the first sentence of this Section 3.1(f).

3.2 PROPRIETARY RIGHTS. (a) This Agreement does not convey to NeoGenesis any
rights in any Tularik Intellectual Property, Tularik Patent Rights or any other
intellectual property, patents or patent applications of Tularik by implication,
estoppel or otherwise except for the rights expressly granted in Sections 2.5,
3.1 and 3.2(f). Title to the Tularik Intellectual Property, Tularik Patent
Rights and any other intellectual property, patents or patent applications of
Tularik shall at all times remain vested in Tularik. This Agreement does not
convey to Tularik any rights in any NeoGenesis Intellectual Property, NeoGenesis
Patent Rights or any other intellectual property, patents or patent applications
of NeoGenesis by implication, estoppel or otherwise except for the rights
expressly granted in Sections 2.5, 3.1, 3.2(d), 3.2(e) and 3.2(i). Subject to
Section 3.2(i) and 3.2(d), title to the NeoGenesis Intellectual Property,
NeoGenesis Patent Rights and any other intellectual property, patents or patent
applications of NeoGenesis shall at all times remain vested in NeoGenesis. Title
to and any interest in Program Intellectual Property described in clause (a) of
the Program Intellectual Property definition (including corresponding Program
Patent Rights) shall be the property of NeoGenesis. Except as described in the
eighth sentence of this Section 3.2(a), title to and any interest in Program
Intellectual Property described in clause (b) of the Program Intellectual
Property definition (including corresponding Program Patent Rights) shall be
jointly held by Tularik and NeoGenesis. Title to and any interest in Program
Intellectual Property described in clause (c) of the Program Intellectual
Property definition (including corresponding Program Patent Rights) shall be the
property of Tularik. Notwithstanding any of the foregoing, Program Intellectual
Property, regardless of inventorship, shall be: (i) the property of NeoGenesis
if such Program Intellectual Property is directly related to the NeoMorph
Screening Library (except as described in Section 3.2(a)(ii)(B) below), ALIS or
QSCD; and (ii) the property of Tularik (A) if such Program Intellectual Property
is directly related to the Targets or the uses thereof or to Tularik's
functional or secondary assays, or to the Products, or (B) if such Program
Intellectual Property relates to Designated Compounds and Derivative Compounds
(including

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       15
<Page>

any generic composition of matter claims with respect thereto and any Selected
Compounds contained therein). The Program Intellectual Property described in
Section 3.2(a)(ii)(B) shall be referred to as the GENERIC RIGHTS.

     (b) If required, patent counsel mutually acceptable to the parties and
selected by the Steering Committee shall determine inventorship of all Program
Intellectual Property in accordance with U.S. patent law (and other U.S.
intellectual property law, if applicable).

     (c) NeoGenesis shall retain the following rights with respect to the
following NeoGenesis Intellectual Property and Program Intellectual Property
owned by NeoGenesis:

     (i) Subject to Sections 2.2(last sentence), 2.4, 2.8, 2.9, 3.1(a),
     3.2(a)(first two sentences), 3.2(c)(ii)(A), 3.2(f), 4A.2(a)(last sentence)
     and 5.2, NeoGenesis may continue to use its NeoMorph Screening Library to
     screen target proteins for other parties; and

     (ii) NeoGenesis shall retain all rights and may continue to use Preliminary
     Compounds created as part of the Screening Program but not selected as
     Primary Active Compounds and Primary Active Compounds not selected as
     Selected Compounds; provided, however, that such Preliminary Compounds and
     Primary Active Compounds (A) may not be used against the Targets and (B)
     shall only be used in the event and to the extent they result from use of
     the NeoMorph Screening Library to screen target proteins for other parties.

     (d) In addition to the license granted under Section 3.1 with respect to
Licensed Technology, NeoGenesis hereby assigns and agrees to assign to Tularik
all of NeoGenesis' right, title and interest in those Designated Screening
Compounds designated by Tularik in accordance with Section 2.8. Such assigned
Designated Screening Compounds and the corresponding NeoGenesis Patent Rights
shall, from the date of assignment by NeoGenesis, be treated as Tularik Patent
Rights for purposes of this Agreement (including Section 3.3(c) and Section 3.4)
and such assigned Designated Screening Compounds and the corresponding
NeoGenesis Intellectual Property shall, from the date of assignment by
NeoGenesis, be treated as Tularik Intellectual Property for purposes of this
Agreement (including Section 3.4). The date of assignment with respect to the
Designated Screening Compounds shall be the date Tularik notifies NeoGenesis
that a particular Selected Screening Compound has been designated as a
Designated Screening Compound and pays the fee for such Designated Screening
Compound specified in Section 4.3. Notwithstanding any provision of this
Agreement to the contrary, Tularik shall remain obligated to pay NeoGenesis in
respect of all such assigned Designated Screening Compounds (and any Derivative
Compounds thereof and any corresponding Product(s)) the milestone fees and
royalties due NeoGenesis under Section 4.4 and Section 4.5 of this Agreement
until the earlier of (i) such time as [*], or (ii) the LATER OF the expiration
or revocation or complete rejection (in the case of a patent application) of the
last to expire or to be revoked or to be completely rejected (in the case of a
patent application) of the patent rights within the assigned NeoGenesis Patent
Rights in this Section 3.2(d) covering such assigned Designated Screening
Compounds (and any Derivative Compounds thereof and any corresponding
Product(s)) or [*] following the First Commercial Sale of such Product(s).

     (e) If, during the term of the Agreement, NeoGenesis has or obtains any
patent or other proprietary right in any Program Intellectual Property (by
ownership or license) that could be asserted to prevent Tularik from practicing
the Tularik Intellectual Property or Program Intellectual Property owned by
Tularik to research, develop, have developed, make, have made, use, distribute,
promote, market, offer for sale, sell, have sold, import and export compounds,
NeoGenesis will grant Tularik a non-exclusive, worldwide, perpetual license (or
sublicense, as the case may be), with the right to sublicense, to such patent or
other proprietary right to the extent necessary or useful to practice the
license granted under Section 3.1 and Tularik will [*]; provided, however, that
the foregoing shall not be construed to grant Tularik any license to utilize
NeoGenesis' NeoMorph Screening Library, ALIS or QSCD except as otherwise
expressly set forth in this Agreement.

     (f) Tularik hereby grants NeoGenesis (i) an irrevocable, exclusive (except
as to Tularik as described below in this Section 3.2(f)), fully-paid, perpetual
license, including the right to grant sublicenses, to any Generic Rights for
which NeoGenesis or its employees and/or agents are the sole inventor, and (ii)
an irrevocable, co-exclusive, fully-paid, perpetual license, including the right
to grant sublicenses, to any Generic Rights for which NeoGenesis or its

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       16
<Page>

employees and/or agents are joint inventors, except that in each case Tularik
will retain exclusive rights in such Generic Rights to the extent necessary or
useful to research, develop, have developed, make, have made, use, distribute,
promote, market, offer for sale, sell, have sold, import and export Designated
Compounds, Derivative Compounds thereof, Products, Shared Products, Independent
Compounds, Derivative Compounds thereof and Independent Products.

     (g) Neither party shall use Program Intellectual Property owned by the
other party or Confidential Information of the other party outside of the
performance of the Program or except as otherwise expressly permitted in this
Agreement.

     (h) Both parties agree that Program Intellectual Property does not
include work done by either party with respect to a particular Screening
Target after the Screening Program activities are completed with respect to
such Screening Target.

     (i) In the event that NeoGenesis has a patent, has filed a patent
application or files a patent application outside the Program that
encompasses a Designated Compound and/or any Derivative Compound and
NeoGenesis is not obligated to exclusively license or assign such patent or
patent application to a third party pursuant to another agreement in
existence at the Effective Date, NeoGenesis shall be deemed to be subject to
an obligation to assign such patent or patent application (or, where
possible, the relevant portion thereof) to Tularik without the payment of any
additional consideration by Tularik but subject to the license granted
NeoGenesis by Tularik under Section 3.2(f) (if applicable). Nothing in this
Section 3.2(i) shall, by implication or otherwise, absolve NeoGenesis of
liability for breach of its representation and warranty set forth in Section
6.2(b).

3.3 DISCLOSURE; PATENT PROSECUTION. (a) Each of NeoGenesis and Tularik shall
promptly disclose to the other in writing any Invention that might, under the
applicable U.S. patent laws, be patentable and constitutes Program
Intellectual Property. Such Program Intellectual Property will be added to
ATTACHMENT B. Within forty five (45) days following the date of such
disclosure regarding the existence of particular Program Intellectual
Property that is [*], the parties shall confer and mutually agree as to
appropriate protection for such Program Intellectual Property, including an
application, preparation, prosecution and maintenance strategy.
Notwithstanding the provisions of this Section 3.3, neither party shall file
any Program Patent Right relating to Program Intellectual Property that is [*]
 .

     (b) NeoGenesis shall have the sole right, but not the obligation, to file,
prosecute, and maintain, at NeoGenesis' sole expense, each of the NeoGenesis
Patent Rights throughout the Territory. NeoGenesis shall promptly furnish or
have furnished to Tularik copies of all patents, patent applications,
substantive patent office actions, and substantive responses received or filed
in connection with such applications (other than patents and patent applications
covering solely NeoGenesis Intellectual Property that is not licensed to Tularik
under Section 3.1 or assigned to Tularik under Section 3.2(d) or 3.2(i)). In the
case of patent applications and responses, copies will be furnished to Tularik
at least fifteen (15) days before filing or mailing, as the case may be. Tularik
may itself or through its attorney offer comments and suggestions with respect
to the matters that are the subject of this Section 3.3(b) and NeoGenesis agrees
to consider such comments and suggestions; PROVIDED that nothing herein shall
obligate NeoGenesis to adopt or follow such comments or suggestions. Tularik
shall cooperate in the preparation, filing, prosecution and maintenance of any
and all patent applications and patents covering Program Intellectual Property
owned by NeoGenesis. NeoGenesis shall promptly provide notice to Tularik as to
all matters that come to its attention that may affect the preparation, filing,
prosecution or maintenance of any patents or patent applications covering
Program Intellectual Property owned by NeoGenesis. NeoGenesis shall not seek
patent protection for any NeoGenesis Intellectual Property or Program
Intellectual Property owned by NeoGenesis that covers generic claims to any
class of compounds developed in the course of the Program until: (i) with
respect to the Screening Program, the earlier of (A) such time as Tularik has
designated Designated Screening Compounds in respect of such class of compounds
in accordance with Section 2.8 or (B) such time as the period of time for such
designation expires with respect to the Selected Screening Compounds derived
from such class of compounds; and (ii) with respect to activities conducted
under Section 4A, the date in Section 4A.2 for each party's election of
Designated Shared Compounds. In the event that NeoGenesis elects not to file for
patent protection under the NeoGenesis Patent Rights or elects not to prosecute
or maintain a patent or patent application under the NeoGenesis Patent Rights it
shall notify Tularik of such decision

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       17
<Page>

at least forty five (45) days prior to the due date of any action or payment
due. Tularik shall then have the right, but not the obligation, to assume the
responsibility therefor at its own cost and expense.

     (c) Tularik shall have the sole right, but not the obligation, to prepare,
file, prosecute, and maintain, at Tularik's sole expense (except as provided
below), each of the Tularik Patent Rights throughout the Territory. Tularik
shall promptly furnish or have furnished to NeoGenesis copies of all patents,
patent applications, substantive patent office actions and substantive responses
relevant to Generic Rights received or filed in connection with such
applications. In the case of such patent applications and responses, copies will
be furnished to NeoGenesis at least 15 days before filing or mailing, as the
case may be. NeoGenesis may itself or through its attorney offer comments and
suggestions with respect to the matters that are the subject of this Section
3.3(c) relating to Generic Rights and Tularik agrees to consider such comments
and suggestions; PROVIDED that nothing herein shall obligate Tularik to adopt or
follow such comments or suggestions. NeoGenesis shall be responsible for all
costs relating to the preparation, filing, prosecution and maintenance of any
and all patent applications covering Generic Rights for which NeoGenesis, its
employees or agents is the sole inventor and [*] of the costs relating to the
preparation, filing, prosecution and maintenance of any and all patent
applications covering Generic Rights for which NeoGenesis, its employees or
agents are [*]. NeoGenesis shall cooperate in the preparation, filing,
prosecution and maintenance of any and all patent applications and patents
covering Program Intellectual Property owned by Tularik or obtained by Tularik
under Section 3.2(d). Tularik shall promptly provide notice to NeoGenesis as to
all matters that come to its attention that may affect the preparation, filing,
prosecution or maintenance of any patents or patent applications covering
Program Intellectual Property owned by Tularik relating to Generic Rights.
Notwithstanding the provisions of this Section 3.3, Tularik shall not file any
patent application covering the Generic Rights without NeoGenesis' prior written
consent, with respect to the Screening Program, before the date specified in
Section 2.8 for Tularik's notice of selection of Designated Screening Compounds
or, with respect to activities conducted under Section 4A, the date in Section
4A.2 for each party's election of Designated Shared Compounds.

3.4 ENFORCEMENT. (a) NeoGenesis shall be solely responsible for defense and
enforcement of (i) NeoGenesis Intellectual Property and NeoGenesis Patent Rights
and (ii) Program Intellectual Property owned by NeoGenesis, but in each case
excluding Licensed Technology. Tularik shall be solely responsible for the
defense and enforcement of (A) Tularik Intellectual Property and Tularik Patent
Rights and (B) Program Intellectual Property owned by Tularik.

     (b) Tularik shall have the first option to pursue any enforcement or
defense of Licensed Technology; PROVIDED, that Tularik pays all costs and
expenses related to the same, keeps NeoGenesis reasonably informed of its
progress and provides NeoGenesis with copies of any substantive documents
related to such proceedings and reasonable notice of all such proceedings.
Tularik's costs and expenses in prosecuting or defending such matters shall be
subject to reimbursement in accordance with Section 3.4(d). Tularik shall notify
NeoGenesis of its decision to exercise its right to enforce or defend Licensed
Technology as soon as possible, but not later than sixty (60) days following its
discovery or receipt of notice of the alleged infringement.

     (c) If (i) Tularik notifies NeoGenesis that it will not exercise its option
to enforce or defend any Licensed Technology in accordance with Section 3.4(b);
(ii) Tularik and NeoGenesis have not otherwise agreed not to pursue or defend
against such infringement for business reasons; (iii) Tularik has not persuaded
the alleged infringer to desist or the person alleging the infringement to
forebear, (iv) Tularik is not diligently pursuing an infringement action or
diligently defending the validity or enforceability of Licensed Technology at
issue; or (v) Tularik has not provided NeoGenesis with evidence of bona fide
negotiations of an acceptable sublicense agreement with the alleged infringer or
person alleging infringement, then NeoGenesis shall have the right to pursue the
alleged infringer or take control of any action initiated by, or being defended
by, Tularik at NeoGenesis' own expense. In any such case, Tularik will, wherever
possible under Applicable Law, substitute NeoGenesis as party plaintiff for
purposes of pursuing any alleged infringer, or as defendant for defending any
Licensed Technology.

     (d) Any recovery of damages with regard to Licensed Technology in any suit
handled by one party pursuant to Section 3.4(b) or Section 3.4(c) shall be
applied first in satisfaction of any unreimbursed expenses and legal fees of the
party handling the suit or settlement thereof. The balance of any recovery
obtained by settlement or otherwise relating to Designated Screening Compounds,
Derivative Compounds thereof and Products shall be distributed: (i)

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       18
<Page>

first to Tularik in an amount equal to its lost profits or a reasonable royalty
on the sales of the infringer (whichever measure of damages the court shall have
applied), and (ii) then to NeoGenesis in an amount equal to the royalties due
NeoGenesis based on such sales (if the court applies a sales of the infringer
measure of damages) or a reasonable approximation of the royalties that Tularik
would have owed to NeoGenesis on sales of Products that Tularik lost to the
infringer (if the court applies a lost profits measure of damages). The balance,
if any, remaining after Tularik has been compensated for lost profits or lost
sales and NeoGenesis has been compensated for lost royalties pursuant to Section
3.4(d)(i)-(ii) shall be paid to Tularik. The balance of any recovery obtained by
settlement or otherwise relating to Designated Shared Compounds, Derivative
Compounds thereof, Shared Products, Independent Compounds, Derivative Compounds
thereof and Independent Products shall be divided equally between the parties.
No settlement, consent judgment or other voluntary final disposition of any suit
regarding Licensed Technology may be entered into without the consent of the
other party, which consent shall not be unreasonably withheld.

     (e) Notwithstanding the provisions of Section 3.4(b), in the event that a
declaratory judgment action alleging invalidity or non-infringement of any of
the patents within Licensed Technology that are within NeoGenesis Patent Rights
covering the NeoMorph Screening Library, ALIS or QSCD is filed, NeoGenesis shall
have the first option, within sixty (60) days after notification of same, to
assume defense of the action concerning such patents at its expense, but Tularik
shall be entitled to participate in such action, at its own expense.

     (f) In any infringement suit as either party may institute to enforce
Licensed Technology, or in any declaratory judgment action alleging invalidity
or non-infringement of any Licensed Technology brought against NeoGenesis or
Tularik, the other party shall, at the request and expense of the party
initiating or defending the suit or action, cooperate and assist in all
reasonable respects, having its employees testify when requested and making
available relevant records, papers, information, specimens and the like.

     (g) Notwithstanding any provisions of Section 3.4 to the contrary, each
party shall promptly give written notice to the other of any certification of
which it becomes aware filed pursuant to the Waxman-Hatch Act (21 U.S.C.
Section 355(b)(2)(A), or Section 355(j)(2)(A)(vii)), or any amendment or
successor statute thereto, at least fourteen (14) days prior to expiration of
the forty five (45) day period set forth in 21 U.S.C. Section 355(c)(3)(c)
(or any amendment or successor statute thereto), then Tularik shall have the
right to bring such an infringement action, in its sole discretion and at its
own expense, in its own name and/or in the name of NeoGenesis. Any recoveries
obtained (by settlement or otherwise) by either party as a result of any
proceeding against a third party infringer brought under this Section 3.4(g)
shall be used to reimburse each party for all litigation costs in connection
with such proceeding paid by that party and any remainder: (i) shall be
deemed Net Sales and NeoGenesis shall receive an amount equal to the royalty
due on such Net Sales and Tularik shall receive the balance of such remainder
to the extent such proceeding relates to Designated Screening Compounds,
Derivative Compounds thereof and Products; and (ii) shall be shared equally
by the parties to the extent such proceeding relates to Designated Shared
Compounds, Derivative Compounds thereof, Shared Products, Independent
Compounds, Derivative Compounds thereof or Independent Products. If Tularik
or its sublicensee initiate suit pursuant to this Section 3.4(g), it will
promptly notify NeoGenesis.

4.   PRICING; PAYMENT

4.1 TECHNOLOGY ACCESS FEE. (a) Upon initiation of the Expanded Collaboration,
Tularik will be obligated to pay NeoGenesis a technology access fee comprised of
one million dollars ($1,000,000) cash PLUS a loan to NeoGenesis of one million
dollars ($1,000,000) in exchange for a note convertible into NeoGenesis equity
on the terms below (CONVERTIBLE NOTE). Such technology access fee shall be
payable in two (2) installments. The first installment will be comprised of a
one million dollar ($1,000,000) loan in exchange for the Convertible Note
payable upon initiation of the Expanded Collaboration. Initiation of the
Expanded Collaboration will take place within thirty (30) days following the
date the Success Criteria are achieved or the date Tularik opts to move forward
with the Expanded Collaboration, regardless of achievement of the Success
Criteria. The second installment will be comprised of one million dollars
($1,000,000) in cash payable upon the earlier of (i) January 15, 2003 and (ii)
the first anniversary of initiation of the Expanded Collaboration. The second
installment will not be payable unless the first installment has been paid.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       19
<Page>

     (b) The convertible debt portion of such technology access fee will be made
pursuant to a Convertible Note Purchase Agreement between the parties and a
Convertible Note will be issued by NeoGenesis to Tularik. The Convertible Note
Purchase Agreement and the Convertible Note will be in the form of ATTACHMENT E
and will contain the specific terms described below. The Convertible Note will
bear interest at five and three quarter percent (5.75%) per annum and, unless
converted as set forth below, all principal and accrued interest shall be due
and payable on the fourth anniversary of the issuance of the Convertible Note.
The principal and any accrued interest under the Convertible Note shall either
(i) convert into NeoGenesis preferred stock at the time NeoGenesis completes its
next succeeding round of preferred stock financing; PROVIDED, that such
conversion shall only occur at Tularik's option if such financing is completed
with a corporate collaborator only, PROVIDED FURTHER, that if Tularik elects not
to participate in such round, such conversion shall occur at the next succeeding
preferred stock financing with a third party that is not a corporate
collaborator or in such a financing with a corporate collaborator at Tularik's
option; OR (ii) convert into NeoGenesis common stock at the time NeoGenesis
completes an initial public offering (IPO); at the price offered in such
financing or IPO, as the case may be. NeoGenesis may repay a portion of the
Convertible Note in cash prior to conversion of the Convertible Note as
permitted above in the event and to the extent that Tularik terminates the
Expanded Collaboration (other than for cause) prior to screening an aggregate of
ten (10) Targets. The amount of such cash repayment shall be determined as
follows: [amount of repayment] = ([10] - (actual number of Targets Tularik
provides for screening during Expanded Collaboration)) x ($100,000) PLUS accrued
interest on the Convertible Note.

     (c) If NeoGenesis completes an IPO prior to the initiation of the Expanded
Collaboration, at Tularik's option, either (i) Tularik will be given adequate
notice and an opportunity to pay the first installment of the technology access
fee by purchasing one million dollars ($1,000,000) of NeoGenesis common stock in
the IPO at the price offered in the IPO, PROVIDED, this option may only be
exercised if the IPO occurs after the first anniversary of the Effective Date or
(ii) wait until the initiation of the Expanded Collaboration, and, at Tularik's
option, either pay the first installment of the technology access fee by
purchasing one million dollars ($1,000,000) of NeoGenesis common stock at its
then current fair market value or pay one million dollars ($1,000.000) in cash.
If Tularik selects option (i) in the foregoing sentence, Tularik shall be deemed
to have elected to initiate the Expanded Collaboration.

4.2 SCREENING FEE. Tularik shall pay NeoGenesis a fee of [*] for each
Screening Target screened pursuant to the Screening Program. Such fee shall
be payable in two (2) installments - the first installment of [*] at the time
such Screening Target is delivered to NeoGenesis and the second installment
of [*] within [*] of Completion of Screening; provided, however, that the
amount of the second installment shall be reduced for a particular Screening
Target by [*] if Completion of Screening does not occur within [*] following
delivery of such Screening Target to NeoGenesis. COMPLETION OF SCREENING
shall be deemed to occur upon delivery of Selected Screening Compounds for a
Screening Target to Tularik (or, if Tularik does not designate any Selected
Screening Compound(s) for such Screening Target within [*] of receipt of the
Final Target Report for such Screening Target, including any supplement
thereto as described in Paragraph 7 of ATTACHMENT A, then at the end of such
[*] period). No payment shall be due NeoGenesis under this Section 4.2 with
respect to Shared Targets.

4.3 SUCCESS PAYMENTS. For each Screening Target, Tularik shall pay NeoGenesis a
success payment of [*] if at least one Designated Screening Compound is
identified by Tularik that shows activity against such Screening Target such
that Tularik initiates a Medicinal Chemistry Effort with respect to such
Designated Screening Compound. Such payment shall be made within [*] after the
initiation of a Medicinal Chemistry Effort by Tularik; PROVIDED, that Tularik
has [*] after the date Tularik identifies the Designated Screening Compound for
such Screening Target to determine whether or not to initiate a Medicinal
Chemistry Effort for such Designated Screening Compound. No payment shall be due
NeoGenesis under this Section 4.3 with respect to Shared Targets.

4.4 MILESTONES. (a) Tularik will pay NeoGenesis milestone payments in respect of
the first Product that is active against each Screening Target as specified in
this Section 4.4.

     (i)  Within thirty (30) days following the date on which Tularik [*],
          Tularik will pay NeoGenesis [*]. Tularik shall promptly notify
          NeoGenesis of the decision to [*].

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       20
<Page>

    (ii)  Within thirty (30) days following the date on which [*] relating to
          such Product, Tularik will pay NeoGenesis [*].

    (iii) Within thirty (30) days following the date on which [*] relating to
          such Product, Tularik will pay NeoGenesis [*].

    (iv)  Within thirty (30) days following the date on which [*] relating to
          such Product, Tularik will pay NeoGenesis [*].

     (v)  Within thirty (30) days following the date on which [*], Tularik will
          pay NeoGenesis [*].

     (b) The milestones identified in Section 4.4(a)(i)-(v) shall be due only
for the first Product that is active against a particular Screening Target,
regardless of (i) the number of Products that are active against such Screening
Target that are identified by the Screening Program or developed and/or
Commercialized by Tularik, and (ii) the number of times a Product hits such
milestone (e.g., if different indications are pursued for the same Product);
PROVIDED, that if the first Product that is active against a Screening Target
does not achieve any milestone(s), such non-achieved milestones shall be paid on
any subsequent Product that is active against such Screening Target and that
achieves such milestone. On the date any one milestone with respect to a Product
is achieved, all lower numbered unachieved milestones shall be deemed to have
been achieved with respect to that Product and shall be paid (except to the
extent they have previously been paid with respect to another Product active
against the relevant Screening Target). No milestone payments shall be due
NeoGenesis under this Section 4.4 with respect to Products that are active
against Shared Targets.

4.5 ROYALTIES. (a) [*] commencing with the First Commercial Sale of each
Product that is active against a Screening Target screened pursuant to the
Screening Program in any country, Tularik shall pay to NeoGenesis royalties
on a Product-by-Product and country-by-country basis for the most recent [*]
period then ended, equal to (i) [*] of the portion of aggregate annual Net
Sales of such Product that [*] and (ii) [*] of the portion of aggregate
annual Net Sales of such Product that [*]. Annual Net Sales will be
calculated on a calendar year basis. Tularik shall pay royalties with respect
to each Product on a country-by-country basis for so long as the license
under Section 3.1 as applicable to such Product remains in effect in such
country.

     (b) If a Product is not covered by a Valid Claim and Tularik notifies
NeoGenesis that there is Substantial Competition in a country with respect to
such Product in a calendar year, the foregoing royalty rates shall be reduced
for Net Sales in such country [*]. In the event that NeoGenesis disputes
Tularik's characterization of a country as one in which Substantial Competition
exists, the parties shall confer to resolve such matter before resorting to
litigation.

     (c) If Tularik is required to make payments (including, without limitation,
royalties, option fees or license fees) to one or more third parties to obtain
licenses or similar rights under patents owned by a third party to avoid
infringement by any Designated Screening Compound, Derivative Compound thereof
or Product (or the Manufacture thereof) of such third party(ies)'
patent-protected technology, then Tularik may, beginning from the date of such
third party payments, deduct [*] of the amount of such third party payments in
any calendar quarter from the royalties payable to NeoGenesis in such calendar
quarter; provided that such deductions shall not exceed [*] of the royalties
otherwise payable to NeoGenesis in such calendar quarter with respect to such
Product.

     (d) In the event that Tularik utilizes any Product against a target protein
that is not a Screening Target or a Shared Target (such that NeoGenesis is paid
pursuant to the provisions of Sections 4.4 and 4.5(a) or Section 4A.9 in respect
of such Product), then Tularik shall pay NeoGenesis milestones and royalties in
respect of such Product as used against such other target in accordance with the
provisions of Sections 4.4 and 4.5(a) at a rate equal to [*] of the applicable
milestones and royalties specified in Sections 4.4 and 4.5(a).

4.6 REMITTANCE. (a) Subject to Section 4.6(c), all royalties and milestone
payments required under this Section 4 and royalty payments required under
Sections 4A.18 and 4A.19 shall be payable in full in the United States in
United

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       21
<Page>

States Dollars, regardless of the countries in which sales are made. For the
purpose of computing Net Sales for which a currency other than United States
Dollars is received, such currency shall be converted into United States
Dollars at the simple average of all Mondays' exchange rate for buying United
States Dollars set forth in THE WALL STREET JOURNAL for the calendar quarter
in which such sales were made.

     (b) In the event that any payment due either party under this Agreement is
not made when due, the amount due shall accrue interest beginning on the fifth
day following the final date on which such payment was due, calculated at the
annual rate equal to the prime interest rate reported in the WALL STREET JOURNAL
for the due date, or, if lower, the maximum rate permitted by law, calculated
from the due date until paid in full. Such payment when made shall be
accompanied by all interest so accrued. Said interest and the payment and
acceptance thereof shall not negate or waive the right of the party to whom
payment is due to any other remedy, legal or equitable, to which it may be
entitled because of the delinquency of the payment.

     (c) If at any time legal restrictions within any country in the Territory
prevent the conversion of the local currency and such currency cannot be removed
from such country such that prompt remittance by the party owing a royalty of
any royalties owed in respect of sales in such country is prevented, the party
owing a royalty shall make payment through any lawful means or methods that may
be available as such party shall reasonably determine. If royalties in any
country cannot be remitted within three (3) months after the end of the relevant
royalty period, then the party owing a royalty shall pay the other party in the
local currency of such country by deposit of the relevant royalties in a bank
account in such country designated by the other party.

4.7 RECORDS. Tularik, its Affiliates and sublicensees shall keep and maintain
for a period of at least [*] from the date of each payment of royalties under
Section 4.5, records (prepared in accordance with GAAP) sufficient to determine
the amounts of Net Sales and payments due under Section 4.5. Within forty-five
(45) days following each March 31, June 30, September 30 and December 31 in
which payments are due under Section 4.5, Tularik shall provide NeoGenesis with
a report including at least: (a) the quantities of Products that Tularik, its
Affiliate(s) and sublicensee(s) sold during the preceding quarter in each
country in which Products or bundled products containing Products were sold; (b)
the monetary amount, in the national currency of such country, of such sales;
(c) actual Net Sales, by country; (d) the currency conversion rate used and U.S.
dollar-equivalent of such sales; (e) the calculation of royalties thereon; (f)
the then aggregate Net Sales for each Product for the applicable calendar year;
and (g) the total royalties so computed and due NeoGenesis. Upon delivery of the
report due for the period ending December 31 of each year, Tularik shall also
report to NeoGenesis the aggregate royalties due NeoGenesis for the entire
preceding year.

4.8 INSPECTION. Tularik and its Affiliates shall, and Tularik shall provide in
any agreements with any sublicensees that such sublicensees shall, each make its
records available for inspection by an independent certified public accountant,
mutually agreed to by NeoGenesis and Tularik, during regular business hours at
such place or places where such records are customarily kept, upon reasonable
notice from NeoGenesis, to verify the accuracy of the reports and payments
required under this Section 4. Such inspection right shall not be exercised more
than [*] in any calendar year nor more than [*] with respect to sales of
Products in any given payment period. NeoGenesis agrees to hold in confidence
all information concerning royalty payments and reports, and all information
learned in the course of any inspection, except to the extent necessary for
NeoGenesis to reveal such information in order to enforce its rights under this
Agreement in a proceeding in accordance with Section 9.1 or if disclosure is
required by law, regulation or judicial order. Any person or entity conducting
such inspection will agree in writing with NeoGenesis to treat all records
reviewed in the course of the inspection as the Confidential Information of
Tularik under terms and conditions no less restrictive than the terms contained
in Section 5.2. The results of each inspection shall be binding on both parties
absent mathematical error. NeoGenesis shall pay for such inspections, except
that in the event there is any upward adjustment in aggregate royalties payable
for any year shown by such inspection of more than [*] of the amount paid,
Tularik shall pay for such inspection.

4.9 TAXES. If, at any time, any jurisdiction within the Territory requires
the withholding of income taxes or other taxes imposed upon payments set
forth in this Section 4, Tularik shall make such withholding payments as
required and subtract such withholding payments from the payments to be made
to NeoGenesis as set forth in this Section 4,

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       22
<Page>

or, if applicable, NeoGenesis will reimburse Tularik or its designee(s) for
the amount of such withholding payments that are not subtracted from the
payments made to NeoGenesis as set forth in this Section 4, within fifteen
(15) days of notice to NeoGenesis. Tularik shall provide NeoGenesis with
documentation of such withholding and payment in a manner that is
satisfactory for purposes of reporting to the U.S. Internal Revenue Service.
Any withholdings paid when due hereunder shall be for the account of
NeoGenesis. Withholding payments made by Tularik pursuant to this Section 4.9
shall be made based upon financial information provided to Tularik by
NeoGenesis, and to the extent that such information is incorrect, NeoGenesis
shall be liable for any deficiency, and any fine, assessment or penalty
imposed by any taxing authority in the Territory for any deficiency in the
amount of any such withholding or the failure to make such withholding
payment. If Tularik is required to pay any such deficiency, or any fine,
assessment or penalty for any such deficiency, NeoGenesis shall promptly
reimburse Tularik for such payments, within fifteen (15) days of notice to
NeoGenesis. The parties will cooperate to minimize, to the extent legally
permissible, the tax liabilities related to this Agreement. Notwithstanding
the foregoing, such cooperation shall not cause any adverse tax consequences
to be incurred by either party which would not have otherwise been incurred
under the provisions of this Agreement, including this Section 4.9.

4A.  SHARED TARGET OBLIGATIONS

4A.1 IDENTIFICATION OF DESIGNATED SHARED COMPOUND CANDIDATES BY STEERING
COMMITTEE. (a) Within [*] following the delivery of Selected Shared Compounds
for a particular Shared Target in accordance with ATTACHMENT A and completion of
optimization, if any, performed on Selected Shared Compounds for such Shared
Target in accordance with ATTACHMENT A, either party may propose to the Steering
Committee one or more Selected Shared Compounds or compounds arising out of
optimization (if any) for such Shared Target as candidates to become Designated
Shared Compounds. The Steering Committee will promptly determine whether each
such Selected Shared Compound is a suitable candidate for Pre-Clinical
Development.

     (b) Within [*] following receipt of notification from the Steering
Committee identifying candidates to become Designated Shared Compounds,
NeoGenesis shall amend ATTACHMENT D to identify any applicable NeoGenesis Patent
Rights not previously identified to the Steering Committee.

4A.2 ACCEPTANCE OF DESIGNATED SHARED COMPOUNDS. (a) If the Steering Committee
determines that a Selected Shared Compound is suitable for Pre-Clinical
Development, then, within [*] of such determination, each party shall provide to
the Steering Committee a written notice as to whether it elects to participate
in and, subject to Section 4A.8, commit resources to conduct, Pre-Clinical
Development and, if warranted based on the outcome of Pre-Clinical Development
activities, Development of such Selected Shared Compound pursuant to the
Development Plan and Development Budget. If both parties make an affirmative
election with respect to any Selected Shared Compound pursuant to this Section
4A.2, then such Selected Shared Compound shall become a DESIGNATED SHARED
COMPOUND. Thereafter, such Designated Shared Compounds will be subject to the
licenses granted pursuant to Section 3.1 and shall no longer be available to
NeoGenesis or any third party in any NeoGenesis compound library, including its
NeoMorph Screening Library, or in any other manner.

     (b) If the Steering Committee determines that a Selected Shared Compound is
not suitable for Pre-Clinical Development, then, within [*] of such
determination, each party shall provide to the Steering Committee a written
notice as to whether it elects to designate such Selected Shared Compound as a
Designated Shared Compound and participate in, and commit resources to conduct,
Pre-Clinical Development of such Selected Shared Compound, notwithstanding that
the Steering Committee has determined that such Selected Shared Compound is not
suitable for Pre-Clinical Development. If both parties make an affirmative
election with respect to whether any Selected Shared Compound shall be
designated a Designated Shared Compound as set forth in Section 4A.2(a), such
Selected Shared Compound shall become a Designated Shared Compound. If one party
makes an affirmative election and the other party makes a negative election with
respect to whether any Selected Shared Compound shall be designated a Designated
Shared Compound, the party making an affirmative election will have the right to
proceed independently to develop such compound as an Independent Compound or
Independent Product under Section 4A.15.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       23
<Page>

4A.3 DISCONTINUED COMPOUNDS. If neither party makes an affirmative election
with respect to any Selected Shared Compound being designated a Designated
Shared Compound pursuant to Section 4A.2, such Selected Shared Compound shall
be neither a Designated Shared Compound nor a compound that may be developed
under Section 4A.15, and Development of products based upon such non-elected
Selected Shared Compound (a DISCONTINUED COMPOUND) may only be subsequently
initiated by a party by notifying the other party of its interest in
initiating Pre-Clinical Development of such Discontinued Compound at any time
on or before [*]. If the other party indicates it is not interested in
participating in, and committing resources to, conduct Pre-Clinical
Development of such Discontinued Compound, the initiating party, upon notice
to the other party, may proceed with Pre-Clinical Development and Development
of such Discontinued Compound as an Independent Compound or an Independent
Product and the initiating party shall be deemed to be the Independent Party
therefor, as provided in Section 4A.15. If the other party indicates it is
interested in participating in and committing resources to conduct
Pre-Clinical Development of such Discontinued Compound, such Discontinued
Compound shall be designated as a Designated Shared Compound as set forth in
Section 4A.2(a). At any time after [*], either party may, upon written notice
to the other party, proceed with Pre-Clinical Development and Development of
a Discontinued Compound as an Independent Compound or an Independent Product,
and such party shall be deemed to be the Independent Party therefor, as
provided in Section 4A.15.

4A.4 NON-PROPOSED COMPOUNDS. If a Selected Shared Compound is not, at any
time, presented to the Steering Committee pursuant to Section 4A.1 (a
NON-PROPOSED COMPOUND), such Selected Shared Compound shall be neither a
Designated Shared Compound nor a compound that may be developed under Section
4A.15. If at any time on or before [*], a party hereunder (the NON-PROPOSED
COMPOUND INTERESTED PARTY) decides to initiate Pre-Clinical Development of
such Non-Proposed Compound, it shall provide written notice to the other
party of such interest and the reasons therefor. The other party will then
have [*] to indicate whether it also is interested in participating in and
committing resources to conduct Pre-Clinical Development of such Non-Proposed
Compound. If the other party is so interested, such Non-Proposed Compound
shall be designated a Designated Shared Compound as set forth in Section
4A.2(a). If the other party is not so interested, the Non-Proposed Compound
Interested Party may proceed with Pre-Clinical Development and Development of
such Non-Proposed Compound as an Independent Compound or an Independent
Product and the Non-Proposed Compound Interested Party shall be deemed to be
the Independent Party therefor, as provided in Section 4A.15. At any time
after [*], either party may, upon written notice to the other party, proceed
with Pre-Clinical Development and Development of a Non-Proposed Compound as
an Independent Compound or an Independent Product, and such party shall be
deemed to be the Independent Party therefor, as provided in Section 4A.15.

4A.5 PRE-CLINICAL DEVELOPMENT OF DESIGNATED SHARED COMPOUNDS. The parties,
under the direction of the Steering Committee, shall diligently conduct
Pre-Clinical Development with respect to any Designated Shared Compound in
accordance with the Development Plan. Unless otherwise agreed by the parties,
each party shall supply fifty percent (50%) of the total Pre-Clinical
Development effort for each Designated Shared Compound in the aggregate, as
determined by the Steering Committee. The costs of conducting such
Pre-Clinical Development shall be shared by the Parties as set forth in
Section 4A.8.

4A.6 DEVELOPMENT OF SHARED PRODUCTS. The parties will use Commercially
Reasonable Efforts to conduct the Development of Shared Products in
accordance with the Development Plan. The role of each party in the
Development process will be determined by the Steering Committee as described
in Section 4A.7, with the parties intending that each party will provide
advisory and supporting services with respect to any phase of the process in
which such party is not actively or primarily involved. Unless otherwise
agreed by the parties, each party shall supply fifty percent (50%) of the
total Development effort for each Shared Product in the aggregate, as
determined by the Steering Committee. The costs of conducting such
Development shall be shared by the Parties as set forth in Section 4A.8. The
Steering Committee will determine appropriate written standards for measuring
each party's required efforts and accounting procedures to confirm and
document each party's performance of its required efforts for any Shared
Product before the parties commence Development thereof. No clinical trials
involving any Shared Product shall be commenced by or on behalf of either
party without the prior approval of the Steering Committee. Nothing contained
in this Section 4A.6 shall be deemed to preclude either party from
terminating its participation in the collaborative Development of a Shared
Product pursuant to Section 4A.14. Any decision by a party not to

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       24
<Page>

participate in Development of a Shared Product pursuant to Section 4A.2, 4A.3
or 4A.4 or to terminate participation in the Development of a Shared Product
pursuant to Section 4A.14, shall not be deemed a breach of this Agreement.
The parties will conduct Pre-Clinical Development, Development, Manufacturing
and Commercialization activities in a manner calculated to minimize aggregate
Development Costs for such Shared Compound and Shared Product consistent with
the Development Plan and the Development Budget for such Shared Compound and
Shared Product.

4A.7 DEVELOPMENT PLAN AND DEVELOPMENT BUDGET. Promptly following acceptance
of a Designated Shared Compound, the Steering Committee, which, for this
purpose and for the purposes set forth in Sections 4A.8-4A.10 and 4A.23,
shall also include an equal number of financial personnel from each party,
shall initiate preparation of the development plan for the Pre-Clinical
Development and Development of such Designated Shared Compound and
Development of any resulting Shared Product (the DEVELOPMENT PLAN) and a
budget (the DEVELOPMENT BUDGET) for proposed Development Costs therefor. The
initial Development Plan for a Designated Shared Compound shall set time
lines and priorities for the various Pre-Clinical Development and Development
activities through Phase I Clinical Trials or Phase IIa Clinical Trials and
identify which party, or whether a third party, is to be responsible for each
activity. The Development Budget shall include a detailed short-term budget
covering all proposed Development Costs of the Development Plan expected
during the initial [*] of implementation of the Development Plan. Each
Development Plan and Development Budget shall be approved by the Steering
Committee unanimously. Both parties recognize that the Development Plan and
the Development Budget represent projections only and will be subject to
frequent changes during the Pre-Clinical Development and Development process.
Each such Development Plan and Development Budget shall be updated as deemed
appropriate by the Steering Committee, but in no event less frequently than
semi-annually, and approved, unanimously, by the Steering Committee not later
than thirty (30) days prior to each January 1 and July 1 of each applicable
calendar year.

4A.8 FUNDING OF PRE-CLINICAL DEVELOPMENT AND DEVELOPMENT. Tularik shall be
responsible for fifty percent (50%) of the Development Costs and NeoGenesis
shall be responsible for the remaining fifty percent (50%) of Development
Costs for each Designated Shared Compound, Derivative Compound thereof and
resulting Shared Product throughout the Territory. In the event the
Development Costs incurred by a party during any calendar quarter exceed [*]
of the Development Costs set forth in the most recently approved Development
Budget for activities to be conducted by such party during such quarter (the
OVERAGE THRESHOLD), then the other party shall not be responsible for paying
its fifty percent (50%) share of any Development Costs in excess of the
Overage Threshold incurred by the party triggering such overage unless such
overage had been approved in advance, or is subsequently ratified,
unanimously, by the Steering Committee (in which case each of the parties
shall be responsible for fifty percent (50%) of all such Development Costs).
In the event such overage has not been approved or ratified unanimously by
the Steering Committee, the party incurring Development Costs in a calendar
quarter exceeding the Overage Threshold in such quarter shall be responsible
for all of the portion of the Development Costs in excess of the Overage
Threshold.

4A.9 FTE RATE. In preparing the Development Budget and determining
Development Costs, each party will use an FTE rate for such party's
development personnel mutually agreed to by the parties based on the then
prevailing FTE rate for such party.

 4A.10 PAYMENT OF DEVELOPMENT COSTS. Within thirty (30) days after each
calendar quarter, each party shall provide the Steering Committee with
detailed information concerning the Development Costs incurred by such party
during such quarter pursuant to the Development Plan and the Development
Budget. Promptly after receipt thereof, the Steering Committee will determine
the amount, if any, that either party has paid in excess of the amount to be
borne by such party for such quarter pursuant to Section 4A.8, and shall so
notify the parties. In the event of an overpayment by a party of its share of
Development Costs in a particular calendar quarter, the other party shall pay
to the party making the overpayment the amount by which such other party
underpaid within thirty (30) days after the underpaying party's receipt of
notice from the Steering Committee that an overpayment has occurred.

4A.11 REGULATORY APPROVALS. Consistent with the Development Plan and
Development Budget and as directed by the Steering Committee, the parties (or
their Affiliates) will (a) prepare and file all documents that are necessary
to conduct clinical studies of Shared Products in connection with the
Development Plan and (b) use Commercially

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       25
<Page>

Reasonable Efforts to file applications for Regulatory Approvals required before
commercial sale or use of a Shared Product as a drug in a country within the
Territory and obtain Regulatory Approvals in each country in the Territory in
which the parties, either individually or jointly, intend to Commercialize
Shared Products in accordance with the Development Plan. The Steering Committee
will be responsible for designating a party by unanimous agreement to be
responsible for filing all regulatory submissions in each country in the
Territory in which Shared Products will be Commercialized. The party not
responsible for filing regulatory submissions for a Shared Product in a country
pursuant to this Agreement shall have a right to cross-reference to all such
filings made by the other party for such Shared Product in any country. The
parties will cooperate in the preparation of all such regulatory filings and in
obtaining Regulatory Approvals under this Section 4A.11, including without
limitation providing access to each party's data and information obtained under
the Program and the Development Plan to the extent necessary for obtaining
Regulatory Approvals of Shared Products.

4A.12 LINE EXTENSIONS. NeoGenesis and Tularik may each prepare and submit to the
Steering Committee for consideration plans for Development of Shared Product
line extensions and the conduct of clinical trials covering indications other
than those for which Shared Products are then being Developed or Commercialized
in the Territory. Any such line extensions or any additional clinical trials for
additional indications will be subject to the approval and supervision of the
Steering Committee as part of the ongoing Development of such Shared Product.

4A.13 THIRD PARTY TECHNOLOGY; CONSENTS TO CERTAIN SUBLICENSES. If either party
becomes aware of (i) an opportunity to participate in research with a third
party that could advance the Pre-Clinical Development of a Designated Shared
Compound or Derivative Compound thereof or the Development of a Shared Product;
or (ii) an opportunity to obtain a license or other right owned or controlled by
a third party relating to the Manufacture, marketing, import, use or sale of a
Shared Product, it shall so notify the other party and the Steering Committee
will determine whether to pursue such opportunity. In the event that the parties
pursue such opportunity under subsection (i), they shall grant appropriate
licenses or sublicenses, as applicable, to such third party solely to perform
the tasks designated and approved by the Steering Committee for such third party
and provide for confidentiality and non-use obligations, and for ownership of or
licenses under such third party's inventions and related intellectual property
rights arising in the course of work performed by such third party pursuant to
this Agreement consistent with those provided in the applicable provisions of
this Agreement. If the parties, in connection with any opportunity described in
subsection (i) or (ii), incur obligations to make payments to a third party,
such payments shall be included in the calculation of Expenses or Development
Costs, as the case may be, of the party making such payment. Neither party shall
enter into any sublicense under which such party shall receive any consideration
from the relevant sublicensee in the form of an equity investment in, or as a
loan to, such party without the other party's prior written consent, not to be
unreasonably withheld.

4A.14 TERMINATION OF PARTICIPATION IN COLLABORATIVE DEVELOPMENT. (a) Either
party may elect, on a Designated Shared Compound-by-Designated Shared Compound,
Derivative Compound thereof-by-Derivative Compound thereof or Shared
Product-by-Shared Product basis, as the case may be, to terminate its
participation in, or to not participate in, the Pre-Clinical Development of a
given Designated Shared Compound or Derivative Compound thereof or Development
of a given Shared Product based upon or incorporating such Designated Shared
Compound or Derivative Compound thereof by written notice to the other party:
(i) [*] for such Designated Shared Compound or Derivative Compound thereof; (ii)
during the period commencing upon receipt by such party of final reports
covering all aspects of [*] for such Shared Product and [*]; or (iii) during the
period commencing [*] for such Shared Product and ending [*]. After receipt of
such notice by the other party in accordance with this Section 4A.14, the party
providing such notice shall no longer be responsible for bearing further
Development Costs for such Designated Shared Compound or Derivative Compound
thereof or Shared Product pursuant to Section 4A.8 (except as set forth in the
next succeeding sentence), in which event the other party will have the right to
proceed independently to Develop such Designated Shared Compound or Derivative
Compound thereof or Shared Product as an Independent Compound or Independent
Product, and the party continuing such Development shall thereafter be deemed to
be the Independent Party therefor, as provided in Section 4A.15. In the event a
party gives notice under this Section 4A.14, such non-Independent Party (i) will
remain responsible for its share of Development Costs for such Designated Shared
Compound or Derivative Compound thereof or Shared Product until [*], and (ii)
will make its personnel, relevant data and other resources available to the
Independent Party as necessary to effect an orderly

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       26
<Page>

transition of Pre-Clinical Development and Development responsibilities, with
the costs of such personnel, relevant data and resources to be [*] a notice
under this Section 4A.14. In the event of a party's termination of participation
in Pre-Clinical Development or Development of a Designated Shared Compound or
Derivative Compound thereof or Shared Product in accordance with this Section
4A.14, such party shall [*] to the Independent Party all Regulatory Approval
submissions, including all applications relating to such Designated Shared
Compound, Derivative Compound thereof and/or Shared Products based upon or
incorporating such Designated Shared Compound or Derivative Compound thereof,
together with all materials and data related thereto in its possession.

     (b) If, at any time during Pre-Clinical Development or Development
activities, both parties elect, on a Designated Shared Compound-by-Designated
Shared Compound basis, Derivative Compound thereof-by-Derivative Compound
thereof basis or a Shared Product-by-Shared Product basis, as the case may be,
to terminate Pre-Clinical Development of a Designated Shared Compound or
Derivative Compound thereof or to terminate Development of a Shared Product, the
parties shall confer and mutually agree on a plan for seeking a purchaser for
the Designated Shared Compound, Derivative Compound thereof or Shared Product,
as applicable.

4A.15 INDEPENDENT DEVELOPMENT. (a) In the event (i) a party, pursuant to
Sections 4A.2, 4A.3, 4A.4 or 4A.14, elects not to, or does not, participate in
and commit resources to the pre-clinical development of a Selected Shared
Compound as a Designated Shared Compound, or the pre-clinical development of a
Discontinued Compound or a Non-Proposed Compound, or (ii) any party unilaterally
terminates its participation in the Pre-Clinical Development or Development of a
Designated Shared Compound, Derivative Compound thereof or Shared Product
pursuant to Section 4A.14, then the party that either made an affirmative
election to conduct such Pre-Clinical Development of such Selected Shared
Compound, or the pre-clinical development of a Discontinued Compound or a
Non-Proposed Compound, or is continuing Pre-Clinical Development or Development
of a Designated Shared Compound, Derivative Compound thereof or Shared Product
(in either case, the INDEPENDENT PARTY), shall have the right to practice the
licenses granted in Section 3.1 and to undertake pre-clinical development of a
Selected Shared Compound, Discontinued Compound or Non-Proposed Compound or to
continue Pre-Clinical Development and Development of such Designated Shared
Compound, Derivative Compound thereof or Shared Product independently as an
INDEPENDENT COMPOUND or INDEPENDENT PRODUCT, [*]. Subject to reinstatement
pursuant to exercise of its Re-Engagement Option set forth in Section 4A.16, the
non-Independent Party's license under Section 3.1 shall be terminated with
respect to such Independent Compound or Independent Product. Neither party may
charge the services of its personnel or any third party to research or develop
an Independent Compound, Derivative Compound thereof or Independent Product to
the other party.

     (b) Until the earlier of the Re-Engagement Expiration Date or the date on
which the Independent Party receives a Re-Engagement Notice for an Independent
Compound, Derivative Compound thereof or an Independent Product from the
non-Independent Party, the Independent Party will (i) inform the other party of
all material information developed in its research and development of each
Independent Compound, Derivative Compound thereof or Independent Product; and
(ii) provide the other party a copy of all proposed regulatory submissions
relating to such Independent Compound, Derivative Compound thereof or
Independent Product at least thirty (30) days prior to submitting such filing to
the applicable Regulatory Authority.

     (c) In the event either party elects to proceed as an Independent Party,
subject to Section 4A.16, such Independent Party shall be entitled to develop
such Independent Compound or any Derivative Compound thereof and Commercialize
such Independent Product at its sole discretion, alone or with a third party
(subject to Section 4A.15(d)), with no obligation to the other party other than
the payment of royalties in accordance with Sections 4A.18 or 4A.19 and those
obligations imposed under Sections 4.6 and 4A.21.

     (d) The Independent Party may not sublicense any intellectual property
rights to the extent such right is necessary or useful to research, Develop,
have Developed, make, have made, use, distribute, promote, market, offer for
sale, sell, have sold, import and export an Independent Compound, Derivative
Compound thereof or Independent Product to any third party without the consent
of the non-Independent Party prior to the Re-Engagement Expiration Date for such
Independent Compound, Derivative Compound thereof or Independent Product.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       27
<Page>

     (e) If either party terminates its research, Development or
Commercialization of an Independent Compound, Derivative Compound thereof or
an Independent Product, then (i) it shall promptly so notify the other party,
(ii) such compound shall no longer be an Independent Compound, Derivative
Compound thereof and such product shall no longer be an Independent Product;
(iii) the licenses granted to such Independent Party by the non-Independent
party for such compound or product shall terminate upon such other party's
receipt of such notice; and (iv) the parties will confer and mutually agree
on a plan for seeking a purchaser for such Independent Compound, Derivative
Compound thereof or Independent Product, as applicable.

4A.16 RE-ENGAGEMENT OPTION. (a) Either party may elect to resume its
participation in the Pre-Clinical Development or Development of an Independent
Compound, Derivative Compound thereof or Independent Product throughout the
Territory by so notifying the Independent Party for such Independent Compound,
Derivative Compound thereof or Independent Product (the RE-ENGAGEMENT NOTICE),
at any time prior to the expiration of the [*] period [*] (RE-ENGAGEMENT
EXPIRATION DATE) for such Independent Compound, Derivative Compound thereof or
Independent Product. If a party so elects to resume participation hereunder,
such Independent Compound, Derivative Compound thereof or Independent Product
shall immediately cease to be an Independent Compound, Derivative Compound
thereof or Independent Product, as applicable, and shall instead be designated a
Designated Shared Compound or Shared Product for all purposes under this
Agreement, including but not limited to calculating each party's responsibility
for paying Development Costs and Expenses and receiving the Share of Profit
commencing upon and continuing after the Independent Party's receipt of the
Re-Engagement Notice.

     (b) If a party provides a Re-Engagement Notice pursuant to Section
4A.16(a), then such party shall pay to the Independent Party [*] of the
non-Independent Party's share, based on the allocation set forth in Section
4A.8, of the costs of Pre-Clinical Development and Development of the
Independent Compound, Derivative Compound thereof or Independent Product
incurred by the Independent Party after the date upon which it commenced
Pre-Clinical Development or Development of such compound or product as an
Independent Compound or Independent Product and prior to the date of the
Re-Engagement Notice, calculated as if such Independent Compound or Derivative
Compound thereof had been a Designated Shared Compound or such Independent
Product had been a Shared Product during such period of Pre-Clinical Development
and Development by the Independent Party therefor (the RE-ENGAGEMENT AMOUNT). In
calculating such amounts, the parties will use the FTE rate as set forth in
Section 4A.9. The non-Independent Party shall pay the Re-Engagement Amount in
[*] beginning on the [*] following the date upon which the Independent Party
receives the relevant Re-Engagement Notice.

4A.17 PROFITS AND LOSSES. Each party's SHARE OF PROFIT shall equal fifty
percent (50%) of all Shared Product Profits for all Shared Products sold in
the Territory, and each party's SHARE OF LOSS shall equal fifty percent (50%)
of all Shared Product Losses for all Shared Products sold in the Territory.
Each party shall be responsible for its Share of Loss and shall be entitled
to receive its Share of Profits. Each party shall also receive fifty percent
(50%) of all Sublicense Revenues in the Territory, which sublicense
agreements shall conform to the requirements of Section 4A.13. Shared Product
Profits, Shared Product Losses and Sublicense Revenues shall be determined
and paid as set forth in Section 4A.22.

4A.18 ROYALTIES PAYABLE ON SALES OF INDEPENDENT PRODUCTS AFTER REVOCATION OF
COMMERCIALIZATION RIGHTS. In the event a party elects to terminate its
participation in the Commercialization of a Shared Product in a country or
countries in the Territory pursuant to Section 4A.23(d), the parties shall
negotiate in good faith for a period of [*] following the non-terminating
party's receipt of such notice to determine the appropriate royalty to be paid
on Net Sales of such Shared Product as an Independent Product by the other party
as an Independent Party in such country or countries. In the event the parties
are unable to agree on the appropriate royalty pursuant to the immediately
preceding sentence, the Independent Party with respect to such Independent
Product shall pay to the other party a royalty on annual Net Sales of such
Independent Product in each such country in the Territory pursuant to Section
4A.19, except that the applicable royalty shall be: [*] of the portion of
aggregate annual Net Sales of such Independent Product in such country that is
[*] of the portion of annual aggregate Net Sales of such Independent Product in
such country that is [*]; and [*] of the portion of annual aggregate Net Sales
of such Independent Product in such country that is [*]. Such royalty will be
payable on [*] in respect of each country in which sales of such Shared Product
occur and in which a party has elected to terminate its participation in the
Commercialization of such

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       28
<Page>

Shared Product until the expiration of the license granted to the
non-terminating party under Section 3.1 with respect to such Shared Product.
Such royalty is subject to offsets as provided in the last sentence of Section
4A.19.

4A.19 ROYALTIES PAYABLE BY THE INDEPENDENT PARTY OTHER THAN IN THE EVENT OF
REVOCATION OF PROMOTION RIGHTS. Except as otherwise provided in Section 4A.18,
the Independent Party will pay the non-Independent Party, in lieu of any Share
of Profits, a royalty on Net Sales of each Independent Product equal to:
     (a) [*] of Net Sales of such Independent Product if the non-Independent
         Party did not participate, or terminates its participation, in the
         Pre-Clinical Development of the relevant compound [*];
     (b) [*] of Net Sales of such Independent Product if the non-Independent
         Party terminates its participation in the Development of the relevant
         Designated Shared Compound pursuant to Section 4A.14 [*] but prior to
         the [*];
     (c) [*] of Net Sales of such Independent Product if the non-Independent
         Party terminates participation in the Development of the relevant
         Shared Product pursuant to Section 4A.14 [*]; or
     (d) [*] of Net Sales of such Independent Product if the non-Independent
         Party terminates participation in the Development of the relevant
         Shared Product pursuant to Section 4A.14 [*].

Such royalty shall be payable on [*] in respect of each country in which sales
of such Independent Product occur until the expiration of the license granted
the Independent Party under Section 3.1 with respect to such Independent
Product. The Independent Party may offset [*] of any royalties it must pay to
third parties pursuant to any licenses necessary to Manufacture and
Commercialize Independent Products against royalties payable by the Independent
Party to the non-Independent Party; PROVIDED, HOWEVER, that in no event shall
the royalties payable by the Independent Party to the non-Independent Party be
reduced to less than [*] of the amounts that would have otherwise been due under
the percentages set forth in this Section 4A.19 or Section 4A.18, as applicable.

4A.20 TAXES. The burden of paying all withholding or similar taxes that may be
imposed by any governmental authority on royalty and Share of Profit payment
amounts provided in this Section 4A with respect to Shared Products shall be
shared equally by Tularik and NeoGenesis. The burden of paying all withholding
or similar taxes that may be imposed by any governmental authority on royalty
payment amounts provided in this Section 4A with respect to Independent Products
shall be paid by the party receiving such royalty, and the party making such
royalty payment shall make such withholding payments as required and subtract
such withholding payments from the payments to be made to the other party in
respect of such Independent Products, or, if applicable, the party receiving
such royalty payment will reimburse the other party or its designee(s) for the
amount of such withholding payments that are not subtracted from the payments
made to the party receiving such royalty payment as set forth in this Section
4A.20, within fifteen (15) days of notice from the party making such royalty
payment in respect of Independent Products. The party that makes any such
withholding payment shall provide the other party with documentation of such
withholding and payment in a manner that is satisfactory for purposes of
reporting to the U.S. Internal Revenue Service. Any withholdings paid when due
hereunder shall be for the account of the party receiving such royalty payment.
Withholding payments made by the party making such royalty payment in respect of
Independent Products pursuant to this Section 4A.20 shall be made based upon
financial information provided to such party by the party receiving such royalty
payment, and to the extent that such information is incorrect, the party
receiving such royalty payment shall be liable for any deficiency, and any fine,
assessment or penalty imposed by any taxing authority in the Territory for any
deficiency in the amount of any such withholding or the failure to make such
withholding payment. If the party making such royalty payment is required to pay
any such deficiency, or any fine, assessment or penalty for any such deficiency,
the party receiving such royalty payment shall promptly reimburse it for such
payments, within fifteen (15) days of notice to the party receiving such royalty
payment. The parties will cooperate to minimize, to the extent legally
permissible, the tax liabilities related to this Agreement. Notwithstanding the
foregoing, such cooperation shall not cause any adverse tax consequences to be
incurred by either party which would not have otherwise been incurred under the
provisions of this Agreement, including this Section 4A.20.

4A.21 RECORDS AND INSPECTION. (a) NeoGenesis and Tularik and, if applicable,
their respective Affiliates and sublicensees, each shall keep accurate books and
accounts of record (prepared in accordance with GAAP) in connection with the
Pre-Clinical Development, Development, Manufacture and/or Commercialization by
or for such

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       29
<Page>

party of all Designated Shared Compounds, Derivative Compounds thereof, Shared
Products, Independent Compounds, Derivative Compounds thereof and Independent
Products in the Territory in sufficient detail to permit accurate determination
of all figures necessary for verification of Development Costs, royalties,
Shared Product Profits, Shared Product Losses, Sublicense Revenues, Expenses and
other compensation required to be paid or expenses required to be shared
hereunder. NeoGenesis and Tularik shall maintain such records for a period of
[*] after the end of the year in which such records were generated.

     (b) Each party and, if applicable, its Affiliates shall, and shall provide
in any agreements with any sublicensees that such sublicensees shall, make such
records available for inspection by an independent certified public accountant,
mutually agreed to by the inspecting party and the party being inspected, during
regular business hours at such place or places where such records are
customarily kept, upon reasonable notice from the inspecting party, to verify
the accuracy of the reports and any compensation required to be paid or expenses
required to be shared hereunder. Such inspection right shall not be exercised
more than once in any calendar year. The inspecting party agrees to hold in
confidence all information concerning payments, expenses and reports, and all
information learned in the course of any inspection, except to the extent
necessary for the inspecting party to reveal such information in order to
enforce its rights under this Agreement in a proceeding in accordance with
Section 9.1 or if disclosure is required by law, regulation or judicial order.
Any person or entity conducting such inspection will agree in writing with the
inspecting party to treat all records reviewed in the course of the inspection
as the Confidential Information of the party being inspected under terms and
conditions no less restrictive than the terms contained in Section 5.2. The
results of each inspection shall be binding on both parties absent mathematical
error. The inspecting party shall pay for such inspections, except that in the
event there is any upward adjustment in aggregate amounts payable for any year
shown by such inspection of more than [*] of the amount paid, the party being
inspected shall pay for such inspection.

4A.22 SHARED PRODUCT REPORTING AND PAYMENTS OF THE PARTIES' SHARE OF
PROFIT/LOSS. (a) Payments and reporting for each Shared Product shall be made as
follows. Within forty five (45) days after the close of each party's accounting
year in which Shared Products are sold, or earlier if possible, each party shall
furnish to the other party a profit and loss statement for such accounting year
setting forth for each country in the Territory in which Shared Products were
developed or sold during such year, Net Sales of each Shared Product, Expenses,
Sublicense Revenues and all data on which the determination of each party's
Share of Profit, Share of Loss or share of Sublicense Revenues was calculated.
If either party owes an amount of Share of Profit or Share of Loss to the other
party pursuant to Section 4A.17, then it shall make such payment within thirty
(30) days after receipt of the profit and loss statement, but in no event shall
such payment be due earlier than sixty (60) days after the end of the relevant
period.

     (b) For the purposes of calculating Shared Product Profit or Shared Product
Loss for a Shared Product, a given item of cost or expense shall be allocated
only to one category of cost and expense and not to multiple categories. Each
party agrees to determine such costs and expenses hereunder with respect to
Shared Products using its standard accounting procedures, consistently applied,
to the maximum extent practical, as if such Shared Product were a solely owned
product of the party, except as specifically provided in this Agreement. The
parties also recognize that such procedures may change from time to time and
that any such changes may affect the definitions of the elements of the Shared
Product Profit or Shared Product Loss. The parties agree that, where such
changes are economically material to either party, adjustments shall be made to
compensate the affected party in order to preserve the same economics as
reflected under this Agreement under such party's accounting procedures in
effect as of the date on which the activity in question (for example,
Development, marketing or Manufacturing) first commences under this Agreement.
Transfers between a party and its Affiliates (or between such Affiliates) shall
not have effect for purposes of calculating revenues, costs, profits, royalties
or other payments or expenses under this Agreement.

4A.23 COMMERCIALIZATION. (a) The Steering Committee shall oversee and implement
all Commercialization activities in the Territory for Shared Products, based on
the principle of maximizing profits from sales of Shared Products. The Steering
Committee shall have the ability to determine whether the objective of
maximizing profits from sales of Shared Products in the Territory is best
achieved through, INTER ALIA, granting sublicenses to a third party or third
parties, creating or entering into joint ventures with third parties or jointly
Commercializing such

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       30
<Page>

Shared Products as provided in this Section 4A.23. In the event the Steering
Committee determines that the foregoing objective is best achieved by activities
other than as provided in this Section 4A.23, the Steering Committee shall
determine by unanimous decision the optimal alternative structure and the
duties, responsibilities and economic parameters for the parties and third
parties in such alternative structure.

     (b) No later than [*] for a Shared Product, the Steering Committee shall
commence preparation of a marketing plan (MARKETING PLAN) and a marketing budget
(MARKETING BUDGET) for such Shared Product. The Commercialization of a Shared
Product in the Territory will be governed by the Marketing Plan and Marketing
Budget. The Marketing Plan and Marketing Budget will describe fully, to the
extent practicable, the proposed plan for Commercialization of the Shared
Product in each country in which the parties Commercialize Shared Products,
including overall marketing strategy, marketing, sales and promotion efforts to
be performed by each party, market and sales forecasts, pricing, reimbursement
and discounting analysis and estimated launch date, as well as preparation of
advertising and other promotional materials to be used in the promotion of
Shared Products. The Marketing Plan will take into consideration market
conditions, regulatory factors and competition with respect to the Shared
Product. The Marketing Budget will include all projected Expenses for the Shared
Product. The initial Marketing Plan and Marketing Budget shall be completed by
the Steering Committee no later than [*] for a Shared Product in any country in
the Territory. Each such Marketing Plan and Marketing Budget shall thereafter be
updated by the Steering Committee every six (6) months, or more frequently if
agreed by the parties.

     (c) NeoGenesis and Tularik shall have the co-exclusive responsibility for
promoting such Shared Product in the Territory, except as otherwise provided in
Section 4A.23(a). Tularik and NeoGenesis shall each diligently perform its
respective obligations under the Marketing Plan and use Commercially Reasonable
Efforts to Commercialize Shared Products in the Territory pursuant to the terms
and conditions hereof. The parties intend that each party shall provide fifty
percent (50%) of the total promotional and marketing effort (including details,
if determined to be an appropriate sales activity for a party by the Steering
Committee) for each Shared Product being Commercialized by the parties in the
Territory, as determined by the Steering Committee. The Steering Committee will
determine appropriate written standards for measuring, and accounting procedures
to confirm and document, each party's marketing and promotional effort under the
Marketing Plan, no later than [*] for any Shared Product. Nothing contained in
this Section 4A.23 shall be deemed to preclude either party from relinquishing
its right to participate in the Commercialization of Shared Products in the
Territory pursuant to Section 4A.23(d), at any time.

     (d) Either party may terminate its participation in the Commercialization
of a Shared Product in any country in the Territory at any time following [*]
prior written notice to the other party. In such case, the other party may
continue Commercialization of such Shared Product as an Independent Product,
either alone or with a third party, and shall thereafter be deemed to be an
Independent Party for such Independent Product solely with respect to such
country or countries, effective as of the date of the terminating party's notice
hereunder, in which case the terminating party's license under Section 3.1 shall
be terminated in the country or countries in which such party has terminated its
participation in the Commercialization of such Shared Product (the TERMINATED
COUNTRIES). In the event a party elects to cease participating in the
Commercialization of a Shared Product in a country in the Territory and the
other party proceeds to Commercialize such Shared Product in the Terminated
Countries as an Independent Product, the terminating party shall (i) [*] to the
Independent Party all regulatory submissions and Regulatory Approvals in such
country relating to such former Shared Product, together with all materials and
data related thereto in its possession, and (ii) [*] to the Independent Party
all other relevant information that will enable such Independent Party to
Commercialize such former Shared Product as an Independent Product in such
country. A non-Independent Party may not reinitiate its participation in the
Commercialization of a Shared Product in any country in the Territory in which
it relinquished such right hereunder. Any relinquishment of a party's right to
Commercialize Shared Products pursuant to this Section 4A.23(d) shall not be a
breach of this Agreement. If both parties terminate their participation in the
Commercialization of a Shared Product, the parties will confer and mutually
agree on a plan for seeking a third party to conduct such Commercialization.

     (e) The parties shall disseminate in the Territory only those promotional
and advertising materials that have been provided or approved for use by the
Steering Committee, and the cost of producing such materials shall be an Expense
of [*]. All such materials shall be consistent with the relevant Marketing Plan
and Marketing Budget

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       31
<Page>

approved, unanimously, by the Steering Committee and neither party shall make
any claims or representations in respect of the Shared Products outside the
scope of those previously approved by the Steering Committee.

     (f) The Steering Committee shall designate a party as being primarily
responsible for each country in the Territory for booking sales, establishing
pricing for Shared Products based upon the market analyses performed by the
parties under the direction of the Steering Committee, obtaining necessary
pricing approvals, handling returns and customer complaints and providing
samples. In addition, the Steering Committee shall determine the policies and
procedures necessary to implement the foregoing, including coordination of the
parties' efforts to train sales and marketing representatives for Shared
Products.

4A.24 TRADEMARKS. (a) The parties shall mutually select the trademark or
trademarks for a Shared Product. To the extent commercially reasonable and
appropriate, a single trademark shall be used for each Shared Product in all
countries in the Territory. To the extent the parties determine that the use of
a single trademark for a given Shared Product is impractical or not advisable
given cultural and other differences among countries in the Territory, the
parties shall agree on the appropriate trademark for a Shared Product for use
within different countries within the Territory; PROVIDED that in no event shall
different trademarks be used for the same Shared Product within the same country
in the Territory (unless such Shared Product is being sold for more than one
indication and the parties mutually agree.) Each trademark shall be used only in
connection with the applicable Shared Product and shall not be used by either
party on, or in connection with, any other product. The Steering Committee shall
determine which party shall own each trademark used to promote Shared Products
in the Territory and assign responsibility to one or both parties for searching
candidate trademark names and filing, prosecuting, maintaining and all
reasonable steps necessary in defending each Shared Product trademark
application(s) and/or trademark(s) (as applicable).

     (b) The party owning a given trademark and related intellectual property
rights in a country in the Territory shall, and hereby does, grant to the other
party a nonexclusive, royalty-free license, with the right to grant sublicenses
only with the prior written consent of the granting party, not to be
unreasonably withheld, to use such trademark to promote and Commercialize Shared
Products as permitted under this Agreement, provided that the party receiving
such license shall refrain from taking any actions that may dilute or otherwise
reduce the value of such trademark. The parties shall approve all trade dress,
logos, slogans, designs and copyrights used on and in connection with any Shared
Product in the Territory. During the term of this Agreement, the Screening
Committee shall approve all printed materials bearing each trademark for a
Shared Product in the Territory, including but not limited to business
materials, printed materials, advertising materials, promotional materials and
any such other materials that may reference or incorporate such trademark.

     (c) In the event that any action or proceeding is brought against either or
both NeoGenesis or Tularik with respect to a Shared Product trademark in the
Territory or relating to any alleged infringement of a third party's trademark,
trade dress or similar intellectual property rights in the Territory arising out
of the parties' promotion or Commercialization of Shared Products pursuant to
this Agreement, each party shall promptly notify the other and cooperate in the
defense of any such action or proceeding, as applicable. The parties shall agree
on the management of such action. In the event Tularik or NeoGenesis becomes
aware of any actual or threatened violation of any trademark for a Shared
Product in any country in the Territory, that party shall promptly notify the
other party and the Steering Committee shall promptly discuss how to proceed in
connection with such actual or threatened violation. Any expenses incurred by
either or both parties for searching candidate trademark names, filing,
prosecuting, maintaining, defending and enforcing trademark application(s)
and/or trademark(s) (as applicable) for Shared Products shall be included as an
element of the Other Allowable Expenses.

4A.25 SUPPLY OF SHARED PRODUCT. The Steering Committee shall be responsible for
determining the sources of, and arrangements for, the clinical and commercial
Manufacture and supply of Designated Shared Compounds and Shared Products in a
manner designed to result in long-term profit maximization for such Shared
Products. The Steering Committee shall endeavor to establish multiple sources of
bulk material and fill and finish services and to establish policies for the
maintenance of inventories of key intermediates, bulk material and finished
products and for such other matters as necessary or useful to assure such supply
of Shared Products in the Territory. The Independent

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       32
<Page>

Party shall arrange for the Manufacture and supply of Independent Compounds,
Derivative Compounds thereof and Independent Products, in both bulk and
finished form.

4A.26 SPECIFICATIONS FOR SHARED PRODUCTS. The parties shall designate one of
the parties to be responsible for establishing, subject to approval by the
Steering Committee, the specifications for bulk and finished Shared Product,
and providing and maintaining any necessary documentation, certificates of
analysis and test results, for each Shared Product. Copies of all such
specifications and other information and documentation will be provided
promptly to each party. In addition, notice of, and results and data from,
all FDA (or its foreign equivalent) audits relating to the Manufacture of
Shared Products will be provided to each party.

4A.27 TERMS OF MANUFACTURE AND SUPPLY. The parties shall establish procedures
acceptable to both parties regarding forecasting of and ordering for each
party's requirements of the Shared Products in the Territory.

4A.28 SIDE EFFECTS AND ADVERSE EVENTS. During the term of this Agreement, each
party shall promptly advise the other by telephone, telefax or overnight
delivery service of every serious or unexpected side effect, adverse reaction or
injury that has been brought to that party's attention and which is alleged to
have been caused by a Shared Product. For each country in the Territory, the
party that has the responsibility for filing the Regulatory Approval and the IND
(or foreign equivalent) in such country for such Shared Product shall have all
rights and responsibilities to report such side effect, adverse reaction or
injury to the appropriate Regulatory Authority(ies) as required by Applicable
Laws. The parties shall establish a procedure for such reporting obligations
prior to commencement of Phase I Clinical Trials for the first Shared Product.

4A.29 COMMUNICATION WITH REGULATORY AGENCIES. If a party is contacted by the FDA
or any equivalent regulatory agency in any country in the Territory during the
term of this Agreement pertaining to a Shared Product, Tularik and NeoGenesis
shall promptly, but always within [*], notify and consult with one another. The
party that has responsibility for regulatory filings for a Shared Product shall
provide an appropriate response to such contact after such consultation with the
other party, except where an earlier response may be required by law or to
assure patient safety.

4A.30 SHARED PRODUCT RECALL. In the event that NeoGenesis or Tularik determines
that an event, incident or circumstance has occurred that may result in the need
for a recall or other removal of any Shared Product or any lot or lots thereof
from the market in a country within the Territory, it shall promptly advise and
consult with the other party with respect thereto. Thereafter, on a
country-by-country basis, the owner of the Regulatory Approval for such Shared
Product in a country shall, in its sole discretion (except as otherwise required
by such government authority), have the right to order a recall or other removal
after such consultation, and the other party shall co-operate with such recall.
Any expenses related to a recall in the Territory for a Shared Product shall be
included in Recall Expenses.

5.   CONFIDENTIALITY

5.1 PUBLICITY. The parties shall agree upon the text and the exact timing of an
initial public announcement relating to the transactions contemplated by this
Agreement as soon as practicable after the Effective Date (such agreement not to
be unreasonably withheld or delayed). Each party may thereafter disclose to
third parties the specific information contained in such public announcement
without the need for further approval by the other party. Thereafter, unless
permitted by the preceding sentence, each party agrees not to issue any press
release or other public statement, written or oral, to the public, the press,
the stockholders or otherwise, relating to this Agreement that has not
previously been approved in writing by the other party. Nothing in this Section
5.1 shall prohibit a party from making such disclosures to the extent required
under applicable federal or state securities laws or any rule or regulation of
any nationally recognized securities exchange. In such event, however, the
disclosing party shall use good faith efforts to notify and consult with the
other party prior to such disclosure and, where applicable, shall diligently
seek confidential treatment to the extent such treatment is available under
applicable securities laws.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       33
<Page>

5.2 CONFIDENTIALITY. (a) Except as permitted in accordance with Section 5.1,
either party may only disclose the general nature, but not the specific
financial or other material terms, of this Agreement without the prior consent
of the other party; PROVIDED that either party may provide a copy of this
Agreement or disclose the terms of this Agreement (i) to any finance provider in
conjunction with a financing transaction, if such finance provider agrees to
keep this Agreement confidential, (ii) to enforce its rights under this
Agreement in a proceeding in accordance with Section 9.1, (iii) to any legal or
financial advisor of such party, or (iv) in response to a subpoena or other
validly issued administrative or judicial process requesting disclosure of same;
PROVIDED, the party that receives such order or process provides prompt notice
to the disclosing party before making any disclosure (to the extent possible)
and permits the disclosing party to oppose or narrow such request for disclosure
and supports any of disclosing party's reasonable efforts to oppose such request
(at disclosing party's expense) and shall disclose the terms of this Agreement
only in the event of a final judgment or administrative order requiring such
disclosure, and only to the extent necessary to comply with such request.

     (b) Confidential Information of each party and Program Intellectual
Property owned by such party will be used by the other party solely for the
purposes permitted by this Agreement. All Confidential Information and any
Program Intellectual Property owned by a party will be received and held in
confidence by the receiving party, subject to the provisions of this Agreement.
Each party acknowledges that, except for the rights expressly granted under this
Agreement, it will not obtain any rights of any sort in or to the Confidential
Information of the other party as a result of such disclosure and that any such
rights must be the subject of separate written agreement(s).

     (c) Each party will restrict disclosure of the other party's
Confidential Information and any Program Intellectual Property owned by such
party to those of its employees and consultants to whom it is necessary or
useful to disclose such Confidential Information and Program Intellectual
Property in connection with the purposes permitted under this Agreement. Each
party shall use reasonable efforts, including at least efforts fully
commensurate with those employed by the party for the protection of its own
Confidential Information, to protect the Confidential Information and Program
Intellectual Property of the other party.

     (d) Either disclosing party may at any time notify the receiving party that
such receiving party must return to the disclosing party the disclosing party's
Confidential Information and any Program Intellectual Property owned by such
party. Each party hereby agrees to, within thirty (30) days of such
notification: (i) return all documents and tangible items it or its employees or
agents have received or created pursuant to this Agreement pertaining, referring
or relating to the other party's Confidential Information and any Program
Intellectual Property owned by such party; and (ii) return or certify (in a
writing attested to by a duly authorized officer of such party) destruction of
all copies, summaries, modifications or adaptations that such party or its
employees or agents have made from the materials provided by the disclosing
party; provided, however, that a party is permitted to retain one copy of such
materials in its legal files to be used to verify compliance with its
obligations hereunder.

     (e) Nothing herein shall prevent a receiving party from disclosing all or
part of the Confidential Information and any Program Intellectual Property owned
by the disclosing party in response to a subpoena or other validly issued
administrative or judicial process requesting disclosure of same; PROVIDED, the
party that receives such order or process provides prompt notice to the
disclosing party before making any disclosure (to the extent possible) and
permits the disclosing party to oppose or narrow such request for disclosure and
supports any of the disclosing party's reasonable efforts to oppose such request
(at disclosing party's expense) and shall disclose such Confidential Information
or Program Intellectual Property only in the event of a final judgement or
administrative order requiring such disclosure, and only to the extent necessary
to comply with such request.

5.3 PUBLICATIONS. Each party recognizes that the publication of papers regarding
results of the Screening Program, including oral presentations and abstracts,
may be beneficial to both parties provided such publications are subject to
reasonable controls to protect Confidential Information. In particular, it is
the intent of the parties to maintain the confidentiality of any Confidential
Information regarding the compounds included in any patent application until
such patent application has been published. Accordingly, each party shall have
the right to review and comment upon any paper proposed for publication by the
other party regarding results of the

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.
                                       34
<Page>

Screening Program hereunder, including oral presentations and abstracts, which
utilizes data generated from the Screening Program and/or includes Confidential
Information of the other party. Before any such paper is submitted for
publication, the party proposing publication shall deliver a complete copy to
the other party at least thirty (30) days prior to submitting the paper to a
publisher. The receiving party shall review any such paper and give its comments
to the publishing party within twenty (20) days of the delivery of such paper to
the receiving party. With respect to oral presentation materials, the parties
shall make reasonable efforts to expedite review of such materials, and shall
return such items as soon as practicable to the disclosing party with
appropriate comments, if any, but in no event later than twenty (20) days from
the date of delivery to the receiving party. The disclosing party shall comply
with the other party's request to delete references to such other party's
Confidential Information in any such paper and agrees to withhold publication of
same for an additional one hundred eighty (180) days (or longer if necessary) in
order to permit the parties to obtain patent protection, if either of the
parties deem it necessary, in accordance with the terms of this Agreement. If
there is a dispute regarding publications, such dispute shall be resolved by the
Steering Committee.

6.   REPRESENTATIONS AND WARRANTIES.

6.1 AUTHORIZATION; ENFORCEABILITY. Each of Tularik and NeoGenesis represent and
warrant to the other that: (a) it is a corporation duly organized and validly
existing under the laws of its jurisdiction of organization and has all
requisite power and authority to enter into this Agreement; (b) it is duly
authorized by all requisite action to execute, deliver and perform this
Agreement and to consummate the transactions contemplated hereby, and that the
same do not conflict or cause a default with respect to such party's obligations
under any other agreement; (c) it has duly executed and delivered this
Agreement; and (d) it is authorized to disclose any and all Confidential
Information made available to the other party pursuant to this Agreement.

6.2 PERFORMANCE. (a) NeoGenesis hereby represents and warrants to Tularik that:
(i) NeoGenesis shall perform the Screening Program using qualified personnel and
in a good and workmanlike manner consistent with industry standards of companies
that are comparable to NeoGenesis performing similar activities under similar
circumstances; and (ii) as of the Effective Date, there is no agreement known to
NeoGenesis to which it is a party and by which it is bound that would conflict
with or be breached by NeoGenesis granting Tularik the licenses in Sections 2.5,
3.1 and 3.2 (e) and the assignments in Section 3.2(d) and 3.2(i).

     (b) NeoGenesis hereby represents and warrants to Tularik that it has not
sought, and will not seek, patent protection on any of the compounds that will
be screened in the conduct of the Screening Program.

     (c) Tularik hereby represents and warrants to NeoGenesis that, as of the
Effective Date, there is no agreement known to Tularik to which it is a party
and by which it is bound that would conflict with or be breached by Tularik
granting NeoGenesis the licenses in Sections 2.5, 3.1 and 3.2(f).

6.3 DISCLAIMER. (A) EXCEPT FOR THE WARRANTIES EXPRESSLY MADE IN SECTIONS
6.1-6.2, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER
EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY
WARRANTY AGAINST INFRINGEMENT OF ANY THIRD PARTY PATENT OR OTHER INTELLECTUAL
PROPERTY RIGHTS, ANY WARRANTY OF MERCHANTABILITY OR ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE WITH RESPECT TO ANY MATTER WHATSOEVER, INCLUDING BUT NOT
LIMITED TO, THE NEOMORPH SCREENING LIBRARY, THE NEOMORPH FOCUSED LIBRARIES,
QSCD, THE PRELIMINARY COMPOUNDS, THE PRIMARY ACTIVE COMPOUNDS, THE SELECTED
COMPOUNDS, THE DESIGNATED COMPOUNDS, THE TARGETS, THE PRODUCTS, THE SHARED
PRODUCTS, THE NEOGENESIS INTELLECTUAL PROPERTY, THE TULARIK INTELLECTUAL
PROPERTY, THE SCOPE, VALIDITY OR ENFORCEABILITY OF THE NEOGENESIS PATENT RIGHTS,
THE TULARIK PATENT RIGHTS OR PROGRAM PATENT RIGHTS, OR SUCH PARTY'S OBLIGATIONS
UNDER THIS AGREEMENT.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       35
<Page>

     (B) THE REPRESENTATIONS AND WARRANTIES OF EACH OF NEOGENESIS AND TULARIK
EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR
DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED
IN SECTIONS 7.2-7.3.

7.   RISK ALLOCATION

7.1 LIMITATION OF LIABILITY. EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATIONS
UNDER SECTION 5 AND EXCEPT AS OTHERWISE PROVIDED IN SECTIONS 7.2-7.3 WITH
RESPECT TO THIRD PARTY CLAIMS, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER FOR LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN CONNECTION WITH THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED,
UNDER ANY THEORY OF LIABILITY.

7.2 THIRD PARTY CLAIMS (EXCLUDING INFRINGEMENT). Subject to the provisions of
Section 7.4, each of NeoGenesis and Tularik (each, in such capacity, an
INDEMNIFYING PARTY) will defend, indemnify and hold harmless the other party,
its subsidiaries, parent corporations, affiliates, officers, directors,
partners, members, shareholders, employees, agents, and their successors and
assigns (each, in such capacity, an INDEMNIFIED PARTY) from and against any
claim, suit, demand, loss, damage, expense (including reasonable attorneys' fees
of Indemnified Party(ies) and those that may be asserted by a third party) or
liability including but not limited to claims for death or personal injury
(collectively, LOSSES) imposed upon the Indemnified Party(ies) by any third
party arising from or related to: (i) any material breach of the Indemnifying
Party's representations and warranties under this Agreement; or (ii) any
negligence or intentional misconduct by the Indemnifying Party (or its
employees, agents, representatives, Affiliates, licensees, sublicensees or
distributors) in performing its obligations under this Agreement; or (iii) the
labeling, packaging, package insert, other materials or promotional claims with
respect to any Shared Product or Independent Product or the Development,
testing, Manufacturing, Commercialization, use or other disposition of any
Shared Product or Independent Product by the Indemnifying Party or by an
Affiliate, licensee, sublicensee, distributor or agent of the Indemnifying
Party; or (iv) (with respect to Tularik as an Indemnifying Party) the labeling,
packaging, package insert, other materials or promotional claims with respect to
any Product or the development, testing, Manufacturing, Commercialization, use
or other disposition of any Product by Tularik or by an Affiliate, licensee,
sublicensee, distributor or agent of Tularik. The foregoing indemnification
action shall not apply in the event and to the extent that such Losses arose as
a result of any Indemnified Party's negligence, intentional misconduct or breach
of this Agreement.

7.3 INFRINGEMENT INDEMNIFICATION. (a) Subject to the provisions of Section 7.4,
NeoGenesis shall defend, indemnify and hold harmless the Tularik Indemnified
Party(ies) from and against any Losses imposed upon them by any third party and
arising from or related to a third party claim that use of NeoGenesis
Intellectual Property or practice of the NeoGenesis Patent Rights by Tularik in
accordance with the terms of this Agreement violates or infringes the
intellectual property rights of any third party. NeoGenesis shall have no
liability or obligation to Tularik under this Section 7.3(a) in the event and to
the extent that the alleged infringement results from willful misconduct or
negligent acts or omissions of Tularik or its Affiliates, or its or their
respective employees, officers, directors or agents.

     (b) Subject to the provisions of Section 7.4, Tularik shall defend,
indemnify and hold harmless the NeoGenesis Indemnified Party(ies) from and
against any Losses imposed upon them by any third party and arising from or
related to a third party claim that use of the Tularik Intellectual Property or
practice of the Tularik Patent Rights by NeoGenesis in accordance with the terms
of this Agreement violates or infringes the intellectual property rights of any
third party. Tularik shall have no obligation or liability to NeoGenesis under
this Section 7.3(b) in the event and to the extent that the alleged infringement
(i) is covered by Section 7.3(a) or (ii) results from willful misconduct or
negligent acts or omissions of NeoGenesis or its Affiliates, or its or their
respective employees, officers, directors or agents.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       36
<Page>

7.4 PROCEDURE. To receive the benefit of indemnification under Sections 7.2 or
7.3, the Indemnified Party must (a) promptly notify the Indemnifying Party of a
claim or suit; PROVIDED, that failure to give such notice shall not relieve
Indemnifying Party of its indemnification obligations except where, and solely
to the extent that, such failure actually and materially prejudices the rights
of Indemnifying Party; (b) provide reasonable cooperation to the Indemnifying
Party (and its insurer), as reasonably requested, at Indemnifying Party's cost
and expense; and (c) tender to the Indemnifying Party (and its insurer) full
authority to defend or settle the claim or suit; PROVIDED that no settlement
requiring any admission by the Indemnified Party or that imposes any obligation
on the Indemnified Party shall be made without the Indemnified Party's consent.
Neither party has any obligation to indemnify the other party in connection with
any settlement made without the Indemnifying Party's written consent. The
Indemnified Party has the right to participate at its own expense in the claim
or suit and in selecting counsel therefor.

8.   TERM AND TERMINATION

8.1 TERM. This Agreement shall take effect as of the Effective Date and shall
remain in effect until the expiration of the last to expire of the licenses
granted hereunder, unless sooner terminated in accordance with Section 8.2.

8.2 TERMINATION. (a) NeoGenesis may suspend work pursuant to the Screening
Program or terminate the Screening Program with thirty (30) days' notice to
Tularik if Tularik fails to pay fees not contested in good faith due under the
Agreement or commits a material breach, unless the nonpayment or breach is cured
within the thirty (30)-day notice period. Tularik may terminate the Screening
Program with thirty (30) days' notice to NeoGenesis if NeoGenesis commits a
material breach unless the breach is cured within the thirty (30)-day notice
period.

     (b) Either party may terminate the license under Section 3.1 with sixty
(60) days' notice if the other party commits a material breach (including
non-payment), unless the breach is cured within the sixty (60)-day notice
period; PROVIDED that if more than one compound is being developed or
commercialized by a party or its Affiliates hereunder, and the other party
terminates this Agreement pursuant to this Section 8.2(b) due to a breach
relating only to a single compound, then the terminating party shall be entitled
to terminate this Agreement only with respect to the applicable compound.

     (c) The parties may terminate this Agreement, or the license under Section
3.1 on a compound-by-compound, product-by-product or country-by-country basis,
at any time upon mutual written agreement of the parties.

     (d) Tularik shall have the right to terminate the license set forth in
Section 3.1 on a Designated Screening Compound-by-Designated Screening Compound,
Derivative Compound thereof-by-Derivative Compound thereof, Product-by-Product
or country-by-country basis at any time upon notice to NeoGenesis.

     (e) If voluntary or involuntary proceedings by or against a party are
instituted in bankruptcy under any insolvency law, or a receiver or custodian is
appointed for such party, or proceedings are instituted by or against such party
for corporate reorganization or the dissolution of such party, which
proceedings, if involuntary, shall not have been dismissed within sixty (60)
days after the date of filing, or if such party makes an assignment for the
benefit of creditors, or substantially all of the assets of such party are
seized or attached and not released within sixty (60) days thereafter, the other
party may immediately terminate this Agreement effective upon notice of such
termination.

     8.3 EFFECT OF TERMINATION. (a) Upon termination (including expiration) of
this Agreement: (i) the parties will terminate all tasks then in process in an
orderly manner, as soon as practical and in accordance with a schedule agreed to
by Tularik and NeoGenesis; (ii) if termination occurs prior to completion of the
Screening Program then NeoGenesis shall deliver to Tularik all materials
developed through the termination of this Agreement; (iii) each party shall pay
to the other party any uncontested monies due and owing up to the time of
termination; and (iv) within thirty (30) days following termination (including
expiration) of this Agreement, NeoGenesis shall deliver to Tularik a
reasonably-detailed written report describing the results of the research
performed under the Screening Program up to the date of such termination.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       37
<Page>

     (b) Upon termination (including expiration) of this Agreement each party
shall return to the other party or certify in writing to the other party that it
has destroyed all documents and other tangible items it or its employees or
agents have received or created pertaining, referring or relating to the
Confidential Information or Program Intellectual Property owned by the other
party; provided, however, that a party is permitted to retain one copy of such
materials in its legal files to be used to verify compliance with its
obligations hereunder.

     (c) The license granted by NeoGenesis under Section 3.1(a) shall survive
any expiration or termination of the Screening Program or this Agreement with
respect to any Designated Compound, Derivative Compound thereof, Product and
Shared Product for which the applicable fees and milestone fees and royalties or
the amounts due under Section 4A, as applicable, have been paid and with respect
to any Independent Compound, Derivative Compound thereof and Independent Product
for which the amounts due under Section 4A have been paid (in each case in
accordance with the terms of this Agreement); PROVIDED that Tularik continues to
pay NeoGenesis the fees and royalties as required by Sections 4.3, 4.4 and 4.5
and complies with Sections 4.6-4.9, or to pay NeoGenesis the amounts due under
Section 4A, as applicable. The license granted by Tularik under Section 3.1(b)
shall survive any expiration or termination of this Agreement with respect to
any Designated Shared Compound, Derivative Compound thereof, Shared Product,
Independent Compound, Derivative Compound thereof and Independent Product for
which the amounts due under Section 4A have been paid (in accordance with the
terms of this Agreement). The license granted under Section 3.1 shall not
survive termination or expiration of the Screening Program or this Agreement
with respect to Designated Compounds, Derivative Compounds thereof, Products,
Shared Products, Independent Compounds, Derivative Compounds thereof and
Independent Products for which the applicable fees and milestone fees and
royalties or the amounts due under Section 4A, as applicable, have not been paid
in accordance with this Agreement. In the event the license granted to Tularik
under Section 3.1 terminates for any reason, each of Tularik's sublicensees at
such time shall continue to have the rights and license set forth in their
sublicense agreements, PROVIDED such sublicensee agrees in writing that
NeoGenesis is entitled to enforce all relevant provisions directly against such
sublicensee.

     (d) Except as otherwise provided herein, neither party shall be liable to
the other party for any compensation or damages by reason of termination of this
Agreement in accordance with this Section 8.

     (e) Nothing herein shall be construed to release either party of any
obligation which matured prior to the effective date of any termination. Either
party's liability for any uncontested charges, payments or expenses due to the
other party that accrued prior to the termination date shall not be extinguished
by termination, and such amounts (if not otherwise due on an earlier date) shall
be immediately due and payable on the termination date.

8.4 SURVIVAL. Sections 1, 2.4, 2.5 (last sentence), 2.6(a), 2.8, 2.9, 3.2, 3.3,
3.4, 4.7, 4.8, 4A.3 (last sentence), 4A.4 (last sentence), 4A.21(b) and 5-9
shall survive any termination or expiration of this Agreement. In addition, the
licenses granted under Section 3.1 shall survive to the extent necessary to
permit a party opting to proceed with Pre-Clinical Development, Development,
Manufacture and Commercialization of a Discontinued Compound or Non-Proposed
Compound as contemplated in the last sentence of Sections 4A.3 and 4A.4,
respectively; PROVIDED, that such party complies with the provisions of Section
4A.15(c) and the Sections referenced therein, which shall survive termination or
expiration for this purpose.

9.   GENERAL PROVISIONS.

9.1 ISSUE RESOLUTION. The parties shall use their best efforts to resolve any
controversy or dispute that arises under or relates to this Agreement through
good faith discussions. The parties shall initiate such discussions using the
following procedure. Either party shall notify the other party of the nature of
the controversy or dispute, providing sufficient detail to permit the other
party to understand same (a DISPUTE NOTICE). The representatives of the parties
shall meet within thirty (30) days after the date that the non-sending party
receives the Dispute Notice to attempt in good faith to reach an agreement about
the nature of the dispute and a resolution of the dispute. Pending resolution

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       38
<Page>

of any dispute covered by this Section 9.1, both parties will continue their
performance under this Agreement including, without limitation, the payment of
all amounts due to the other party that are not in dispute.

9.2 GOVERNING LAW. This Agreement shall be governed and construed in accordance
with the internal, substantive laws of the State of Delaware to the exclusion of
any choice or conflict of laws rule or provision that would result in the
application of the substantive law of any other jurisdiction. Notwithstanding
the foregoing, the parties shall use United States (Federal) patent laws, as
applicable, for purposes of governing and construing Sections 3.2-3.4 of this
Agreement. The United Nations Convention on Contracts for the International Sale
of Goods shall not apply to the transactions contemplated by this Agreement.

9.3 AMENDMENT AND WAIVER. No provision of or right under this Agreement shall be
deemed to have been waived by any act or acquiescence on the part of either
party, its agents or employees, but only by an instrument in writing signed by
an authorized officer of each party. No waiver by either party of any breach of
this Agreement by the other party shall be effective as to any other breach,
whether of the same or any other term or condition and whether occurring before
or after the date of such waiver.

9.4 INDEPENDENT CONTRACTORS. Each party represents that it is acting on its own
behalf as an independent contractor and is not acting as an agent for or on
behalf of any third party. This Agreement and the relations hereby established
by and between Tularik and NeoGenesis do not constitute a partnership, joint
venture, franchise, agency or contract of employment. Neither party is granted,
and neither party shall exercise, the right or authority to assume or create any
obligation or responsibility on behalf of or in the name of the other party or
its Affiliates. Each party shall be solely responsible for compensating all its
personnel and for payment of all related FICA, workers' compensation,
unemployment and withholding taxes. Neither party shall provide the other
party's personnel with any benefits, including but not limited to compensation
for insurance premiums, paid sick leave or retirement benefits.

9.5 ASSIGNMENT. Neither party may assign this Agreement or any of its rights and
obligations under this Agreement without the prior written consent of the other
party; PROVIDED, that either party may assign this Agreement to (a) any Person
to which such party transfers all or substantially all of its assets or with
which such party is consolidated or merged; (b) any Person that owns a majority
of the voting stock of such party; or (c) a single Person of which such party
owns a majority of the voting stock; PROVIDED, FURTHER, that in each instance
the assignee expressly assumes all obligations imposed on the assigning party by
this Agreement in writing and the other party is notified in advance of such
assignment.

9.6 SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure to the benefit
of the parties hereto and their respective successors and permitted assigns.

9.7 NOTICES. Unless otherwise provided herein, any notice, report, payment or
document to be given by one party to the other shall be in writing and shall be
deemed given when delivered personally or mailed by certified or registered
mail, postage prepaid (such mailed notice to be effective on the date which is
three (3) business days after the date of mailing), or sent by nationally
recognized overnight courier (such notice sent by courier to be effective one
business day after it is deposited with such courier), or sent by telefax (such
notice sent by telefax to be effective when sent, if confirmed by certified or
registered mail or overnight courier as aforesaid) to the address set forth on
the signature page to this Agreement or to such other place as any party may
designate as to itself by written notice to the other party.

9.8 SEVERABILITY. In the event any provision of this Agreement shall for any
reason be held to be invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof. The parties agree that they will negotiate in good faith or
will permit a court to replace any provision hereof so held invalid, illegal or
unenforceable with a valid provision which is as similar as possible in
substance to the invalid, illegal or unenforceable provision.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       39
<Page>

9.9 CAPTIONS. Captions of the sections and subsections of this Agreement are
for reference purposes only and do not constitute terms or conditions of this
Agreement and shall not limit or affect the meaning or construction of the
terms and conditions hereof.

9.10 WORD MEANINGS. Words such as HEREIN, HEREINAFTER, HEREOF and HEREUNDER
refer to this Agreement as a whole and not merely to a section or paragraph
in which such words appear, unless the context otherwise requires. The
singular shall include the plural, and each masculine, feminine and neuter
reference shall include and refer also to the others, unless the context
otherwise requires.

9.11 ENTIRE AGREEMENT. The terms and provisions contained in this Agreement
(including the Attachments) constitute the entire understanding of the parties
with respect to the transactions and matters contemplated hereby and supersede
all previous communications, representations, agreements and understandings
relating to the subject matter hereof. No representations, inducements, promises
or agreements, whether oral or otherwise, between the parties not contained in
this Agreement shall be of any force or effect. No agreement or understanding
extending this Agreement or varying its terms (including any inconsistent terms
in any purchase order, acknowledgment or similar form) shall be binding upon
either party unless it is in a writing specifically referring to this Agreement
and signed by a duly authorized representative of the applicable party.

9.12 RULES OF CONSTRUCTION. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of
this Agreement shall not be construed against either party by reason of the
extent to which such party or its professional advisors participated in the
preparation of this Agreement.

9.13 COUNTERPARTS. This Agreement may be executed in multiple counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

9.14 FORCE MAJEURE. Except as otherwise provided in this Agreement, in the event
that a delay or failure of a party to comply with any obligation created by this
Agreement is caused by a Force Majeure condition, that obligation shall be
suspended during the continuance of the Force Majeure condition.

9.15 FURTHER ASSURANCES. Each party covenants and agrees that, subsequent to the
execution and delivery of this Agreement and without any additional
consideration, it will execute and deliver any further legal instruments and
perform any acts which are or may become reasonably necessary to effectuate the
purposes of this Agreement.

IN WITNESS WHEREOF the parties have caused this Agreement to be executed on
their behalf by their duly authorized representatives intending it to take
effect as an instrument under seal as of the Effective Date.

<Table>
<Caption>

NEOGENESIS DRUG DISCOVERY, INC.                   TULARIK INC.

<S>                                            <C>
By: /s/ Robert Adelman                         By: /s/ William J. Rieflin
--------------------------------------         ---------------------------------
Robert Adelman                                 William J. Rieflin
Vice President, Business Development           Executive Vice President,
                                               Administration

NOTICE ADDRESS:                                NOTICE ADDRESS:
NeoGenesis Drug Discovery, Inc.                Tularik Inc.
840 Memorial Drive                             Two Corporate Drive
Cambridge, MA 02139                            South San Francisco, CA 94080
Phone: 617.868.1500                            Phone: 650.825.7000
Fax: 617.868.1515                              Fax: 650.825.7303
</Table>

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       40
<Page>

                                  ATTACHMENT A
                                 SCREEN PROGRAM

The Screening Program to be performed by NeoGenesis with respect to the Targets
will screen at least [*] compounds contained in the NeoGenesis NeoMorph
Screening Library against each Target using the protocol described below.

1. Tularik will provide NeoGenesis with at least [*] of each of the purified
functionally-active Target proteins and may, at Tularik's option, provide
additional quantities if requested by NeoGenesis. NeoGenesis will perform
initial experiments on the Targets to determine screening conditions in
NeoGenesis' ALIS protocols. NeoGenesis will establish SOPs for ALIS screening
based on the preceding experiments.

2. Using the SOPs, NeoGenesis will perform ALIS screening of at least [*] and up
to [*] compounds from the NeoMorph Screening Library against each Target. The
ALIS screening will be carried out under moderately stringent conditions to
identify compounds that bind to the Target with binding affinities better than
[*] micromolar (Kd < [*]) (each such compound is referred to as a PRELIMINARY
COMPOUND).

3. If NeoGenesis identifies a Preliminary Compound(s) for the Target and Tularik
is able to provide NeoGenesis with a second protein that differs from the Target
but is of the same functional class of protein as the Target, NeoGenesis will
screen such second protein against the Preliminary Compound(s) to determine the
relative selectivity of the Preliminary Compound for the Target(s).
Alternatively, if Tularik is unable to deliver a second protein of the same
functional class, NeoGenesis will screen an unrelated protein selected by the
Screening Committee against the Preliminary Compound(s) to assay the specificity
of the Preliminary Compounds.

4. If NeoGenesis identifies a Preliminary Compound(s) for the Target, NeoGenesis
will re-synthesize a NeoMorph library containing each such Preliminary Compound
and subject each such Preliminary Compound to ALIS screening for confirmation of
binding to the Target(s).

5. After performing the selectivity analysis and confirmatory ALIS screening
described in Paragraphs 3 and 4 above on the Preliminary Compound(s), the
Steering Committee will review the structure(s), binding affinities and target
specificities of such Preliminary Compound(s) and choose at least [*] (unless
there are fewer than [*]) Preliminary Compounds as discrete compound(s) (each
such compound is referred to as a DISCRETE COMPOUND) for further testing as
described below.

6. NeoGenesis will purify all Discrete Compounds and subject them to screening
on an individual basis for confirmation of binding to the Target. In addition,
at Tularik's option, either (i) NeoGenesis will deliver to Tularik between [*]
of each Discrete Compound and Tularik will evaluate the activity of these
Discrete Compound(s) in a Target-based functional assay and will notify
NeoGenesis of the results of such assays, including any Discrete Compounds which
have demonstrated activity in the Target-based functional assays (each, a
PRIMARY ACTIVE COMPOUND) within [*] after completion of such assays and not
later than [*] after the Discrete Compounds are delivered by NeoGenesis or, (ii)
NeoGenesis will evaluate the activity of the Discrete Compound(s) in
Target-based functional assay(s) that have been delivered to NeoGenesis by
Tularik and will notify Tularik of any Primary Active Compounds within [*] after
completion of such assays and not later than [*] after the Target-based
functional assay is delivered by Tularik.

7. If either Tularik or NeoGenesis identifies one or more Primary Active
Compounds pursuant to Paragraph 6, then NeoGenesis will prepare a report for all
Primary Active Compound(s) that details the chemical structures, binding
affinities, Target specificities, functional activities and competition analysis
data for such Primary Active Compound(s) (each, a FINAL TARGET REPORT).
NeoGenesis will deliver such Final Target Report to Tularik when it notifies
Tularik of such Primary Active Compounds or, if Tularik has conducted the
functional assays, within [*] of receipt of the results of such assays from
Tularik; PROVIDED that competition analysis data may be delivered as a
supplement to the Final Target Report within [*] of receipt of the results of
such assays from Tularik.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       41
<Page>

8. Tularik will select up to [*] Primary Active Compounds per Screening Target,
for further study or optimization by NeoGenesis (each, a SELECTED SCREENING
COMPOUND). The Steering Committee will select up to [*] Primary Active Compounds
per Shared Target, for further study or optimization (each, a SELECTED SHARED
COMPOUND). Selected Screening Compounds and Selected Shared Compounds are
referred to, collectively, as SELECTED COMPOUNDS.

9. In the Proof of Concept Stage, NeoGenesis will perform, at Tularik's
option, either (a) [*] of optimization on [*] Selected Screening Compounds
identified by Tularik or (b) [*] of optimization on [*] Selected Screening
Compound identified by Tularik. To perform such optimization, NeoGenesis will
create NeoMorph Focused Libraries based upon such Selected Screening
Compounds and will perform high stringency-ALIS screening to improve Kd
values to [*] micromolar or better (i.e., Kd LESS THAN= [*](mu)M). In the
event that Tularik wishes to have NeoGenesis perform additional cycles of
optimization of other Selected Screening Compounds for a Screening Target in
the Proof of Concept Stage, the parties shall negotiate a budget and schedule
for such work (the budget to set forth expected hours of work payable at the
FTE Rate). In the event that Tularik wishes to have NeoGenesis perform
optimization in the Expanded Collaboration of Selected Screening Compounds,
the parties shall negotiate a budget and schedule for such work (the budget
to set forth expected hours of work payable at the FTE Rate.) Optimization on
Selected Shared Compounds will be performed as determined by the Steering
Committee.

10. (a) NeoGenesis will provide Tularik with at least [*] of each discrete
Selected Screening Compound(s) for further evaluation by Tularik in
Target-based secondary assays and, at Tularik's option, exploratory chemistry
or toxicological studies. Any additional quantities of Selected Screening
Compounds will be furnished to Tularik at cost, which shall be based on the
FTE Rate.

     (b) NeoGenesis will provide Tularik with at least [*] of each discrete
Selected Shared Compound(s) for further evaluation by Tularik in Target-based
secondary assays and, at the option of the Steering Committee, exploratory
chemistry or toxicological studies. Tularik will notify NeoGenesis of any
such Selected Shared Compound(s) which demonstrate activity in the
Target-based secondary assays within [*] after completion of such assays and
not later than [*] after the discrete Selected Shared Compounds are delivered
by NeoGenesis. Any additional quantities of Selected Shared Compounds will be
furnished at the instruction of the Steering Committee.

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       42
<Page>

                                  ATTACHMENT B
                         PROGRAM INTELLECTUAL PROPERTY
                         [TO BE SUPPLIED AS DEVELOPED]

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       43
<Page>

                                  ATTACHMENT C

                                SHARED TARGETS:

                                      [*]

                               SCREENING TARGETS:

                                      [*]

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       44
<Page>

                                  ATTACHMENT D
                            NEOGENESIS PATENT RIGHTS
                 [TO BE SUPPLIED BY NEOGENESIS AS APPLICABLE]

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       45
<Page>

                                  ATTACHMENT E
                   NOTE PURCHASE AGREEMENT AND PROMISSORY NOTE

 THIS CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES
   ACT OF 1933, AS AMENDED. THIS NOTE MAY NOT BE SOLD OR TRANSFERRED IN THE
   ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH ACT.

                                 NON-NEGOTIABLE
                        CONVERTIBLE PROMISSORY TERM NOTE
$1,000,000.00                                             ___________ __, 200_

                                                        Cambridge, Massachusetts

     FOR VALUE RECEIVED, NeoGenesis Drug Discovery, Inc., a Delaware corporation
("Payor"), subject to the terms of this Note, promises to pay to Tularik Inc., a
Delaware corporation, or its assigns ("Lender") the principal sum of One Million
Dollars ($1,000,000.00) on [the date that is four years after the date on which
this note is issued] (the "Maturity Date"), and to pay interest on the principal
amount, from the date hereof through and including the date on which such
principal amount is paid in full, at a rate of 5.75% per annum[, compounded
annually based on a 365-day year]. Interest hereunder shall commence with the
date hereof and shall continue to accrue on the outstanding principal until paid
in full on the Maturity Date. Any terms used herein but not otherwise defined
shall have the respective meanings given in that certain Agreement (the
"Screening Agreement") between Payor and Lender dated as of September [___],
2001.

1. This note ("Note") is issued pursuant to the terms of that certain Note
Purchase Agreement (Convertible into Common Stock) ("Note Purchase Agreement")
between Payor and Lender and dated as of the date hereof.

2. All payments of principal and interest shall be in lawful money of the United
States of America and shall be made to Lender at any address designated by
Lender. Notwithstanding anything contained to the contrary herein or in the Note
Purchase Agreement, Payor may prepay the principal amount of this Note according
to the formula contained in this Section 2, without penalty or additional fees,
in the event that Lender terminates the Expanded Collaboration (other than for
cause) prior to the screening of an aggregate of ten (10) Targets. The maximum
amount of such prepayment shall equal the product of (A) ten (10) less the
number of Targets (as defined in the Screening Agreement) provided by Lender
during the Expanded Collaboration pursuant to the terms of the Screening
Agreement multiplied by (B) $100,000. All interest accrued and unpaid up to the
date of such prepayment shall also be prepaid by Payor, without penalty or
additional fees.

3. Subject to Section 4 below, in connection with Payor's consummation of a
preferred stock financing that occurs prior to the occurrence of an IPO
referenced in Section 5, the then outstanding principal balance and accrued and
unpaid interest shall be converted automatically into shares of Payor's
preferred stock issued in such financing (the "Preferred Stock"), at a
conversion price equal to the price of the Preferred Stock in such preferred
stock financing, such that the total number of shares of Preferred Stock issued
upon conversion shall equal the total amount of principal and accrued and unpaid
interest then outstanding under this Note divided by the gross per share sale
price of the Preferred Stock in such preferred stock financing. The Preferred
Stock received by Lender shall rank PARI PASSU with other Preferred Stock issued
in such preferred stock financing and contain the same terms and conditions as
enjoyed by other investors in such preferred stock financing.

4. Notwithstanding anything to the contrary contained in Section 3 above, Lender
shall have the option to convert all (but not less than all) of the principal
and interest then outstanding under this Note in the event Payor consummates a
preferred stock financing with a corporate collaborator. Upon such a preferred
stock financing with a corporate collaborator, at Lender's option, the principal
balance and interest then outstanding under this Note shall be converted into
shares of preferred stock at a conversion price equal to the per share

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       46
<Page>

price of the preferred stock paid by such corporate collaborator in such
preferred stock financing, such that the total number of shares of Preferred
Stock issued upon conversion shall equal the total amount of principal and
accrued and unpaid interest then outstanding under this Note divided by the
gross per share sale price of the Preferred Stock in such preferred stock
financing with a corporate collaborator. A company shall be deemed a `corporate
collaborator' if such company has a commercial (other than solely as an investor
in Payor) or collaborative relationship with Payor.

5. In connection with Payor's consummation of an IPO that occurs prior to the
occurrence of a preferred stock financing referenced in Section 3 or Section 4,
the then outstanding principal balance and accrued and unpaid interest shall be
converted automatically into shares of Payor's common stock, par value $.001 per
share (the "Common Stock"), at a conversion price equal to the gross per share
price of the Common Stock sold in the IPO, such that the total number of shares
of Common Stock issued upon conversion shall equal the total amount of principal
and accrued and unpaid interest then outstanding under this Note divided by the
gross per share sale price of the Common Stock in the IPO. As used herein, the
term "IPO" shall mean the first public offering of Payor's Common Stock on a
firmly underwritten basis, pursuant to a registration statement on Form S-1 (or
a similar form of general application prescribed by the Securities and Exchange
Commission), filed under the Securities Act of 1933, as amended.

6. In the event of any default hereunder, Payor shall pay all reasonable
attorneys' fees and court costs incurred by Lender in enforcing and collecting
this Note.

7. Payor hereby waives demand, notice, presentment, protest and notice of
dishonor.

8. The terms of this Note shall be construed in accordance with the laws of the
State of Delaware, as applied to contracts entered into by Delaware residents
within the State of Delaware, which contracts are to be performed entirely
within the State of Delaware.

9. Any term of this Note may be amended or waived only with the written consent
of Payor and Lender hereof.

10. This Note is non-transferable except with the prior written consent of
Payor.

                                        NeoGenesis Drug Discovery, Inc.

                                        By:  ________________________

                                        Name: _______________________

                                        Title:  ________________________

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       47
<Page>

                         NEOGENESIS DRUG DISCOVERY, INC.
                        --------------------------------
                             NOTE PURCHASE AGREEMENT

                          CONVERTIBLE INTO COMMON STOCK
                        --------------------------------

                               __________ __, 2001

IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF
THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS
INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE
SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING
AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS
DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

                             NOTE PURCHASE AGREEMENT
                          CONVERTIBLE INTO COMMON STOCK

THIS NOTE PURCHASE AGREEMENT is made as of _________ __, 200_ by and between
NeoGenesis Drug Discovery, Inc., a Delaware corporation (the "Corporation"), and
Tularik Inc., a Delaware corporation (the "Lender").

     In consideration of the mutual promises hereinafter set forth the parties
hereto agree as follows:

SECTION 1.  TERMS OF THE LOAN

1.1 THE LOAN. Subject to the terms of this Agreement, the Corporation shall
borrow from the Lender and the Lender shall lend to the Corporation an amount
equal to One Million Dollars ($1,000,000) (the "Loan Amount") pursuant to that
non-negotiable convertible promissory note in the form attached hereto as
Exhibit A (the "Note").

SECTION 2.  THE CLOSING

2.1 CLOSING DATE. The closing of the purchase and sale of the Note (the
"Closing") shall be held on ________ __, 200_ at 10:00 a.m. at the offices of
Bingham Dana LLP, 150 Federal Street, Boston, MA 02110 (the "Closing Date").

2.2 DELIVERY. At the Closing (i) the Lender will deliver to the Corporation a
check or wire transfer funds in the amount of the Loan Amount; and (ii) the
Corporation shall execute the Note and deliver the Note to the Lender.

SECTION 3.  REPRESENTATIONS AND WARRANTIES OF THE CORPORATION

The Corporation hereby represents and warrants to the Lender as follows:

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       48
<Page>

3.1 CORPORATE POWER. The Corporation will have at the Closing Date all requisite
corporate power to execute and deliver this Agreement and to carry out and
perform its obligations under the terms of this Agreement.

3.2 AUTHORIZATION. All corporate action on the part of the Corporation, its
directors and its stockholders necessary for the authorization, execution,
delivery and performance of this Agreement by the Corporation and the
performance of the Corporation's obligations hereunder, including without
limitation the issuance and delivery of the Note, have been taken or will be
taken prior to the Closing. This Agreement and the Note, when executed and
delivered by the Corporation, shall constitute valid and binding obligations of
the Corporation enforceable in accordance with each of their terms. The
Corporation's common stock, par value $.001 per share (the "Common Stock"), or
preferred stock, par value $.001 per share (the "Preferred Stock"; the Common
Stock and the Preferred Stock, collectively, the "STOCK"), when issued in
compliance with the provisions of this Agreement and the Note, will be validly
issued, fully paid and nonassessable and free of any liens or encumbrances. The
Corporation will at all times reserve and keep available, solely for issuance
and delivery upon the conversion of the Preferred Stock, when such Preferred
Stock, if any, is issued to the lender, all Common Stock issuable from time to
time upon such conversion.

3.3 GOVERNMENTAL CONSENTS. All consents, approvals, orders, or authorizations
of, or registrations, qualifications, designations, declarations or filings
with, any governmental authority, required on the part of the Corporation in
connection with the valid execution and delivery of this Agreement, the offer,
sale or issuance of the Note and the Stock issuable upon conversion of the Note
or the consummation of any other transaction contemplated hereby shall have been
obtained and will be effective at the Closing, except for notices required or
permitted to be filed with certain state and federal securities commissions.

3.4 OFFERING. Assuming the accuracy of the representations and warranties of the
Lender contained in Section 4 hereof, the offer, issue and sale of the Note are
and will be exempt from the registration and prospectus delivery requirements of
the Securities Act of 1933, as amended (the "1933 ACT").

SECTION 4.  REPRESENTATIONS AND WARRANTIES OF THE LENDER

4.1 PURCHASE FOR OWN ACCOUNT. The Lender represents that it is acquiring the
Note, and the Preferred Stock issuable upon conversion of the Note, solely for
its own account and beneficial interest for investment and not for sale or with
a view to distribution of the Note or the Preferred Stock or any part thereof,
has no present intention of selling (in connection with a distribution or
otherwise), granting any participation in or otherwise distributing the same,
and does not presently have reason to anticipate a change in such intention.

4.2 INFORMATION AND SOPHISTICATION. The Lender acknowledges that it has received
all the information it has requested from the Corporation and considers
necessary or appropriate for deciding whether to acquire the Note. The Lender
represents that it has had an opportunity to ask questions and receive answers
from the Corporation regarding the terms and conditions of the offering of the
Note and to obtain any additional information necessary to verify the accuracy
of the information given the Lender. The Lender further represents that it has
such knowledge and experience in financial and business matters that it is
capable of evaluating the merits and risk of this investment.

4.3 ABILITY TO BEAR ECONOMIC RISK. The Lender acknowledges that its investment
in the Note involves a high degree of risk, and represents that it is able,
without materially impairing its financial condition, to hold the Preferred
Stock (if applicable) for an indefinite period of time and to suffer a complete
loss of its investment.

4.4 FURTHER LIMITATIONS ON DISPOSITION. Without in any way limiting the
representations set forth above, the Lender further agrees not to make any
disposition of all or any portion of the Preferred Stock (if applicable) unless
and until:

     (a) There is then in effect a Registration Statement under the 1933 Act
     covering such proposed disposition and such disposition is made in
     accordance with such Registration Statement; or

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       2
<Page>

     (b) (i) The Lender shall have notified the Corporation of the proposed
     disposition and shall have furnished the Corporation with a detailed
     statement of the circumstances surrounding the proposed disposition, and
     (ii) if reasonably requested by the Corporation, such Lender shall have
     furnished the Corporation with an opinion of counsel, reasonably
     satisfactory to the Corporation, that such disposition will not require
     registration under the 1933 Act.

Notwithstanding the provisions of Sections 4.4(a) and 4.4(b), no such
registration statement or opinion of counsel shall be necessary for a transfer
by the Lender to affiliates of the Lender, if such affiliates agree in writing
to be subject to the terms hereof to the same extent as if they were the Lender
hereunder.

4.5 EXPERIENCE. The Lender represents that it is an "accredited investor" as
such term is defined in Rule 501 under the 1933 Act.

4.6. LOCK UP. The Lender agrees not to effect (and to cause its affiliates not
to effect) any sale, distribution, pledge, encumbrance or any other transfer of
any kind (including any "hedging" or other transaction intended to shift or
limit risk of ownership) of the Stock (or any interest therein), including a
sale pursuant to Rule 144 (or any similar provision then in force) under the
1933 Act, during the 180-day period beginning on the date of any public offering
of the Common Stock of the Corporation.

SECTION 5. MISCELLANEOUS

5.1 BINDING AGREEMENT. The terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the
parties. Nothing in this Agreement, express or implied, is intended to confer
upon any third party any rights, remedies, obligations or liabilities under or
by reason of this Agreement, except as expressly provided in this Agreement.

5.2 GOVERNING LAW. This Agreement shall be governed by and construed under the
laws of the State of Delaware as applied to agreements among Delaware residents,
made and to be performed entirely within the State of Delaware.

5.3 COUNTERPARTS. This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

5.4 TITLES AND SUBTITLES. The titles and subtitles used in this Agreement are
used for convenience only and are not to be considered in construing or
interpreting this Agreement.

5.5 NOTICES. All notices required or permitted hereunder shall be in writing and
shall be deemed effectively given: (i) upon personal delivery to the party to be
notified, (ii) when sent by confirmed telex or facsimile, (iii) five (5) days
after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (iv) one (1) day after deposit with a nationally
recognized overnight courier, having specified next day delivery, with written
verification of receipt.

5.6 MODIFICATION; WAIVER. No modification or waiver of any provision of this
Agreement or consent to departure therefrom shall be effective unless in writing
and approved by the Corporation and the Lender.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
date set forth in the first paragraph hereof.

NEOGENESIS DRUG DISCOVERY, INC.

By:  _____________________________

Name:  ___________________________

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       3
<Page>

Title:  _________________________

TULARIK INC.

By:  _____________________________
Name:  William J. Rieflin
Title: Executive Vice President, Administration

Address Two Corporate Drive
     South San Francisco, CA  94080
Phone  (650)-825-7300
Fax    (650)-825-7303

EIN:   94-3148800

*=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION.

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]